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INTRODUCTION   
 
 
  The main physiological functions of the androgens testosterone (T) and dihydrotestosterone 
(DHT) involve the development and maintenance of the male phenotype. T is mainly produced 
in the testis and converted to DHT in several target organs, including the prostate. Androgens 
have a hydrophobic cholesterol-derived steroid structure, which allows free traveling between 
the extra- and intracellular space. The intracellular target of androgens is the androgen receptor 
(AR). Upon androgen binding, the AR translocates to the nucleus and regulates transcription of 
androgen target genes.  
 
 1.1  NUCLEAR RECEPTORS 
 
  The AR belongs to the group of steroid receptors, which is a subgroup of the nuclear receptor 
(NR) family of transcription factors. In vertebrates and invertebrates, more than 150 members of 
the NR superfamily have been identified. During the last decades, this family of physiologically 
highly important proteins has been subject of study by many research groups, resulting in an 
overwhelming number of publications. In this section a comprehensive overview of general NR 
functioning is given, based on excellent reviews published on this subject 
1-11
. Where 
appropriate, references to key publications are included in the text. In section 1.2, more detailed 
information of the AR is presented. 
 
1.1.1  General features of nuclear receptors 
  Based on phylogenetic studies, the NR family can be subdivided into six different subtypes 
12
. 
The group of type I receptors includes the thyroid hormone receptors (TRα and TRβ), the 
vitamin D receptor (VDR), the retinoic acid receptors (RARα, RARβ and RARγ), the 
peroxisome proliferator activated receptors (PPARα, PPARβ and PPARγ), and the Drosophila 
ecdysone receptor (EcR). Members of the type II receptor group are the retinoic X receptors 
(RXRα and RXRβ) and orphan receptors like COUP-TF, Rev-Erb, TR2, and TR4, for which the 
ligand has not been identified as yet, or which can function without stimulation by a ligand 
13
. 
The type III receptors comprise the group of steroid receptors, which includes the AR, the 
glucocorticoid receptor (GR), the mineralocorticoid receptor (MR), the progesterone receptor 
(PR), and the estrogen receptors (ERα and ERβ). The closely related orphan receptors estrogen 
related receptors (ERRs) also belong to the type III receptors. The NR subtypes IV, V and VI all 
include various orphan receptors.  
  In general, NRs are ligand-activated transcription factors. Upon ligand binding, NRs undergo 
conformational changes that result in a cascade of events leading to DNA binding and 
transcription activation or repression of specific target genes. The liganded, and in some cases 
the unliganded, receptor is able to bind as a homo- or heterodimer to specific sites in the DNA 
and subsequently recruits coactivators or corepressors, general transcription factors and RNA 
polymerase II (RNApolII), to ultimately regulate transcription of target genes. Protein-protein 
interactions play a prominent role in these processes 
14-19
. A simplified scheme of these events is 
depicted in Figure 1A. 
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Figure 1.  A) Schematical overview of intracellular NR functioning. GTF = general transcription factors, PolII = 
RNA polymerase II, HRE = hormone response element. B) Schematical representation of NR functional domains. 
NTD = N-terminal domain, DBD = DNA binding domain, H = hinge region, LBD = ligand binding domain. 
 
1.1.2  Structure and functional domains of nuclear receptors   
  NRs have a modular structure composed of a non-conserved amino-terminal domain (NTD), a 
highly conserved central DNA-binding domain (DBD), a moderately conserved carboxyl-
terminal ligand-binding domain (LBD), and a flexible hinge region located between the DBD 
and the LBD (Figure 1B). 
1.1.2.1  The amino-terminal domain 
  The NTD is the most variable domain both in size and amino acid composition. Until now, for 
none of the NRs the three-dimensional structure of this domain has been resolved. It is generally 
assumed that the NTD has an unorganized, flexible structure, which hampers crystallization. 
Small regions in the NTD might adopt a more structured conformation upon protein-protein 
interactions in transcription initiating complexes. However, structures of such complexes have 
not been elucidated as yet.  
  For most NTDs, a trans-activation function, AF-1, has been established. The AF-1 domains in 
the different NRs do not show structural homology and are mapped at quite distinct positions in 
the NTD. AF-1 is promoter and cell dependent, which indicates interactions of the NTD with 
promoter and cell specific proteins involved in transcriptional regulation 
14
. An increasing 
number of NTD interacting proteins has been identified. The NTD, if bound to a DBD, can 
autonomously activate expression of target genes, as proven by the constitutive activity of 
truncated NRs lacking their LBD. The LBD functions as an activation lock, which is opened by 
binding of its cognate ligand.  
A 
B 
NTD DBD LBD H 
hormone cytoplasm 
HRE 
mRNA 
NR NR 
protein 
NR 
Pol II 
coactivator 
NR 
nucleus 
GTF 
transcription 
- C N - 
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1.1.2.2  The DNA binding domain 
  Ligand-activated NRs bind through their highly conserved DBDs to hormone response 
elements (HREs) in the regulatory regions of target genes. HREs have specific consensus 
sequences for high affinity binding to the different NR subgroups, and are composed of an inverted 
or direct imperfect repeat of two 6 bp half-sites separated by a spacer of variable length. NRs bind 
to HREs as homo- or heterodimers, each receptor to one HRE half-site 
20, 21
. 
  The DBD is composed of two zinc clusters and a carboxyl-terminal extension (CTE). The N-
terminal zinc cluster of steroid receptors contains three amino acids, denoted as the P-box, which 
determine DNA binding specifity 
22, 23
. The C-terminal zinc cluster contains a dimerization 
interface, the D-box (Figure 2A). For several NRs, crystallographic analyses have revealed the 
DNA-bound DBD dimer structures with detailed data on protein-protein and protein-DNA 
interaction sites (reviewed in ref. 24). Adjacent to the C-terminal part of each zinc cluster a short α-
helical structure can be recognized. The helix flanking the N-terminal zinc cluster enters the major 
groove in the DNA. This conserved recognition α-helix enables the amino acid residues of the P-
box to bind to receptor specificity determining sites in the HREs. Two phenylalanine residues in 
this helix are also involved in nuclear export of NRs in the presence of ligand 
25, 26
. The helix 
flanking the C-terminal zinc cluster, the CTE, is positioned perpendicular to the other helix, in this 
way exposing the D-box, facilitating dimerization (Figure 2B) 
20
.  
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  A) Schematic representation of the NR DBD structure. CTE = carboxy-terminal extension. B) Tertiary 
structure of a DNA bound NR DBD dimer. 
1.1.2.3  The hinge region 
  The hinge region forms a flexible link between the DBD and the LBD, allowing easy rotation of 
the latter domain. The amino acid sequence of the hinge region is not conserved among NRs. In 
many NRs, the hinge region contains a bipartite nuclear localization signal (NLS) essential for 
nuclear import of the liganded receptor 
27
.  
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1.1.2.4  The ligand binding domain 
  Small variations excluded, NR LBDs have a canonical structure consisting of 12 α-helices, folded 
in a three-layered anti-parallel sandwich conformation 
28, 29
. The ligand-binding pocket is lined by 
many amino acid residues throughout the LBD and varies with the structure of the ligands of the 
respective receptors. Upon agonist binding, helix 12 is repositioned like a lid over the ligand 
binding pocket in a manner favoring NR activation. This is illustrated for the RXRα and RARγ in 
Figure 3. Binding of antagonists induces a different LBD conformation leading to an unfavorable 
positioning of helix 12, thereby causing blocking of receptor function 
30-33
.  
  In addition to ligand binding, the LBD might be involved in homo- or heterodimerization. It also 
interacts with chaperone proteins like heat shock proteins, and harbors the ligand-dependent 
transcription activation function 2 (AF-2).  
  The AF-2 structure is conserved among many NRs. A core region in the AF-2 domain, which 
is in helix 12, appears essential for ligand-dependent transcriptional activity 
34-38
. A general 
mechanism has been proposed, in which the AF-2 core plays a central role in the generation of 
an interaction surface, allowing binding of NR coactivators to the LBD 
31
. Coactivators can 
modulate the transcriptional activity of a broad range of NRs (see section 1.1.5). A large number 
of coactivators that bind to NRs has been described. The interaction with NRs is not limited to 
the LBDs, but also involves binding to the NTDs, resulting in cooperation or even synergy 
between AF-1 and AF-2 activities 
39-42
.  
 Unliganded or antagonist bound receptors can bind to corepressors by an interaction interface in 
the LBD that overlaps the coactivator binding site 
43
. Recruitment of corepressors inhibits 
receptor functioning leading to silencing of gene transcription 
44
. 
  In addition to the motif found in the DBD, for the MR, ER and AR, a nuclear export signal 
(NES) has been identified in the LBD. This second NES is, in contrast to the DBD NES, active 
in the absence of ligand and inhibited when ligand is present 
45
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  Two-dimensional representation of an NR LBD structure. Left: RXRα LBD without retinoic acid (RA). 
Right: RARγ LBD bound by RA. From ref. 29. 
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1.1.3  The nuclear receptor subfamily of steroid receptors 
  Through binding to their respective receptors, steroid hormones mediate biological processes like 
cell growth, cell differentiation, and homeostasis. The GR regulates storage, mobilization and 
metabolism of carbohydrates and fatty acids. The MR plays an important role in maintaining 
electrolyte levels within a narrow range. ERα, ERβ, and PR mediate development and maintenance 
of the female phenotype, but also play a role in males. The AR is responsible for the male 
phenotype, but is also important for female development.  
  The structures of steroid receptors are highly conserved. The highest percentage homology is 
present in the DBDs and LBDs. GR, PR, and MR DBDs show up to 80 % homology with the AR 
DBD. This conservation level is reflected in the HRE preferences of the steroid receptors. GR, MR, 
PR and AR homodimers all bind with high affinity to a consensus HRE, the inverted repeat 
AGAACAnnnTGTTCT, generally denoted as glucocorticoid response element (GRE) 
46-49
. ERα 
and ERβ are quite distinct from the other steroid receptors. Their structures deviate more from 
these receptors and the high-affinity DNA binding site is an inverted repeat of the consensus 
halfsite AG
G
/TTCA. Most type I and II NRs also bind to this sequence, which might be present as a 
single half-site or in a direct or inverted tandem repeat orientation in the regulatory sequences of 
target genes 
16, 50
. Because GR, MR, PR, and AR recognize the same high affinity GRE, many 
genes can be regulated by more than one steroid receptor. However, the physiological function of 
the different receptors is quite distinct, which can only partly be explained by their tissue specific 
expression pattern. So, additional mechanisms are required for a hormone specific response in case 
multiple receptors are simultaneously present in one and the same cell. Several mutually not 
exclusive mechanisms to explain steroid specific transcriptional regulation include selective 
interactions of receptors with specific and general transcription factors and coregulators, 
coregulator levels, ligand availability, local chromatin structure at the regulatory sites of the 
receptor target genes and, as recently described for the AR, steroid receptor specific HREs (see 
1.2.6 and Chapter 5) 
4, 7, 51-56
. 
  The AF-1 functions of the steroid receptors have roughly been mapped. For each receptor a region 
in the NTD has been defined, which is required for optimal transcriptional activity. Within these 
regions, a core region that is essential for AF-1 activity has been established. The AF-1 regions in 
different receptors are not identical and map at different parts of the NTD. Two PR isoforms are 
known, PR-A and PR-B. PR-B has an amino-terminal extension harboring an AF-3 function that 
enhances AF-1 activity 
57
. Like in other NR subgroups, the extent to which the separate AF-1 and 
AF-2 activities contribute to steroid receptor activity varies among the different receptors. In 
addition, cell and promoter context determine the relative activities of AF-1 and AF-2. 
Furthermore, AF-1 and AF-2 activities can act synergistically, as was found for ERα, ERβ, GR, 
PR and AR 
39-42
. 
  Unlike other NRs, in the unliganded inactive state steroid receptors are bound by heat shock 
protein complexes. These complexes bind preferentially to the LBDs and are supposed to be 
involved in proper LBD folding, intracellular transport, nuclear import and protection against 
degradation. Most studies indicate that heat shock protein complexes dissociate from the steroid 
receptor upon ligand binding, thereby enabling the receptor to dimerize, bind to DNA and activate 
transcription of its target genes 
58
. 
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1.1.4  Nuclear receptors in transcription regulatory complexes  
  To regulate transcription, the activity of NRs is directly and indirectly modulated by many 
other proteins, which can be components of large protein complexes. These complexes function 
in a spatiotemporal sequence, of which the dynamics are not yet completely understood. A 
model of protein complexes, and protein-DNA and protein-protein interactions involved in 
transcriptional gene regulation by NRs is depicted in Figure 4. It is based on many studies 
utilizing a variety of experimental approaches, including electrophoretic mobility shift assays 
(EMSA), two-hybrid assays, reporter gene assays, chromatin immuno precipitation (ChIP), 
fluorescence resonance emission transfer (FRET), and real-time movement measuring in living 
cells by fluorescence recovery after photobleaching (FRAP). The model includes binding of 
nuclear receptor, coregulators, chromatin remodeling complexes, and Mediator complexes, 
ultimately leading to activation or inhibition of transcription initiation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  Schematic model of transcriptional regulation by NRs. A) Transcriptional activation, ligand (agonist) is 
in red. B) Transcriptional repression, ligand (antagonist) is in dark red. For further description see text of this 
section (1.1.4). 
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  In the model ligand-bound NRs bind as a dimer to their cognate response elements present in 
target genes. It is known that some NRs have direct access to DNA, which might be dependent 
on nucleosomal phasing of their cognate recognition sites 
59
. Interaction of NRs with DNA 
might be very transient with tenths of seconds to seconds per cycle 
60-62
. For GR and ERα it has 
been shown that they can be removed from their DNA binding sites by proteasomes. This would 
fasten cycling and thereby allow the continuous response to fluctuations in hormone levels 
63,64
. 
The chaperone protein hsp90 might stabilize GR binding by inhibiting removal from its 
response element 
63
. Unlike FRAP experiments, ChIP experiments have shown that transcription 
factors and coregulators can be recruited to promoter/enhancer sequences within minutes 
64
. It is 
possible that proteins present in transcription initiation complexes individually and rapidly 
exchange multiple times within a binding cycle observed with ChIP. 
  Binding of a NR dimer to DNA is followed by recruitment of coregulators, which might be 
coactivators or corepressors. The best known NR coactivators are the p160 proteins, which are 
described in more detail in section 1.1.5 
60
.   
  Coactivators, in turn, recruit factors with strong histone acetyltransferase (HAT) activity, like 
the cointegrators CREB binding protein (CBP)/p300 and p300/CBP-associated factor (p/CAF). 
Some p160 coactivators also have weak intrinsic HAT activity 
65, 66
. Subsequently, histones on 
target genes are acetylated on lysine residues. This decreases histone affinity for DNA, which 
results in an opened chromatin structure allowing ongoing recruitment of all required protein 
complexes favoring gene transcription 
67-69
. Acetylation also disrupts internucleosomal contacts, 
thereby disturbing higher order chromatin structures 
70
. In case of transcription inhibition, a NR 
corepressor is recruited, which in turn recruits proteins with histone deacetylase activity 
(HDACs) through which histones will be deacetylated resulting in tightening of chromatin 
conformation and thereby preventing transcriptional activation 
44, 71-73
. Examples of NR 
corepressors are described in more detail in section 1.1.6.  
  Nucleosome disruption and thereby activation of gene transcription is also conferred by the 
protein arginine methyltransferases: protein arginine methyltransferase 1
 
(PRMT1) and cofactor 
associated arginine (R) methyltransferase 1 (CARM-1/PRMT4), which both can methylate 
histones. These histone methyltransferases (HMTs) are recruited by p160 coactivators and p300 
74-77
.   
  The chromatin structure on transcribed genes is not only modified by HATs and 
methyltransferases, but also by ATP dependent chromatin remodeling complexes. In fact, ERα, 
its coactivator SRC-1, and p300, were all found to bind to components of a remodeling complex 
78, 79
. Remodeling complexes confer unwinding of DNA and release of histones in a non-
covalent and ATP-driven manner (reviewed in refs 80, 81). Three groups of these complexes 
have been found. The best known is the switch/sucrose non-fermenting (SWI/SNF) complex. It 
was first identified in yeast; the human homologs are the Brahma related proteins. A second 
complex is imitation switch (ISWI), which was originally identified in Drosophila. However, 
involvement in NR mediated transcription activation was only established for the SWI/SNF 
complexes. Other described complexes are Mi-2/ nucleosome remodeling and histone 
deacetylation (Mi-2/NURD) complexes, which act on chromatin regions that have become 
deacetylated by HDACs. These contain histone deacetylase activity, which confers further 
tightening of the chromatin structure of a gene that has to be silenced.  
  Crosslinking assays have revealed that the GR and the human SWI/SNF complex bind on a 
tandemly repeated MMTV promoter in an alternating fashion, with a cycle time of 
approximately 5 min. 
62
. This indicates that within one exchange cycle, after conferring the first 
 17
step in opening the chromatin by recruitment of HATs, the GR is removed from its DNA 
binding site, leaving the stage for further chromatin remodeling. 
  Another large complex involved in transcriptional regulation is the Mediator complex, of 
which orthologs have been found in mammalians, Drosophila, C. elegans and yeast. This 
complex consists of about 25 subunits. The Mediator complex was initially identified as the 
thyroid receptor-associated proteins (TRAP) or the vitamin D receptor–interacting proteins 
(DRIP) or activator-recruited cofactor (ARC) 
82-85
. A universal code for each Mediator protein 
in different species is now available 
86
. FRET experiments have shown that NRs can directly 
interact with components of the Mediator 
87
. The Mediator complex binds with its 
DRIP205/TRAP220 subunit (MED1) to the NR LBD in a ligand-dependent manner, through an 
LXXLL motif which is also found in many coactivators (see section 1.1.5) 
88-92
. ChIP 
experiments have revealed that the TR first recruits p160 and p300, followed by the Mediator 
complex. This finding is substantiated by the observation that recruitment of the Mediator is 
stimulated by inhibition of HDAC activity, which indicates that histone acetylation is required 
for recruitment of the Mediator complex to chromatin 
93
. Consistent with this observation, 
synergism was observed between the Mediator complex and p300/CBP-SRC for ERα-mediated 
transcription with chromatin templates, but not with naked DNA 
94
. ChIP experiments with the 
ERα and its recruited proteins showed that the time scale of Mediator cycling is in the same 
order as that of the receptor and its coregulators, indicating a cooperating role for the Mediator 
complex in transcriptional regulation 
64
.  
  The Mediator complex can bind RNApolII thereby functioning as a scaffold to recruit other 
components of the transcription machinery 
95
. In addition to transcription initiation, the 
Mediator complex enables re-initiation of transcription by providing access for multiple rounds 
of transcription 
96
. The composite nature of different promoters will influence the conformation 
of bound NRs, which is ultimately transmitted to the recruited Mediator complex (reviewed in 
ref. 97). The conformation of the Mediator complex, in turn, will determine the number of 
RNApolII molecules that can start transcription in a defined period of time. 
  A summarizing spatiotemporal model of the events occuring to regulate transcription by NRs 
can be as follows:  
  After ligand binding, NRs can freely bind to and depart from their cognate DNA binding sites 
very quickly, giving target genes the opportunity to respond immediately to changes in hormone 
concentration. This could imply that NRs have left the response element directly following the 
recruitment of coregulators, which has been proposed as a 'hit and run' mechanism 
61
. After 
binding to chromatin, NRs recruit nucleosome disrupting HATs and HMTs via their 
coactivators and chromatin remodeling complexes to further disturb chromatin structures at the 
regulatory sites of the NRs target genes (Figure 4A). In case of transrepression, inhibition of 
transcription is established by recruitment of HDACs via their corepressors, which may also be 
guided by chromatin remodeling complexes (Figure 4B). The loosened chromatin enables 
recruitment of the general transcription factors and RNApolII to the transcription initiation site 
via the Mediator complex. Many of the spatiotemporal details on transcriptional regulation are 
not elucidated as yet, therefore the model described above is expected to be extended and 
modified. 
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1.1.5  Nuclear receptor coactivators 
  NRs function in large networks of proteins and protein complexes that dynamically interact to 
activate or inhibit transcription initiation. An overview of the recent knowledge on these 
networks was described in section 1.1.4. Proteins that directly or indirectly activate or enhance 
transcriptional activation of NR target genes are generally considered as coactivators. Examples 
are: the chromatin remodelling complexes, the Mediator complex, HATs, HMTs, and the group 
of proteins that recruit all these proteins to the NRs (reviewed in ref. 98). This latter group 
includes the p160 coactivators, which have been studied in most detail.  
  Three distinct human p160 steroid receptor coactivator proteins have been identified, SRC-1, 
TIF2/SRC-2, and SRC-3, also known as ACTR, AIB1, RAC3, or TRAM-1 
65, 99-103
. NCoA-1 is 
the mouse homolog of SRC-1, GRIP-1/NCoA-2 in the mouse is homologous to TIF-2, and 
p/CIP is the mouse homolog of SRC-3 
104, 105
.  
  P160 coactivators contain several functional domains (Figure 5). Best studied in this regard is 
the NR interacting domain, or NR box, which contains three LXXLL motifs (L = leucine, x = 
any residue) 
106
. The leucine residues in these motifs are indispensible for receptor interaction, 
and flanking residues play a modulating role herein. The LXXLL motifs interact with a 
hydrophobic cleft in the NR LBD in a ligand-dependent manner. This cleft is lined by a charged 
clamp formed by a conserved lysine in helix 3 and a conserved glutamic acid in the AF-2 core in 
helix 12 
107
. Through an amino-terminal glutamine(Q)-rich region and independent of its 
LXXLL motifs, p160 coactivators can bind to NR NTDs, resulting in synergism of AF-1 and 
AF-2 activities, which might be necessary for optimal receptor functioning 
39, 41, 42, 108, 109
. 
  P160 coactivators contain also binding domains for the HAT containing cointegrators 
CBP/p300 and  p/CAF (see 1.1.4), which play an essential role in gene transcription as has been 
demonstrated in knock-out models 
110, 111
. If fused to a heterologous DBD, p160 coactivators 
can autonomously transactivate through two activation domains, AD1 and AD2 (see Figure 5). 
AD1 coincides completely with the CBP/p300 binding domain, and partly with the PCAF 
binding domain, which also contains the Q-rich region 
100, 105, 112
. To some extent, SRC-1 and 
SRC-3 can acetylate histones by their weak intrinsic HAT domain, formed by the Q-rich region 
and AD2 
65, 66
. AD2 can bind to the HMTs CARM1 and PMRT1 
74, 76
. 
 
 
 
 
 
Figure 5.  Schematical repesentation of  a p160 NR coactivator. NID = nuclear receptor interacting domain, AD = 
activation domain, Q-rich = Q-rich region. 
 
  The physiological function of p160 coactivators has been established in knock-out and null 
mutant mice (reviewed in refs 98, 113). SRC-1 inactivation led to decreased growth of steroid 
target organs, like uterus, mammae, testes and prostate, indicating a role for SRC-1 in ER, PR 
and AR function 
114
. Pituitary resistance to thyroid hormone was also observed, whereas PPARα 
regulated genes were unaffected in SRC-1 null mice 
114, 115
. These mice showed compensatory 
overexpression of TIF-2/SRC-2, indicating redundancy between these two coactivators 
114
. 
Furthermore, SRC-1 null mice exhibit moderate motor dysfunction and delayed development of 
cerebellar Purkinje cells 
116
.  
  SRC-2 plays a critical role in reproductive behaviour and function, and is the most prominent 
SRC family member expressed in the testis. Both male and female SRC-2 knock out mice 
00000
AD1 Q-richNID
- CN -
AD2
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showed reduced fertility 
117
. An AR mutation, which disrupts the interaction with SRC-2 was 
reported in some men with oligospermic infertility 
118
. SRC-2 is a coactivator of PPARγ as 
reflected in fat accumulation in mice lacking SRC-2 
119
. In addition, SRC-2 was found to form a 
fusion oncoprotein, as a result of a translocation causing leukemia 
120
. 
  SRC-3 null-mutant mice showed dwarfism, deficiency in mammary gland development, and 
other abnormalities in the female reproductive system 
121, 122
. Very high levels of SRC-3 mRNA 
were found in many ER-positive breast and ovarian tumors 
123, 124
. This indicates an important 
role in estrogen stimulation of these tumors as substantiated by the observation that SRC-3 
depletion in MCF-7 cells inhibited their estrogen-dependent growth 
125, 126
. SRC-3 is also 
thought to facilitate the estrogen mediated vasoprotective effects of estrogens via ER activation 
127, 128
. 
  P300 inactivation is lethal in the embryonic stage, indicating potential redundancy of related 
CBP cannot overcome p300 deficiency 
110
. Inactivation of CBP is associated with the severely 
disabling Rubinstein-Taybi syndrome 
129
. As compared with the p160 coactivators, the higher 
importance of CBP/p300 proteins correlates with their evolutionary strong conservation.   
  The viability and fertility of SRC-1 and SRC-3 null mutants are indications for redundancy 
among SRC family members. Indeed, analysis of knock-out mice lacking SRC-1 and SRC-2 
revealed that SRC-1 can partially compensate for loss of SRC-2/TIF2. A TIF2
-/- 
 mutant showed 
an impaired testicular function, which was further decreased by inactivation of one or both 
SRC-1 alleles 
130
. A p/CIP
-/-
SRC-1
-/- 
mouse displayed impaired brown fat development and 
defective adaptive thermogenesis, which are due to absence of activation of certain PPARγ 
target genes 
131
. 
  Based on the data on mutant mice and the tissue specific expression patterns it can be assumed 
that each member of the SRC family has preferential functions. During recent years, a number 
of studies has been published that are consisitent with this observation (reviewed in refs 132-
134). The individual SRC proteins each preferentially bind to a different subset of NRs. They 
even can distinguish between different NR subtypes. For example, ERα has a higher affinity for 
SRC-1 and SRC-3 than ERβ, and PR-A interacts more efficiently with SRC-1 than PR-B. The 
GR has an extra level of binding preference through a second charge clamp in the LBD. 
Moreover, the three different NR boxes of SRC proteins show NR binding specificities. The GR 
shows the highest affinity to NR-box 3 of SRC-2, whereas TRβ prefers NR-box 2. Ligands can 
specify NR box affinity of a particular NR or even NR subtype. Different peptides, selected by 
phage-display, were found to bind to ERα activated by different ligands. For several NRs, 
crystallographic studies have revealed different conformations of the coactivator binding 
interface in LBDs bound by different ligands. SRC recruitment can be promoter dependent as 
was found for the MMTV promoter on which the GR recruits SRC-1 and SRC-3, but not SRC-2 
135
. The functionality of the interactions between SRC-1 and the AR NTD or LBD was also 
found to vary in a promoter-dependent fashion 
136
. 
   A large number of other NR coactivating proteins with less defined function has been 
identified, many of which contain LXXLL motifs. These factors are thought to bind directly to 
multiple NRs through these motifs in a ligand-dependent manner. In addition to the numerous 
coactivators that interact with DNA bound NRs, another category of coactivators is formed by 
proteins that positively influence NR activity prior to or after DNA binding. These proteins are 
involved in: synthesis, proper folding and stabilization, nuclear trafficking, nuclear import and 
export, or degradation of the NR. A detailed description of those kinds of coactivators is beyond 
the scope of this thesis.  
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1.1.6  Nuclear receptor corepressors  
  In addition to transcription activation, transcriptional silencing is required for balanced 
regulation of transcription. Unliganded type I receptors, antagonist bound type III receptors, and 
orphan receptors, are able to repress transcription, also called transrepression. To inhibit 
transcription, NRs recruit corepressors, which bind HDACs that tighten nucleosomal structures 
by their histone deacetylating capacities 
44
. In this way  a non-permissive environment is created 
for appropriate transcription initiation.  
  Several corepressors are known, including the related corepressors NR corepressor (NCoR) 
and silencing mediator for retinoid and thyroid hormone receptor (SMRT) 
72, 137
. NCoR and 
SMRT show high sequence similarity and share key functional domains (Figure 6).  
 
 
 
 
 
Figure 6.  Schematical repesentation of the NR corepressor NCoR. RD = repression domain, mSin3BS = mSin3 
binding site, RID = receptor interacting domain. 
 
  Corepressors have two or three NR interacting domains (RIDs) through which they bind to NR 
LBDs. Each RID contains a receptor interaction motif (CoRNR box) with a consensus sequence 
LxxI/HIxxxI/L. This motif is predicted to adopt an amphipathic α-helical conformation similar 
to that of the LXXLL motifs in coactivators 
43, 138, 139
. Like LXXLL motifs, the hydrophobic 
residues of the CoRNR boxes are essential in receptor interaction, flanking amino acid residues 
play a modulating role in this interaction. The coactivator binding cleft in the LBD is also 
involved in corepressor binding. However, compared to the LXXLL motif, the CoRNR box 
helix is NH2-terminally extended, which most likely prevents binding of the corepressor to the 
hydrophobic cleft in the agonist activated LBD. In the unliganded state of type I receptors or 
antagonist bound type III receptors, helix 12 of the LBD is thought to be displaced by the 
extended CoRNR helix 
43
. 
  SMRT and NCoR recruit different classes of HDAC subtypes through three or four different 
repressor domains (RDs), respectively 
140-143
. This recruitment might be direct or via the Sin3A 
protein 
144-146
. To deacetylate histones in association with corepressor and DNA bound NRs, 
HDACs have to gain access to their target site. Therefore, chromatin-remodeling activity is also 
required. Indeed, the Mi-2/NURD remodeling complexes were found to contain HDAC activity 
147-149
.  
  Like for the coactivators, receptor specificity has been established for NCoR and SMRT. The 
TR prefers to recruit NCoR, whereas the RAR isoforms bind much better to SMRT than to 
NCoR. PPARα and PPARδ only bind to SMRT, whereas the orphan receptor Reverb 
exclusively binds to NCoR. In the two corepressors, specific CoRNR box motif residues of 
individual RIDs have been identified to confer these receptor specificities 
150
. 
  The three-dimensional structures of several NR LBDs bound to agonists and antagonists have 
been elucidated (reviewed in ref. 151). The agonistic and antagonistic forms provide interaction 
interfaces suitable for binding to coactivators or corepressors, respectively. The interaction 
interfaces are overlapping, which is illustrated by a single mutation in the TR LBD that changes 
its interaction interface from a SRC-1-binding to an NcoR-binding interface 
152
.  
  Whether a ligand acts as an agonist or antagonist is not only determined by the conformation it 
induces to an NR LBD, but is also dependent on the coactivators and corepressors present in a 
RID1mSin3BS
- CN -
RID2RD2 RD4 RD1 RID3RD3 
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cell. To which extent coactivators and corepressors influence NR function is determined by their 
stoichiometry, which is cell-type specific and depends on cell activity state 
54
. In case of NCoR 
excess, the vitamin D analog Gemini was found to shift from an agonist to an inverse agonist by 
disabling coactivator interaction and stimulating corepressor recruitment 
153
. This indicates a 
coregulator interface conformation that is dynamic rather than static, and the equilibrium 
between the different conformations is dependent on the ligand structure, the cell-specific 
coactivator/corepressor ratio and presumably other factors like the promoter context of the 
receptors target genes. This is also substantiated by the fact that corepressors and coactivators, 
to some extent, can compete for binding to agonist bound RAR and ERβ 
154, 155
. Additionally, 
two proteins, transducin β-like R1 and Ski-interacting protein, were found to mediate exchange 
of NR corepressors for coactivators 
156, 157
. 
  Another kind of corepressors includes receptor interacting protein 140 (RIP 140) and ligand-
dependent corepressor (LcoR) 
158, 159
. These corepressors resemble the p160 coactivators in that 
they are recruited by agonist bound NR LBDs through their LXXLL motifs. LCoR has one, and 
RIP140 even has ten LXXLL motifs. Both corepressors function by HDAC-dependent and -
independent mechanisms. 
  Like for the coactivators, the number of proteins identified to have corepressing activity is still 
growing. Further details on this subject are beyond the scope of this thesis.  
 
1.1.7  Post-translational modifications of nuclear receptors 
  In addition to cofactors that modulate the chromatin structure, NR function is also regulated by 
different kinds of direct post-translational modifications, like acetylation, methylation, 
ubiquitylation, sumoylation and phosphorylation. These modifications are reviewed in refs 160-
162. 
  P300 and CBP, which are recruited by p160 coativators, can acetylate histones, but also 
transcription factors, among which the AR and ERα. Through acetylation, activation of ERα is 
attenuated, whereas AR activation is stimulated 
163
. TRβ1 acetylation was found to be associated 
with p300 recruitment 
164
.   
  P160 coactivators recruit, in addition to HATs also HMTs, like CARM1 and PMRT1 (see 
section 1.1.4) 
74, 165
. Although these HMTs can methylate histones and other proteins in the 
transcription initiation complex, no methylation of NRs and their coregulators by these HMTs 
has been reported.  
  Ubiquitin is a well-conserved 76-amino acid protein, which is conjugated to many different 
substrates, including NRs. Poly-ubiquitylation of proteins leads to their proteasome-mediated 
degradation, whereas mono-ubiquitylation is involved in transcriptional regulation. The AR, 
ERα, GR, PPARα, RARγ, RXRα, and TR were all found to be degraded by the ubiquitin-
proteasome system 
166-171
. However, overall activity of the GR is increased by this system, 
suggesting that a high turn-over of GR on target promoters favors the opportunity for other GR 
molecules to start another round of transcription 
63
.  
  Sumoylation involves the conjugation of the 101-amino acid small ubiquitin-like molecule-1 
(SUMO-1) protein (18% homology with ubiquitin) to lysines of a target protein. Sumoylation 
influences proteins with respect to their subcellular localization, subnuclear sequestration, 
stability, or ability to regulate gene transcription. Sumoylation of the GR increases its 
transcriptional activity probably by stabilization of this receptor, whereas AR-dependent 
transcription is repressed by sumoylation 
172-175
. However, the effect on AR may be caused by 
sumoylation of GRIP1, which probably impairs their co-localization 
176
. In contrast, 
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sumoylation of SRC-1 was shown to enhance PR-SRC-1 interaction thereby increasing PR 
activity 
177
. 
  NRs can be phosphorylated at serine, threonine and tyrosine residues in their NTDs and LBDs 
as well as in their DBDs. The kinases involved are mitogen-activated protein kinases (MAPKs), 
cyclin dependent kinases (CDKs), Akt, protein kinase A (PKA), and protein kinase C (PKC). 
The number of phosphorylation sites ranges from one in the VDR to at least 13 in the PR. 
Phosphorylation of ERα, ERβ, PPARα and AR NTDs by MAPKs or Akt stimulates recruitment 
of coactivators and of the transcription machinery, thereby facilitating chromatin remodelling 
and transcription initiation 
178-183
 The GR and PPARγ are inhibited by phosphorylation of their 
NTDs, probably by promoting the ubiquitin-proteasome mediated degradation 
184-189
. 
Phosphorylation of the ERα and RARα LBDs favors receptor dimerization and coactivator 
recruitment 
183, 190-192
. DBD phosphorylation has been observed for the VDR, ERα, and RARα, 
which interferes with DNA binding and receptor dimerization 
193-196
. Excessive kinase activity 
may activate NRs in a ligand-independent manner. This was illustrated in breast, ovarian and 
prostate cancers, which showed estrogen and androgen-independent growth and had abberant 
MAPK and Akt activities 
180, 197-200
.  
  NR coregulators are also subject to the post-transcriptional modifications described above. 
SRC-3 can be acetylated by CBP, which modulates one of its lysines leading to an inhibition of 
binding to CBP. This modification may form a negative feedback loop 
201
. For the ER, which is 
not sumoylated and the PR, which can be sumoylated, it has been established that sumoylation 
of SRC-1, but not of these receptors, increased their binding to this coactivator 
177
. Sumoylation 
of p300 leads to recuitment of a HDAC, which represses its activity. HDACs, in turn are also 
regulated by sumoylation 
202
. P160 family members and CBP/p300 are particularly subject to 
become phosphorylated by the different kinase pathways 
203-206
. Phosphorylation of the 
corepressor SMRT inhibits its interaction with NRs and causes its redistribution from the 
nucleus to the cytoplasm 
207
. Phosphorylation-dependent ubiquitylation was found for RARγ, 
indicating a mechanism of initial receptor activation followed by tagged degradation 
208
. The 
liganded PR is also degraded upon phosphorylation, however, its degradation pathway is not 
clear yet 
209, 210
. Taken together, cross-talk with other signal transducing pathways can 
sophistically modulate NR and cofactor function. This might result in stimulation or inhibition 
of transcription regulation. 
 
1.1.8  Additional nuclear receptor functions  
  In addition to the classic ligand-induced transcriptional regulation of target genes NRs can be 
involved in other pathways, including ligand-independent transactivation, DNA-binding-
independent transactivation, and even transcription-independent function. Illustrating examples 
are described below. 
  For several NRs ligand-independent functions have been described. Unliganded TR and RAR 
can bind to HREs and recruit corepressors thereby repressing transcription 
211-213
. Ligand 
binding to these receptors causes dissociation of the corepressors, allowing coactivator binding. 
Another mode of ligand-independent action involves the orphan receptors (type V NRs). These 
are constitutively active, have an LBD structure similar to that of agonist-bound 
transcriptionally active NRs, but have an empty ligand-binding pocket or no ligand-binding 
pocket at all 
214, 215
. Mutations of a conserved tyrosine in the LBD induce constitutive activation 
of the ERα and ERβ. However, antiestrogens could completely abolish this ligand-independent 
activation 
216, 217
.  
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  Several ligand responsive NRs can also be activated in the absence of ligand. For example, in 
reporter assays the chicken progesterone receptor (cPR) could be activated by 8-Br cAMP 
218
. 8-
Br cAMP activated p42/p44 MAPK and increased phosphorylation of SRC-1, which then 
contributed to the ligand-independent activation of the cPR 
219
. Dopamine can activate a number 
of NRs including cPR and ERα in the absence of their cognate ligands 
220, 221
. Treatment with 
dopamine causes PR-dependent induction of mating behavior in female rats and mice, whereas 
PR null mice are not responsive 
222-225
. The ERα is also responsive to cell signaling pathways in 
the absence of ligand. In cells maintained in phenol red-free, charcoal-stripped serum, the ERα 
shows substantial basal transcriptional activity. This activity can be inhibited by a pure anti-
estrogen such as ICI 182780 
221
. Epidermal growth factor (EGF)-dependent activation of human 
ERα was observed in transfected hormone depleted HeLa cells, whereby Ser118 was 
phosphorylated 
226
. Substitution of serine by alanine abrogated the hormone-independent 
activation 
227
. In the absence of ligand, AR activity can be induced by EGF, keratinocyte growth 
factor (KGF), interleukin 6 (IL-6), and forskolin (see for more details section 1.2.5.1.3.4) 
228-230
. 
Aberrant activation of AR by cell signaling pathways is presumed to be involved in many cases 
of androgen-independent prostate cancer (see section 1.2.5.1.3.4). The GR needs ligand for 
activation, but can be extra stimulated by activators of PKA and PKC 
220, 231-233
. RARα can be 
activated in the absence of retinoic acid by the catalytic subunit of PKA 
191
. In CV1 cells, 
RARα, RARβ, RXRα, RXRβ, and RXRγ, but not RARγ, could be activated in the absence of 
ligand and after treatment with the phosphatase inhibitor okadaic acid, which was not observed 
if the cells were treated with dopamine 
234
. The VDR could be acivated by okadaic acid or by 
dopamine 
234
. 
  NRs can also regulate transcription independent of HRE binding, which is referred to as 
'transcriptional cross-talk'. For example, in the presence of agonists, GR, TR, RAR, and ERβ 
inhibit AP-1-dependent transcription, whereas ERα is activating. Antiestrogen bound ERβ can 
activate AP-1 directed transcription 
235, 236
. 
  Non-genomic signaling mechanisms of NRs have also been reported and include recruitment 
of signaling pathways that are often associated with cell membrane receptors such as G-protein-
coupled receptors (GPCRs), ion channels or enzyme-linked receptors 
237
. For plasma membrane 
associated ERs it has been suggested that they are involved in the regulation of cell membrane 
ion channels, GPCRs, and tyrosine kinases and MAPKs 
238-242
. They also can activate adenylate 
cyclase production, and induce phospholipase C activation 
243, 244
. This results in a rapid 
increase in intracellular Ca
2+
 concentration due to Ca
2+
 mobilization from the endoplasmic 
reticulum and to the formation of inositol 1,4,5-trisphosphate and diacylglycerol 
244
. The ER is 
also supposed to be involved in the Src/Ras/MAPK signal transduction pathway by interaction 
with c-Src 
238
. In breast cancer cells, the B isoform of the PR stimulates the activated ER to 
recruit the Src/p21ras/ERK pathway 
245
. A specific polyproline motif in the NH2-terminal 
domain of PR mediates direct progestin-dependent interaction of PR with SH3 domains of 
various cytoplasmic signaling molecules, including c-Src tyrosine kinases 
246
. Testosterone is 
also able to regulate the MAPK family of protein kinases. Recent work indicates that, via a cell 
membrane associated AR, testosterone induces a rapid rise in the intracellular free Ca
2+
 
concentration in macrophages 
247
. Similar findings were reported for the VDR 
248
. In addition to 
protein kinase signaling pathways, non-transcriptional actions of NRs can be mediated by the 
recruitment of lipid kinases. E2-bound ERα interacts with the regulatory subunit of the lipid 
kinase PI3K, triggering activation of the catalytic subunit and increasing intracellular production 
of phosphoinositides 
249
. Interaction with PI3K was also found for other NRs, such as the AR 
and the GR 
250
.  
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1.2  THE ANDROGEN RECEPTOR 
 
  The AR is essential in development of the male phenotype and controls male fertility and 
sexual behaviour. High AR levels are present in the tissues of the male urogenital tract, 
including the prostate. Low AR expression was found in many other tissues including mammary 
gland, kidney, liver brain, genital skin fibroblasts and keratinocytes, hair follicles, cardiac and 
skeletal muscle, and salivary glands 
251, 252
. The androgens, T and DHT are the main AR ligands. 
T is produced in the Leydig cells of the testis. In target tissues it can be converted into the more 
active DHT by 5α-reductase 
253, 254
. 
  In addition to its role in prostate development and maintenance, the AR is involved in prostate 
carcinogenesis. Orchiectomy or inhibition of AR activity by anti-androgens causes shrinkage of 
the normal prostate and of tumor prostatic tissue, including loss of luminal epithelial cells (see 
for review ref. 255). Therefore, AR signaling is an important subject of research. 
 
1.2.1  General features of the AR 
  The AR gene maps to chromosome band  Xq11.2-q12 and is composed of 8 exons spanning 
186 kbp 
256-258
. Two hAR mRNA species of approximately 8.5 and 11 kb have been identified 
256, 259-262
. These transcripts differ only in the sizes of their 3'-UTRs. The AR NTD is encoded by 
part of exon 1. Exons 2 and 3 code for the AR DBD, each for one zinc cluster domain. The AR 
LBD is encoded by part of exon 4, exons 5, 6, and 7, and part of exon 8.  
  The size of the human AR can be variable, due to variation in the length of poly-glutamine and 
poly-glycine stretches in its NTD (Figure 7) 
256, 259
. In the AR from other species these stretches 
are absent or have a considerably different size and are located in a different part of the NTD. 
Amino acid numbering in this thesis corresponds to an AR length of 919 amino acids, as 
employed by The Androgen Receptor Gene Mutations Database 
(http://www.mcgill.ca/androgendb) 
263
.  
  The AR can be phosphorylated in the absence or presence of androgens resulting in isoforms 
displayed as a 110-112-114 kDa triplet in an SDS-PAGE gel. As a result of alternative 
translation initiation, a truncated 87 kDa AR has been found in fetal tissues and genital skin 
fibroblasts 
264, 265
. It constitutes 10% of the total AR protein level, but its in vivo relevance is not 
known. 
  The AR DBD and LBD primary struture are well conserved between species. The AR NTD 
contains only short conserved regions, the homology of amino acid stretches 1-36, 234-247 and 
501-529 are most obvious. These regions are expected to be of functional importance and are 
discussed in the next section.  
 
 
 
 
 
 
 
 
 
Figure 7.  Schematical overview of AR NTD functional subdomains. FXXLF = FXXLF motif, polyQ = poly-
glutamine stretch, polyG = poly-glycine stretch, TAU = transactivation unit.  
TAU-1 
FXXLF poly Q poly G 
TAU-5 
- C N - 
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1.2.1.1  The AR NH2-terminal domain 
  In the AR NTD several functional subdomains have been identified (Figure 7). The NTD 
harbours the transcription activation unit 1 (TAU1). TAU1 comprises a region of approx. 250 
amino acid (aa) residues (100-370) and is active in the full-length ligand activated AR. 
However, in a truncated AR lacking the LBD, another region containing aa 360-485, termed 
TAU5, functions as a constitutively active transactivation domain 
266
. Depending on the cellular 
context, deletion of TAU5 causes a small or more pronounced decrease in activity of the full 
length AR 
266, 267
. In contrast, TAU1 is indispensible for ligand-induced activation of the full-
length AR 
266
. These findings indicate that the unliganded LBD prevents TAU1 activity, which 
is reversed upon ligand binding. Indeed, the TAU1 region by itself shows a constitutive activity 
that is approx. 40% of the activity of the complete NTD 
267
. TAU1 in the rat AR was even 
further narrowed to two regions, AF-1a and AF-1b, which correspond to aa 172-185 and aa 296-
360 in the human AR. Deletion of either subdomain caused a minor reduction of AR 
transcriptional activity, but absence of both AF-1a and AF-1b resulted in a 90% decrease in 
activity 
268
. However, another study indicated that AF-1b was dispensible 
267
.  The importance 
of TAU1 and TAU5 in AR activity is further substantiated by the finding that the NTD is 
essential in p160 coactivator binding. Although the AR LBD can bind to p160 coactivators, the 
AR NTD also interacts with these coactivators. TAU5 directly interacts with the glutamine-rich 
region of SRC-1, whereas TAU1 seems to attenuate indirectly this interaction 
267
. 
  It has been predicted that the NTD contains several small α-helical structures, but a well-
defined structure of the  complete AR NTD could not be established. It is presumed that the AR 
NTD adopts an induced fit conformation in response to binding other proteins, as proposed for 
binding of the general transcription factor TFIIF 
269
. 
 The region aa 234-247, which constitute the most conserved part of AR NTD was found to bind 
to the carboxy terminus of the Hsp70-interacting protein (CHIP), a negative regulator of AR 
(see also section 1.2.2.2) 
270
.  
  The highly conserved region aa 16-36 is predicted to fold in a long amphipathic α-helix, 
indicating a protein-protein interaction domain. Aa 23-27 is located within this region and 
comprise the LXXL-like motif, FQNLF. This motif is essential in the direct ligand-dependent 
interaction between the AR NTD and AR LBD, the so-called N/C interaction. This interaction 
will be extensively discussed in section 1.2.3 and Chapter 2. Some AR coregulators have also 
been found to contain FxxLF motifs, through which they, like the motif in AR NTD, bind to the 
AR LBD coactivator groove, thereby competing with the N/C interaction (reviewed in ref. 271, 
see also section 1.2.2.1). Recently, the melanoma antigen gene protein 11 (MAGE-11) has been 
identified as a protein that interacts with a region in the AR NTD overlapping with the FXXLF 
motif. Binding of MAGE-11 increases AR activity (see section 1.2.2.1) 
272
.  
  The region aa 501-529 is the third part of the NTD that is highly conserved between ARs from 
different species. However, for this region no specific function has been established as yet. 
  In addition to the proteins described above, many other proteins, including other coactivators 
and corepressors, have been found to interact with the AR NTD and influence AR function. An 
overview of these proteins can be found in The Androgen Receptor Gene Mutations Database 
(http://www.mcgill.ca/androgendb) 
263
. A selection of these proteins is given in section 1.2.2.  
 
1.2.1.2  The AR DNA binding domain  
  The AR binds with high affinity to the consensus androgen response element (ARE) 5'-
AGAACAnnnTGTTCT-3', which is shared with the GR, PR and MR. Also, more or less AR 
 26
specific AREs have been reported in the regulary regions of genes that show androgen-specific 
transcriptional regulation. These AREs contain one perfect or almost perfect half-site, whereas 
the second half-site can vary considerable from the consensus sequence (reviewed in ref. 55). 
Based on crystallographic data of the AR DBD bound to an AR specific ARE, the mechanism of 
AR binding to a specific ARE has been elucidated. One AR binds to a high affinity consensus 
half-site, the second AR can have a weaker affinity to the second half-site, because the AR 
DBD, unlike other steroid receptors, contains an additional interface that stabilizes the AR 
dimer/ARE complex. Dimerization strength of the other steroid receptors would not be 
sufficient to retain stable binding to an AR-specific ARE. The orientation of the AR dimer on 
the ARE is in a head-to-head fashion on both non-specific and AR-specific AREs (Figure 8) 
24
. 
More details on this subject are described in section 1.2.4 and Chapter 3.  
  Like other NRs, the AR DBD was found to contain a non-classical NES, which is necessary 
and sufficient for nuclear export, indicating a role for the DBD in nucleo-cytoplasmic shuttling 
of the AR
26
. In addition, a second NES has been postulated in the AR LBD (see section 1.2.1.4) 
45
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.  Overall architecture of the AR DBD complexed to an AR-specific ARE. The two AR DBD subunits are 
in red and blue, repectively, the hexameric ARE half-site is in gold, the spacer and flanking base pairs are black. 
From ref. 24. 
 
1.2.1.3  The AR hinge region 
  The hinge region of the androgen receptor contains a bipartite nucleoplasmin-like NLS (aa 
605-624), which is essential for nuclear import of the receptor 
273, 274
. The NLS is blocked by the 
unliganded LBD, because only in the presence of androgens the AR is transported to the 
nucleus. AR mutants lacking the LBD are constitutively localized to the nucleus. 
  Between aa 628 and 646 a domain has been identified that inhibits AF-2 activity of AR LBD. 
Mutations in this region enhanced the weak (see 1.2.1.4) AF-2 transactivation by TIF2 
indicating that the hinge region plays an inhibitory effect on coactivator-mediated AF-2 function 
of AR 
275, 276
. Alternatively, region 628-646 might bind an inhibitory protein, thereby negatively 
influencing the overall activity of the AR. 
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 1.2.1.4  The AR ligand binding domain 
  Crystallographic data have revealed the three-dimensional structure of the AR LBD (Figure 9) 
277
. Although no helix 2 has been identified, helix numbering is further consistent with the 
general NR 12-helical LBD structure, as was previously predicted by comparison modeling 
278
. 
AR LBD helices 10 and 11 actually form one long helix, and helix 12 appeared to be longer 
than proposed by modeling. The crystallographic structure was elucidated for the AR LBD 
complexed with DHT and complexed with the synthetic androgen R1881. A dynamic structure 
was indicated for the AR LBD, because binding of DHT induced a continuous helix 12, which 
was apparently split into two separate helices upon binding of R1881. Indications for the 
influence of the ligand on LBD conformation were earlier provided in limited proteolytic 
digestion experiments, in which the AR bound to either agonists or antagonists showed protease 
protected fragments of different sizes 
279
. 
  The ligand binding pocket in the AR LBD is primarily formed by 18 amino acid residues 
scattered throughout helices 3, 4, 5, 10 and 11 
277
. The positions of all individual amino acid 
residues relative to the bound ligand have been identified. Substitutions of amino acids that are 
in contact with or in the vicinity of the ligand have been found in prostate cancer specimens and 
in the androgen insensitivity syndrome 
280-282
. These substitutions impair AR function or render 
the AR, also responsive to female sex hormones, glucocorticoids, and even antagonists 
283
. More 
details on AR related diseases and AR ligand specificity can be found in section 1.2.5 and in 
Chapter 4.   
   Like was found for other NRs, helix 12 of the AR LBD is folded like a lid over the ligand-
binding pocket when occupied with an agonist 
277
. The resulting conformation of the LBD 
provides an interface for coactivator binding. In case of antagonist binding, the resulting 
conformation might lead to corepressor recruitment and/or inhibition of coactivator binding. 
However, although the coactivators SRC-1, TIF2 and GRIP1 can bind to the AR LBD through 
their LXXLL motifs, this binding is not essential for AR function. This is reflected by an AR 
deletion mutant lacking the NTD, that can itself not be activated by androgens 
266
. This mutant 
needs overexpression of a p160 coactivator to be activated, indicating very weak AR AF-2 
activity 
40, 284
. 
  Although p160 coactivator binding to the AR LBD might not be essential for full length AR 
function, different LBD conformations induced by different ligands might influence coactivator 
binding to the NTD. Indications for this were found in interactions with coregulators. The anti-
androgen bicalutamide (BCA) is unable to activate the AR. It cannot induce coregulator 
recruitment, although a BCA-bound AR is able to bind to DNA 
285, 286
. However, as indicated by 
FRAP experiments the time period of interaction with DNA is very short 
287
. Cyproterone 
acetate (CPA) elicits a transcriptionally productive AR-GRIP1 interaction, reflecting its partial 
antagonistic character. CPA was also found to induce recruitment of the corepressor SMRT to 
the AR NTD 
288
. So, the outcome of CPA activity may depend on the ratio of coactivators and 
corepressors present in a cell.  
  A separate category of AR coregulators, including ARA54, ARA70 and RAD9 (see section 
1.2.2), were found to bind to the LBD through their FXXLF motifs, which are related to the 
LXXLL motifs found in most coactivators 
289
. An FXXLF motif (see also section 1.2.1.1), 
which can bind to the AR LBD, was also found in the NTD. This motif establishes a ligand-
dependent interaction between these two domains, the N/C interaction. This interaction might 
contribute to AR activity, dependent on the promoter context 
290
. 
  The AR LBD shows a preference for FXXLF motifs over LXXLL motifs. Computer modeling 
and crystallographic analyses of AR LBD bound to FXXLF and LXXLL motif containing 
 28
peptides, have revealed a larger coactivator groove for the AR LBD compared to the ER-LBD. 
This larger groove provides suitable contact sites for the bulky phenylalanine side chains of the 
FXXLF motif, whereas LXXLL motifs have less favorable interactions with the amino acids 
lining the AR coactivator groove 
162, 291, 292
. Detailed information on the N/C interaction and 
FXXLF motifs can be found in section 1.2.3 and Chapter 2.  
  An AR NES is localized in the AR LBD between amino acids 742 and 817. In the absence of 
ligand, this NES is active and dominant over the NLS in the hinge region (see previous section). 
Ligand binding inhibits the NES and simultaneously releases repression of the NLS, leading to 
an increase of AR nuclear localization 
45
. The AR LBD also plays an important role in 
stabilization of AR-DNA interaction as revealed by  FRAP analysis 
293
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.  AR LBD helical structure. Numbers of the helices are indicated, coact = helix of a coactivator that 
interacts with the coactivator groove, androgen molecule is in red. 
 
1.2.2  AR coregulators 
  Many proteins have been found to interact with the AR. A portion of these proteins was 
identified as AR coregulators, either coactivator or corepressor. In addition, a number of 
proteins have been descibed that do not interact directly with the AR, but can indirectly 
influence receptor activity. These proteins might also be considered as AR coregulators. An 
overview of AR-interacting proteins is presented in the AR mutations database 
(http://www.mcgill.ca/androgendb) 
263
. In this section, an overview of AR coactivators and 
corepressors is given, in Tables 1 and 2, respectively. Selected proteins are discussed in sections 
1.2.2.1 and 1.2.2.2.  
9
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1.2.2.1  AR coactivators 
  The most studied group of NR coactivators is the family of p160 (SRC) proteins. All three 
members are capable of enhancing AR activity. SRC-1 and TIF2 (SRC-2) were found to bind to 
the ligand-activated AR LBD through their LXXLL motifs, but this interaction, as compared to 
other NRs, is weak. SRC-1 also binds to the AR NTD region 360-494 (TAU5) through its 
glutamine-rich region, which is essential for its recruitment, whereas the LXXLL motif is 
dispensable for coactivation of the AR 
108
. However, depending on the promoter context, 
LXXLL-guided SRC-1 binding to the AR LBD contributes to the total AR activity 
136
. 
  Male SRC-1 knockout mice do not display a significant androgen-insensitive phenotype 
114
. 
They are fertile, but their testes are smaller than those of wild-type mice. Androgen treatment of 
castrated SRC-1 knockout mice showed prostate growth albeit less if compared to wild-type 
castrated mice. These data suggest compensation of the SRC-1 absence by other coactivators. 
Indeed, in SRC-1 knockout mice the TIF2 mRNA level is elevated 
114
. This might explain why 
the SRC-1 knockouts showed normal fertility. Combinatory knockout models have provided 
more insight in the redundancy of SRC coactivators. SRC-1
-/-
/TIF2
-/-
 mice, which were not 
viable after birth, and SRC-1
+/-
/TIF2
-/-
 mice showed severe testis degeneration. The latter were 
sterile, whereas SRC-1
+/+
/TIF2
-/-
 mice were hypofertile 
130
. These findings indicate that SRC-1 
can partially compensate for the lack of TIF2 in a dose-dependent manner. Also SRC-3 seems 
important in androgen-regulated development of the male phenotype, since its glutamine-repeat 
was found to be shorter in undermasculinized subjects 
294
. This observation might indicate 
absence of redundancy by SRC-1, TIF2 or non-SRC coactivators. However, details of the 
mechanism of inhibition of AR function by the shortened poly-glutamine stretch in SRC-3 
remains to be established. More recently it has been reported that in a transgenic mouse model, 
in which the AR DBD was swapped by the Gal4-DBD, AR
GAL4DBD
 mice, the AR activity in 
testes was decreased in a TIF2 +/- background, and even more decreased in TIF2 null mutants 
compared to wild type. However, SRC-1 +/- mice showed no significant changes in AR
GAL4DBD
 
activity. These findings indicate that TIF2 might serve as the preferential coactivator of AR in 
the testis 
295
. 
  The general coactivator CBP, SRC-1, and AR are coexpressed in luminal epithelial cells of the 
prostate and in a subpopulation of prostate stromal cells. If transfected in CV-1 cells, CBP 
enhances AR-dependent transcription. Coimmunoprecipitation experiments have revealed that 
the AR and CBP can be found in the same multi-protein complex. An AR deletion mutant 
lacking the LBD and region aa 38-296 of the NTD is still capable to bind CBP, indicating a 
ligand-independent interaction 
296
. 
  Tip60 (Tat-interactive protein, 60 kDa), first identified in complex with the Tat protein of the 
human immunodeficiency virus-1, is an NR type III-specific coactivator 
297, 298
. It displays HAT 
activity and can directly acetylate the AR, which is necessary for Tip60-mediated AR 
coactivation 
299, 300
. PIRH2 can interact with both Tip60 and the AR, and enhances AR activity 
301
. PIRH2 also binds to the AR corepressor HDAC1, which leads to inhibition of transcriptional 
repression 
301
. 
  AR-associated protein 70, ARA70, binds to the AR LBD and was shown to enhance androgen-
induced AR transcriptional activity 
302
. Overexpression of ARA70 changes the AR antagonists 
OH-FL and BCA into agonists and it also induces AR transcription at physiological E2 
concentrations in females 
303-305
.  
  ARA55 binds to the AR LBD and, when hypophosphorylated, is thought to act as an AR 
coactivator in the nucleus 
306, 307
. Like ARA70, it can enhance the AR(T877A) mutant response 
to OH-FL 
305
. The phosphorylated form of ARA55 is found in focal adhesions that are 
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connected with the extracellular matrix 
307, 308
. This property indicates that phosphorylated 
ARA55 might be involved in regulation of anchorage-dependent growth, differentiation and 
apoptosis. ARA55 contains LIM domains known as protein-protein interaction sites, but it is not 
known whether ARA55 recruits other coregulators via these domains 
309
. 
  ARA70, ARA55, and ARA54 contain the LXXLL-related motif FXXLF (see sections 1.2.1.1 
and 1.2.1.4). The FXXLF peptide motifs of ARA70 and ARA54 specifically bind to the AR 
LBD. However, the ARA55 FXXLF motif was unable to bind to the AR LBD, indicating that 
other regions in ARA55 are responsible for AR interaction 
289
. FXXLF and related motifs will 
be discussed extensively in section 1.2.4.  
  ARA267β, which is homologous to mouse NSD1 (NR-binding SET(Su(var)3-9, Enhancer of 
Zeste, and Trithorax)-domain-containing protein), and its amino-terminal shortened isoform, 
ARA267α, can bind both the AR NTD and AR LBD and enhance DHT induced transcription 
310
. Both ARA267 proteins contain a SET domain, which is known to interact with components 
of the SWI/SNF complex. Whether the SET domains of the ARA267 proteins play a role in the 
recruitment of the SWI/SNF complex to the AR remains to be established. NSD1 contains an 
FXXLL motif, through which it can bind to the AR LBD 
311
. 
  MAGE-11 (see also section1.2.1.1) has been identified as a protein that binds to the region in 
the AR NTD that contains the FXXLF motif. It stabilizes the unliganded AR and in the presence 
of an agonist it competes with the N/C interaction, thereby increasing the exposure of the LBD 
coactivator groove to the recruitment and activation by coactivators 
272
. 
  Two related AR coactivators, PIASαx and PIAS1, are members of the protein inhibitor of 
activated signal transducer and activator of transcription (STAT) family. STATs are 
transcription factors that are phosphorylated in response to interferon, interleukines, and EGF 
312
. So, it is possible that the PIAS proteins mediate cross-talk between cytokines and androgen 
signalling, but AR activation by these proteins may also be a distinct regulatory process. PIAS1 
is a target of androgen receptor-interacting nuclear kinase (ANPK) and is expressed in Sertoli 
and Leydig cells, and in spermatogenic cells 
313, 314
. PIASxα, identified as androgen receptor 
interacting protein 3 (ARIP3), is also expressed in the testis and was found to facilitate the AR 
N/C interaction (see section 1.2.4) 
315
. PIAS proteins contain amino-terminal LXXLL motifs 
and bind to the AR in an androgen-dependent manner. The LXXLL motifs of PIASxα were 
found to interact with GRIP1, but it is not clear as yet whether the motifs are also involved in 
AR binding 
176
.  
  Filamentous actin (F-actin) binding proteins β-catenin, gelsolin, supervillin, and filamin-A 
determine cell morphology by regulating actin polymerization and depolymerization. β-catenin 
also acts as a coactivator of downstream transcription factors of the Wnt signalling pathway 
316
.  
Interactions between the Wnt and AR signalling pathways, can both activate or inhibit AR 
activity 
317, 318
. β-catenin was found to function as an AR coactivator in prostate cancer cells 
319
. 
The histone methyltransferase activity of CARM (see section 1.2.2.4) can function in synergy 
with β-catenin and p300 as a coactivator of the AR. Through β-catenin, CARM1 binds 
indirectly to the AR, but no methylation of AR has been found 
76
. The exact AR coactivating 
mechanism of CARM1 is still to be elucidated. Recently, β-catenin was found to be involved in 
insulin-like growth factor 1 (IGF-1) mediated activation of the AR 
320
. Gelsolin interacts with 
the AR LBD by an FXXFF motif in a T-dependent manner and functions as an AR coactivator 
in the prostate cancer cell line DU145 
321, 322
. Supervillin can coactivate the AR and binds to 
both the AR NTD and AR LBD 
88
. It also activates the GR and is predominantly localized to the 
plasma membrane at sites of intercellular contacts 
323
. This suggests a role for supervillin in 
transducing signals from cellular adhesion sites to the nucleus, thereby influencing NR function. 
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Filamin-A is a protein that can cross-link F-actins. It can also interact with the AR hinge region. 
Mutant filamin-A disables the AR to translocate to the nucleus, thereby inhibiting AR regulated 
transcription 
324
. 
  Androgen receptor trapped clone 27, ART27, is an AR coactivator that binds to the AR NTD. 
It is expressed in prostate epithelial cells, in muscle, and in breast tissues, but not in AR positive 
stromal cells of the prostate 
325
. ART27 is associated with growth suppression and cell 
differentiation, which is illustrated by its enhancement of PSA production 
326
. 
  The four and a half of LIM-only protein 2 (FHL2) is an AR coactivator that is predominantly 
expressed in the heart and to a lesser extent in epithelial and stromal prostate cells. FHL2 
requires the full-length AR to enhance its activity 
327
. It contains an FXXLF motif, but a peptide 
fragment with this motif is unable to interact with the AR LBD 
289
. FHL2 interacts also with β-
catenin (see above), but stimulation of AR activity by both FHL2 and β-catenin was found to be 
additive and not synergistic 
328
.  
  The ubiquitin-protein ligase E6 associated protein (E6-AP) (see also section 1.2.3) has an 
intrinsic transactivation function, and can act as a coactivator for RARα, TR, ER, PR, GR and 
AR, in a ligand-dependent manner. Coactivation is independent of the ubiquitylation capacity of 
this enzyme, which indicates that coactivation and ubiquitylation are distinct processes 
329
. It 
could be presumed that the ubiquitinating activity contributes to NR activity by targeting 
degradation of corepressors, as was found for NCoR, or it could be involved in degradation of 
components of the preinitiation complex, thereby facilitating reinitiation of transcription. The 
AR interaction domain of E6-AP has not been identified as yet. Ubc9 (or UBE2I) (see also 
section 1.2.3) is related to the ubiquitin-conjugating enzymes and can act as a coactivator for the 
ligand-bound AR. Instead of ubiquitylation, Ubc9 rather is involved in covalent linking of 
SUMO-1. Similar to E6-AP, the coactivation function of Ubc9 is independent of its sumoylation 
capacity. Ubc9 binds to the AR DBD-hinge region 
172
. 
 
Table 1. AR coactivators. Modified and extended from ref. 271. 
Coactivator Alternative name Binding  to Comments References 
SRC-1 NCoA-1, p160 NTD, DBD, 
LBD 
Enhances AR N/C interaction; Interacts with 
CBP/p300; General nuclear receptor coactivator; Weak 
acetyltransferase activity. 
66, 99, 108, 
136, 330 
TIF2 GRIP1,NcoA-2, 
SRC-2 
NTD, DBD, 
LBD 
General nuclear receptor coactivator; Facilitates AR 
N/C interaction. 
100, 104, 284, 
331 
SRC-3 AIB1, NcoA-3, 
ACTR, p/CIP, 
Rac3, TRAM1 
unknown Enhances transcription by AR,  PR, TR and RAR; 
Interacts with CBP/p300; Acetyltransferase activity. 
65, 101, 303, 
332 
Tip60 - hinge-LBD Acetylates AR; Also coactivates PR and ER; Family 
member of the MYST/SAS histone acetyltransferases.  
298-300 
hPIRH2 - unknown Binds to AR, Tip60, and HDAC1. Enhances AR by 
reducing HDAC1 protein levels 
301 
SNURF RNF4 DBD RING finger protein; Interacts with AR, ER and PR; 
May recruit cromatin remodeling factor HMGI(Y). 
313 
ARA54 - LBD Ring finger protein; Ligand dependent coactivator of 
AR and PR.  
333 
ARA55 Hic5 LBD Contains a LIM domain; Ligand dependent coactivator 
of AR, PR, GR and ER. 
289, 305-307, 
309, 334 
ARA70 ELE1, RFG DBD, LBD Ligand dependent coactivator of AR, GR, ER and 
PPARγ; Bridging factor to p/CAF and TFIIB. 
302-305, 335, 
336 
FHL2 DRAL, Slim3 unknown Ligand dependent and prostate-specific coactivator of 
AR; LIM only protein. 
327, 328 
ARA160 TMF NTD Enhances AR, PR and GR function; Synergistic with 
ARA70. 
337 
ARA267β NSD1 NTD, LBD Interacts with AR, ER, TR, RAR and RXR; Contains 
SET and domains ARA267α is N-terminal shortened  
ARA267β 
310, 311 
ARIP3 PIASαx DBD Facilitates AR N/C interaction; represses transactivation 
of the probasin promoter at high levels (AR:ARIP3 = 
1:200) 
315 
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Coactivator Alternative name Binding  to Comments References 
1:200) 
PIAS1 - DBD, LBD Coactivator of AR and GR, but a corepressor of PR; 
Expression in rat testes at onset of spermatogenesis 
314 
E6-AP - unknown Interacts with AR, ER, PR and GR; Ubiquitinylates 
target protein, which is separate from coactivation. 
329 
Ubc9 - DBD-hinge Interacts with AR and GR; Sumoylates target protein, 
which is separate from coactivation.  
172, 338 
Gelsolin - LBD Enhances AR in prostate and muscle cells; Actin 
filament severing and capping protein. 
321 
Caveolin-1 - NTD, LBD Membrane protein associated with caveoli membrane 
structures. 
339 
β-catenin - unknown Ligand dependent coactivator; Also interacts with 
FHL2 to activate Wnt-responsive genes (independent of 
AR). 
319, 320, 328 
Filamin-A - hinge Involved in AR nuclear import; Represses AR function 
by interfering with the N/C interaction and competing 
for TIF2.  
324, 340 
Supervilin - NTD, LBD Interacts with AR and GR; Actin-binding protein. 88 
ANPK PKY DBD Stabilizes AR protein 313 
ARA24 Ran NTD Interacts with AR NTD polyglutamine repeat. 341 
BRCA1 - NTD, LBD Enhances AR transcription synergistically with ARA55 
and ARA70. 
342 
BRCA2 - NTD, LBD Enhances AR function, which may be antiproliferative 
in (male) breast cancer. 
343 
Cyclin E - NTD Enhances AR activity independent of cell cycle 
progression. 
344 
pRb - NTD, DBD Tumor suppressor; Enhances AR transcription and 
represses TR by binding to the TR coactivator Trip230 
(hMED12).  
345 
BAG-1L - unknown Enhances AR activity; Regulates Hsp70 function. 345 
Hsp40 dnaJ, ydj1p LBD Mutation of Hsp40 in yeast reduces AR transactivation; 
Member of the chaperone heterocomplex. 
346, 347 
CBP p300 NTD, DBD Facilitates AR N/C interaction; interacts with SRC 
family members; acetyltransferase activity; Coactivator 
of multiple transcription factors. 
296, 330, 348 
RIP140 - NTD, DBD, 
LBD 
Coactivator at low receptor-coactivator ratios, but 
repressor at high ratios; Influences activity of AR, ER, 
PPARα and PPARγ 
349 
ZAC1 - LBD Interacts with AR, GR, ER and TR; AR coactivator in 
HeLa cells (synergistic with TIF2) and AR corepressor 
in 1471.1 cells.  
350 
PGC-1 LEM6 unknown General nuclear receptor coactivator. 351 
SRA - unknown Enhances transcription of AR, PR, GR and ER; 
Functions as a RNA transcript and associates with an 
SRC-1 containing coregulator complex. 
352 
RAF IDE NTD Enhances AR and GR DNA binding. 353 
HMG-1/-2 - unknown Enhances DNA binding of AR, PR, GR and ER; 
Abundant chromatin-associated protein; Does not 
recognize a specific DNA binding sequence. 
354 
MAGE-11 - NTD Binds  the AR NTD FXXLLF motif; Competes with the 
AR N/C interaction; Stabilizes the unliganded AR   
272 
ART-27 - NTD Associated with growth suppression and cell 
differentiation of prostate epithelial cells, low or 
negligible levels in prostate cancers showing 
dedifferentiation. 
325, 326 
CARM1 - indirect Functions in synergy with β-catenin and p300; Binds 
through β-catenin indirectly to the AR; Overexpressed 
in prostate carcinoma. 
355, 356 
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1.2.2.2  AR corepressors 
  Although the number of identified AR corepressors is less than that of AR coactivators, the list 
of AR inhibiting proteins is still growing 
357
. The best-studied AR corepressors so far are NCoR 
and SMRT.  
  AR transcription activity can be inhibited by cotransfection of small amounts of the 
corepressor NCoR in the presence of partial antagonists, higher NCoR expression levels can in 
the presence of agonists even inhibit AR activity 
358, 359, 360
. Possibly NCoR can easily compete 
with coactivators for binding to the agonist-bound AR, because interaction of coactivators with 
the AR LBD via its coactivator binding groove is not strong 
358
. These results indicate that AR 
activity will not only be determined by the presence of agonists and/or (partial) antagonists, but 
also by the ratios of coactivators and corepressors in a cell. The partial antagonist CPA and the 
antagonist OH-FL show agonistic activities for the AR mutant T877A, present in the lymph node 
derived prostate cancer (LNCaP) cell line. These activities were hardly affected by NCoR. 
However, cotransfection of the coactivator TIF2 strongly enhanced the activity of the AR-
mutant 
359
. This indicates that the antagonist-bound T877A mutant preferentially binds to 
coactivators reflecting its activation by antagonists. NCoR mediated repression of AR seems 
independent of HDACs, as was shown by deletion of the HDAC-interacting domain of NCoR 
358
. Both the AR NTD and LBD are required for NCoR binding, which is dependent on the 
CoRNR boxes and independent of ligand and helix 12 
358, 360
. The observations that AR and 
NCoR are present in the same complexes, as shown by co-immunoprecipitation and ChIP 
analysis of endogenous proteins, is strong evidence that NCoR is of relevance for regulation of 
AR function under physiological conditions 
358, 360
. 
  Like NCoR, SMRT can bind to both the AR NTD and LBD. It interacts with the LBD via the 
RID2 corepressor motif. This interaction is enhanced by the presence of the AR DBD-hinge 
region 
361
. SMRT binding to the AR can occur in CV1 cells in the presence of R1881 or the 
partial antagonist CPA, but not with the antagonists BCA or OH-FL 
288
. However, in human 
kidney 293 cells SMRT can be recruited to the AR in the presence of OH-FL or BCA, indicating 
cell-dependent SMRT function 
361, 362
. SMRT weakly decreases AR activition by agonists, but 
strongly enhances the AR inhibiting activity of (partial) antagonists 
288, 361
. In addition, the 
antagonist mifepristone (RU486) induces binding of the AR to SMRT, and also to NCoR. This 
interaction seems even stronger than that induced by CPA, OH-FL and BCA 
363
. It was also 
found that the coactivator SRC-1 can compete with SMRT for binding to the AR NTD, 
indicating a modulating role for relative coregulator levels in AR function 
364
.  
  RAD9, a member of the Rad family of checkpoint proteins involved in DNA damage 
detection, DNA repair, and cell cycle arrest, was found to interact with the AR LBD. An 
FXXLF motif in the C terminal region of RAD9 mediates this interaction, thereby inhibiting the 
AR N/C interaction 
365
. In this way, cross talk between checkpoint proteins and AR signalling 
can occur.  
  Dosage-sensitive sex reversal adrenal hypoplasia congenita critical region on the X-
chromosome gene I (DAX1) is an atypical nuclear receptor, lacking a DBD 
366
. It binds to the 
AR LBD and can sequester the AR in the cytoplasm 
367
.  
  Short heterodimeric partner (SHP) is an orphan nuclear receptor that can bind to the AR NTD 
and LBD and inhibits the activation functions of both AR subdomains. Through its LXXI/LL 
motifs SHP binds to the AR LBD in an androgen-dependent manner. SHP was shown to 
compete with the AR coactivators TIF2 and FHL2 for AR LBD binding 
368
. SHP induced AR 
repression was found to be mediated by recruitment of HDACs 
369
.   
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  The highly conserved region aa 234-247 was found to have an AR inhibiting function if bound 
to CHIP (see also section 1.2.1.1). CHIP binds to the unliganded AR, which might promote AR 
degradation 
270
. Two mutations, A234T and E236G (see also 1.2.5.2.3), detected in a transgenic 
mouse prostate cancer model, reduced the interaction with CHIP 
370
.  
 
Table 2.  AR corepressors. Modified and extended from ref. 357. 
Corepressor Alternative name Binding to Comments References 
ARR19 - DBD Inhibits AR activity by recruitment of HDAC4; co-
translocates in the nucleus with AR 
371 
DJBP - DBD Recruits  a HDAC1 and mSin3A containing complex. 372 
HDAC1 - DBD-LBD Inhibits AR activity; no effect on AR protein levels. 300, 373 
NCoR - LBD Antagonist-dependent corepressor; competes with 
TIF2; binding to AR depends on corepressor nuclear 
receptor boxes, but is independent of ligand. 
358-360 
PIASγ - unknown Represses AR activity independent of its sumoylation 
activity, probably by recruiting HDACs. 
374 
SMRT 
 
- NTD, LBD Ligand-dependent corepressor by inhibiting AR N/C 
interaction and competing for p160 coactivators.  
288, 361-364 
TGIF - DBD Represses AR activity through the HDAC pathway 375 
Calreticulin - DBD Corepresses AR, GR, RAR and RXR; inhibits DNA 
binding and transcription. 
376 
Tip110 - LBD Binds to AR through its LXXLL motif; prevents  
binding of AR to AREs. 
377 
DAX1 - LBD Inhibits ligand-dependent transactivation and AR N/C 
interaction; relocalizes AR in nucleus and cytoplasm; 
inhibits ER and SF1. 
367 
LATS2 KPM LBD Inhibits AR N/C interaction; lower expression in 
prostate tumors than in normal prostate. 
378 
RAD9 - LBD FXXLF motif within C-terminus; interrupts AR N/C 
interaction. 
365 
ARA67 PAT1 NTD (strong), 
DBD, LBD 
Promotes cytoplasmic retention of AR. 379 
PAK6 - hinge, LBD Inhibits nuclear translocation of the ligand-bound 
AR; also inhibits ER. 
380-382 
Akt - unknown Phosphorylates the AR; represses AR-ARA70 
binding 
383, 384 
PTEN - DBD Inhibits AR via a PI3K/Akt independent pathway in 
early passages of LNCaP cells. 
384, 385 
CHIP - NTD Binds to the unliganded AR, which is thought to 
promote AR degradation  
270, 370 
Cyclin D1 - unknown Reduces AR activity independent of cell cycle 
progression; coactivator of ER. 
386, 387 
HBO1 - DBD, LBD Ligand-dependent corepressor; member of the 
MYST/SAS protein family. 
388 
RIP140 - NTD, DBD, 
LBD 
Coactivator at low receptor-coactivator ratios, but 
repressor at high ratios; influences activity of AR, 
ER, PPARα and PPARγ 
349 
SHP - NTD. LBD LXXLL motif mediated interaction with AR LBD; 
inhibits AR and ER. 
368, 369, 389 
SMAD4 - DBD, LBD Inhibits SMAD3-enhanced AR activity by decreasing 
AR-SMAD3 interaction.  
390-392  
SRY - DBD Inhibits AR activity. 393 
TR2 - unknown Inhibits androgen-mediated transactivation in PC3 
cells; overexpression causes suppressed PSA 
expression 
394 
ZAC1 - LBD Interacts with AR, GR, ER and TR; AR coactivator in 
HeLa cells (synergistic with TIF2) and AR 
corepressor in 1471.1 cells.  
350 
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1.2.2.3  The AR in transcription regulatory complexes 
  During the last decade many studies have addressed the question of AR function in cooperation 
with the plethora of transcription regulatory proteins. Data are ranging from direct interactions 
with coactivators and corepressors through complex participation in chromatin remodeling, 
Mediator function, and ultimately to recruitment and activation of the general transcription 
machinery. In the majority of the studies on this subject the PSA promoter and enhancer have 
been used as AR target. A comprehensive overview of the relationship between the AR and 
transcription regulatory complexes is given below.  
AR regulated recruitment of coregulators 
  In several studies the complex process of recruitment of coregulators to AR regulated genes 
has been described, however, the outcomes of the different studies are in some cases conflicting. 
First, it has been shown that androgens induce recruitment of TIF2, SRC-3, and CBP/p300 to 
the prostate specific antigen (PSA) enhancer. ChIP experiments in LNCaP cells revealed that the 
coactivators are preferentially recruited to the strong 4 kbp upstream enhancer of the PSA gene 
and much less efficiently to the proximal PSA promoter. Remarkably, promoter-independent 
recruitment of RNApolII to the enhancer and subsequent induction of transcription has been 
observed. SRC-3 was found to facilitate RNApolII recruitment 
395
. A second study revealed that 
for both PSA and the closely related kalikrein gene KLK2 more AR is loaded onto the enhancers 
than onto the promoters, but the residence time of the AR on the enhancers was more transient 
396
. However, in contrast to the previous study, RNApolII was found to be assembled on the 
promoters. The reason for this discrepancy is not understood. Binding by different anti-
androgens resulted in different AR occupation on enhancer/promoter regions: BCA-bound AR 
is able to bind to the PSA promoter, but not to the enhancer, whereas the partial antagonists CPA 
and RU486 were capable of promoting AR loading on both the PSA enhancer and promoter 
396
. 
CPA and RU486, but not BCA, bound AR led to occupation of both the PSA enhancer and 
promoter by GRIP1, p300, and RNApolII. Like BCA, CPA and RU486 were also able to induce 
recruitment of NCoR to the PSA promoter. Consistent with these findings, treatment with the 
pure anti-androgen BCA does not result in histone acetylation 
396
. 
  In an earlier report androgen-induced association of RNApolII with both the PSA promoter and 
enhancer has been described 
362
. However, quantitative differences between both AR target 
regions were not addressed. Based on this study a model was proposed in which protein-protein 
contact between the PSA enhancer and promoter is via RNApolII, thereby looping out the 
interval DNA. A scenario of a 'facilitated tracking' mechanism was proposed, whereby 
RNApolII trails from the enhancer along the entire 4 kb PSA upstream sequence to the promoter 
395
. This would be in accordance with the finding that the AR can reside for a longer time period 
on the promoter and RNApolII mainly occupies the promoter, indicating an analysis time point 
at which AR and RNApolII have reached the end point of the 'preinitiation trail' 
396
.  
AR interplay with components of chromatin remodeling complexes 
  Although many aspects of chromatin remodeling in AR function remain to be elucidated, a few 
of the large number of components of chromatin remodeling complexes have been identified to 
be directly involved in AR function.  
  An interaction of AR with Brahma (BRM), one of the core ATPases of the SWI/SNF 
chromatin remodeling complex, was found, correlating with the agonistic or antagonistic 
properties of the tested ligands 
397
. The two largest subunits of the human SWI/SNF chromatin 
remodeling complex, hOsa1, which is identical to BRM related gene 1(BRG1)-associated factor 
250 (BAF250) or ARID1A, and hOsa2 , which is similar to hOsa1, were found to stimulate AR 
and GR transcriptional activity 
398
. Both Osa proteins can interact with hBRM and BRG1, which 
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are necessary for activation of the PSA promoter, but addition of the PSA enhancer sequence to 
the reporter gene overruled this requirement. In contrast, the promoter of the probasin gene 
maintained a low activation level in the absence of SWI/SNF. Addition of the PSA enhancer to 
the probasin promoter did not bypass the requirement of the chromatin remodeling complex to 
achieve increased AR induced activation of this promoter 
399
. These findings suggest different 
mechanisms of chromatin remodeling for enhancer and promoter regions and also for different 
promoters. 
  BAF57 is an accessory component of SWI/SNF that can directly bind to the AR. It is recruited 
to endogenous AR targets such as the PSA enhancer upon ligand activation, and loss or 
inhibition of BAF57 inhibits AR activity 
400
.  BAF57, together with hBRM, was found to be 
required for the proliferation of androgen-dependent prostate cancer cells 
400
. In addition, 
BAF57 can cooperate with p160 coactivators and ARA70 and ARA55 to activate transcription 
of AR target genes 
400
.   
  SWI3-related gene product (SRG3), a component of the mouse SWI/SNF complex, is a 
homologue of human BAF155 and recruits SRC-1. Coactivation of the AR by SRG3 is 
independent of BRG1 and BRM, indicating that the complete SWI/SNF complex is not required 
401
. 
  AR interaction protein 4 (ARIP4) is a SNF2-like protein with DNA-dependent ATPase 
activity. It was found to modestly enhance AR activity on minimal promoters, but not on the 
probasin promoter 
402
. It remains to be established whether ARIP4 is needed for activation of 
AR regulated natural promoters. 
AR interactions with the Mediator complex  
  Ligand-dependent transcription by the AR in LNCaP cells was found to be enhanced by the 
TRAP220 (MED1, according to the unified nomenclature for Mediator subunits 
86
), TRAP170 
(MED14), and TRAP100 (MED24) components of the Mediator complex 
403
. In lysates from a 
Hela-derived cell line, E19, pull-down experiments have shown that in the presence of T or DHT 
the AR directly binds to TRAP220 through its LBD. ChIP assays have revealed that TRAP220 
is recruited to the PSA promoter in R1881 treated LNCaP cells 
403
. 
AR interactions with the general transcription machinery 
  Three components of the general transcription machinery have been identified that interact 
with the AR. These are the general transcription factors II F and H (TFIIF, TFIIH) and the 
positive transcription elongation factor b (P-TEFb). 
  AR NTD strongly binds to the TFIIF subunit RAP74 (TFIIF is a tetramer of two RAP74 and 
two RAP30 subunits), modest binding was found with the TFIIF subunit RAP30 
404
. RAP74 to 
AR NTD interaction, which is mainly via the C-terminal domain of RAP74, resulted in 
increased protease resistance of the AR NTD, indicating that the assumed flexible structure of 
this AR subdomain can fold into a more stable conformation upon interaction with TFIIF 
269, 405
.  
  The highly conserved AR NTD region 224-258 contains several conserved hydrophobic 
residues that are involved in TFIIF binding: M244, L246, and V248 
406
. Outside this region also 
S159, S162, S340, and S343 were found to be involved in binding to TFIIF 
405
. So, interaction 
sites for TFIIF are scattered throughout TAU1 in the AR NTD. None of the residues involved in 
TFIIF binding are binding sites for SRC-1, because this coactivator binds to the C-terminal part 
of the AR NTD, aa 360-494, which includes TAU5 
108
. The distinct binding sites for TFIIF and 
SRC-1 enable the AR NTD to make multiple protein-protein interactions simultaneously with 
coactivators and components of the general transcription machinery 
405
. TFIIF was found to play 
a role in cooperation with TFIIE and TFIIH to overcome stalling of RNApolII after the 
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formation of the initial phosphodiester linkage 
407
. So, the AR might be linked to transcription 
elongation through TFIIF binding. 
  TFIIH contains a kinase moiety, CAK, that interacts with AR NTD and enhances AR activity. 
This interaction may provide efficient communication between AR, GTFs and RNApolII. 
Transfection of CAK in LNCaP and PC3 cells enhanced AR activity in a ligand-dependent 
manner, whereas in DU145 cells AR activation by CAK was ligand-independent. It was 
suggested that CAK can phosphorylate the AR, thereby enhancing the activity of the receptor 
408
.  
  The AR can interact with PITALRE, a kinase subunit of P-TEFb. Mutation of this kinase 
resulted in preferential inhibition of AR-mediated transcription activation. A nuclear run-on 
transcription assay of the PSA gene revealed that transcription efficiency of the distal region of 
this gene was increased after androgen treatment 
409
. So, interactions of AR with TFIIF and P-
TEFb are both suggested to influence transcription elongation. 
  AR NTD was also shown to bind to the general transcription factor TATA binding protein 
(TBP) 
404
. The second largest subunit of RNApolII (RPB2) is able to bind to the AR and can 
enhance AR transactivation 
410
. However, more detailed information of these interactions is 
lacking.  
1.2.2.4  Post-translational modifications of the AR 
  AR function can be regulated by post-translational modifications like phosphorylation, 
acetylation, ubiquitinylation, and sumoylation. 
  Phosphorylation mainly occurs at the AR NTD 
411
. Serines at positions 16, 81, 256, 308 and 
424 are phosphorylated in an androgen-dependent manner, whereas S94 is constitutively 
phosphorylated. Phosphorylation of S650 in the hinge region is also induced by androgens and 
necessary for optimal AR activity depending on cell and promoter context. Specific agonists 
might differentially regulate the AR phosphorylation status. The functional role of AR NTD 
phosphorylation is not clear yet. PKA, PKC and epidermal growth factor (EGF) up-regulate the 
androgen-induced phosphorylation of S650, and can also phosphorylate the AR independent of 
androgen. This strongly suggests that kinase pathways influence AR function by ligand-
independent AR activation or by sensitization of the AR to reduced ligand levels 
412, 413
. 
Apparently, cross-talk occurs between androgen and growth factor signaling pathways 
414
. 
  E6 associated protein (E6-AP) (see also section 1.2.2.1) is an E3-type ubiquitin-protein ligase 
with an intrinsic transactivation function. It can function as a coactivator of many NRs, 
including AR, in a ligand-dependent manner. However, this coactivation is independent of the 
ubiquitinylation capacity of this enzyme 
329
. A defect in the E6-AP ubiquitinylation function 
causes the Angelman syndrome, a genetic neurological disorder, but a role of disturbed AR 
ubiquitylation in this disease has not been established 
415, 416
. Recently, the proto-oncogene 
Mdm2 E3 ligase has been shown to catalyze AR ubiquitylation and proteolysis in vivo. ChIP 
analysis has revealed that Mdm2 associates with the PSA promoter and is a component of a 
promoter-bound multi-protein complex  containing AR and HDAC1 
417
. 
  Ubc9 (see also section 1.2.2.1) is a homologue of the E2-type ubiquitin-conjugating enzymes 
and was found to act as a coactivator of the ligand-bound AR. In stead of ubiquitylation, Ubc9 
rather is involved in covalent linking of the small ubiquitin-like molecule-1 (SUMO-1). Similar 
to E6-AP, the coactivation function of Ubc9 is independent of its sumoylation capacity. Ubc9 
binds to the AR DBD-hinge region and has been shown to sumoylate the AR at K386 as the 
principal sumoylation site and to a lesser extent K520 
172
. A corresponding lysine in the PR 
(K388) can also be sumoylated 
177
. Sumoylation defective mutants of AR and PR showed higher 
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transactivating activity than the wild-type receptors, indicating an attenuating role for 
sumoylation 
172, 177
. Ubc9 can also bind to and sumoylate the GR DBD, but its effect on receptor 
activity has not been established yet 
172
. Potential SUMO-1 acceptor sites in the GR (K277, 
K293, K703) and AR (K386 and K520) are located in negative control motifs that restrict the 
transcriptional synergy of these two receptors 
418
.  Whereas ubiquitylation is often involved in 
protein degradation, sumoylation plays a role in subcellular localization, especially in 
intranuclear targeting, protein stability, and gene transcription 
419, 420
. Because these protein 
modifying mechanisms each have lysine residues as their targets, they might compete with each 
other, depending on the cellular needs 
421
.  
  In addition to acetylation of histones, CBP/p300 and p/CAF are also able to acetylate 
transcription factors 
422
. AR acetylation augments its ligand-dependent transcriptional activity. 
A highly conserved lysine-rich motif, 
630
KLKK
633
, is the acetylation target site in the AR 
423
. 
Acetylation neutralizes positively charged lysines, which may lead to conformational changes 
that affect protein-protein or protein-DNA interactions of the AR. The HAT activity of Tip60 
can activate the AR by direct acetylation 
299, 300
. 
  Although CARM1 (see section 1.2.2.1) can increase AR activity it was not found to methylate 
the AR protein 
356
. Possibly this activation is mediated by histone or coactivator methylation.  
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1.2.3  AR LBD interaction with AR NTD and AR coactivators  
 
1.2.3.1  AR N/C interaction 
  In full-length AR, TAU1 (aa 100-370) has been identified as essential in transcription activity 
of the AR NTD. However, deletion of AR LBD shifted the main transcription activation unit in 
AR NTD from TAU-1 to TAU-5 (aa 360-485) 
266
. This finding led to the hypothesis of an 
interaction between the AR NTD and the AR LBD. Indeed, an androgen-dependent functional 
NTD-LBD interaction, designated AR N/C interaction, has been detected in protein-protein 
interaction systems. This interaction could be blocked by anti-androgens 
424, 425
. The N/C 
interaction is direct, as assessed by in vitro pull down experiments 
331
.     
  Initial deletion mapping studies from our group indicated three regions in the AR NTD to be 
involved in the functional interaction with the AR LBD: aa 3-36, aa 172-185 (AF-1a), and aa 
370-494 
268, 284
. The first region appeared to be an essential interaction domain 
284
. Mutational 
analysis of AF-1a decreased the functional N/C interaction as well as AR transactivation, but an 
AF-1a peptide was not able to interact with the AR LBD, indicating an indirect role for this 
domain in N/C interaction 
40, 267
 (and Steketee, unpublished). As region 370-494 encompasses 
TAU-5, which probably is a p160 coactivator binding site, it contributes to the transcriptional 
function of the AR NTD/AR LBD protein complex rather than to the N/C interaction itself 
267, 
284
. Initial studies from others pointed to the aa 14-150 region as the AR N/C interaction domain 
425
. Combined, these findings indicated that the most important interaction domain of the AR 
NTD is constrained to residues 14-36. 
  For aa 16-36 a remarkably long amphipathic α-helical structure was predicted, suggesting an 
important protein interaction interface. In vivo and in vitro protein interaction experiments have 
shown that aa 16-36 can interact autonomously with the AR LBD and is essential for N/C 
interaction. Within aa 16-36, the motif 
23
FQNLF
27
 appeared to be pivotal for direct N/C 
interaction 
426, 427
. Protein interaction assays showed that the hydrophobic residues F23, L26 and 
F27 each were indispensable. Amino acids flanking the 
23
FQNLF
27 
motif modulate AR N/C 
interaction 
290, 291, 427-429
. Therefore, aa 23-27 is referred to as an FXXLF motif in which X can 
be any amino acid. Region aa 370-494 (encompassing TAU5) contains an FXXLF-related motif, 
433
WHTLF
437
, which was postulated to affect the 
23
FQNLF
27
 mediated functional interaction 
with the LBD 
426
. However, a peptide containing this region was not able to interact with the AR 
LBD, which excluded 
433
WHTLF
437
 as an autonomous interaction motif in AR NTD (Steketee 
unpublished results). 
  Like for the AR NTD, AR LBD amino acids involved in AR N/C interaction have been studied 
in detail. The AR FXXLF motif 
23
FQNLF
27
 shows similarities to LXXLL motifs present in NR 
boxes of p160 coactivators, and therefore it was hypothesized that the FXXLF motif could bind 
to the coactivator groove in the AR LBD in a similar manner as LXXLL motifs 
106, 430, 431
. As 
described in section 1.2.2, these LXXLL motifs are essential in the interaction with NR LBDs. 
They bind to a hydrophobic cleft in LBDs, which is lined by the highly conserved charged 
lysine residue in helix 3 and the glutamic acid residue in helix 12 
106
. In AR, amino acid residues 
corresponding to this 'charged clamp' are K720 and E897, respectively. Both were shown to be 
involved in the ligand-dependent interaction between the AR FXXLF motif and AR LBD, but 
solely K720 is involved in LXXLL-AR LBD binding 
40, 284, 291, 292, 331, 432-434
. So, the FXXLF-
mediated AR N/C interaction is comparable, but not completely identical to the LXXLL-
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mediated coactivator-AR LBD interaction. In section 1.2.4.4, a detailed mechanistic description 
of the FXXLF-AR LBD interaction is given.  
  The AR functions as a homodimer to regulate transcription of its target genes. Initial studies 
aiming at unraveling the AR N/C interaction have been carried out with the FXXLF motif and 
LBD coactivator groove present in separate AR protein fragments. Therefore it could not be 
determined from those experiments whether the interaction is intra- or intermolecular or a 
dynamic combination of both. More recent FRET experiments in living cells with cyan 
fluorescent protein (CFP) and yellow fluorescent protein (YFP) attached to either end of the AR 
(CFP-AR-YFP) showed that after androgen treatment an N/C interaction occurs both in the 
cytoplasm and in the nucleus 
435
. A FRET signal between single tagged CFP-AR and AR-YFP 
fusion proteins indicated dimerization of AR (intermolecular interaction). This interaction is 
preferentially found in the nucleus. Deletion or mutation of the FXXLF motif in both CFP-AR 
and AR-YFP did not alter the dimerization signal, but clearly diminished the FRET signal of 
CFP-AR-YFP. These results indicate that the AR N/C interaction is intramolecular in the 
cytoplasm as well as in the nucleus, and that AR dimerization does not rely on FXXLF-
mediated intramolecular interaction.  
1.2.3.2  Relevance of AR N/C interaction in receptor function 
  The exact role of N/C interaction in full-length AR function has not been completely 
established as yet. However, several studies have given clues that contribute to elucidating the 
relevance of the interaction.  
  Ligand-dependent AR N/C interaction was found to slow ligand dissociation thereby 
increasing AR activity 
291, 331, 426, 436
. Several AR LBD mutations in androgen insensitivity 
syndrome (AIS) patients have been found with a reduced or completely abolished N/C 
interaction 
331, 436-438
. However, not all AIS mutants cause similar conformational changes 
leading to disturbance of AR N/C interaction. So, disturbance of N/C interaction cannot be used 
as a general indicator of AIS. However, if disruption of AR N/C interaction is found for an AIS 
mutant, this may give a clue for the mechanism of that particular AR mutant. An N/C interaction 
deficient AR mutant can be translocated to the nucleus, which implies that the N/C interaction is 
not necessary for nuclear import 
439
.  
  Both the ligand-dependent N/C interaction and the transactivating function of the AR (T877A) 
mutant found in LNCaP prostate cancer cells could not only be induced by androgens, but also 
by non-cognate ligands as estrogens, progestagens and anti-androgens at physiological or 
therapeutic concentrations 
424
. This reflects the broadened ligand-specificity of this AR mutant 
(see section 1.2.5.1.3.2), and thus indicates a physiological role of the N/C interaction.  
  The N/C interaction was proposed to be a prerequisite for p160 coactivator recruitment, 
supporting an important role of AR NTD in p160 interaction 
40, 108
. This would also be 
consistent with the exclusion of TIF2 binding to the AR LBD reported as an effect of the N/C 
interaction 
440
. However, the AR N/C interaction was found to be influenced in a negative or 
positive manner by different coactivators as well as corepressors 
441
. So, there is no clear 
correlation as yet between the N/C interaction and coactivator/corepressor interaction with AR. 
  The N/C interaction might play a modulating role in AR-mediated transcription. N/C 
interaction disrupting AR mutants tended to be less active on non-specific AREs than on 
androgen-specific AREs (see section 1.2.5.4) 
290
. 
  Recently, it was found that an AR deletion mutant lacking the FXXLF motif does not bind to 
the MMTV promoter and PSA enhancer assembled on chromatin in Xenopus or mammalian 
cells 
439
. However, this AR mutant can bind to a consensus ARE in vitro and activates the 
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MMTV promoter in transient transfection, which are supposed to be experimental conditions 
without proper chromatin structures. The mutant is also diminished in its binding to the ATPase 
subunit of SWI/SNF, Brg1 
439
. These findings indicate a role of N/C interaction in chromatin 
embedded AR function. In section 1.2.2.3 a more detailed description of interplay of AR with 
components of chromatin remodeling complexes has been presented. 
  An artificial chromatin embedded promoter containing 4 linked AREs could be activated by 
the AR FXXLF deletion mutant, indicating that multiple AREs can overcome the chromatin 
constraints for the N/C interaction deficient AR 
439
. Although the MMTV promoter also 
contains 4 AREs, the ARE arrangement might be insufficient to accommodate the AR mutant 
properly if packaged in chromatin. In transient transfected LNCaP cells an AR deletion mutant 
lacking aa 1-36 was able to activate an MMTV-driven reporter, but much less efficient the 6 
kbpPSA promoter/enhancer (Steketee, unpublished results). Apparently, PSA transcription has 
specific demands with respect to the AR N/C interaction, which may be chromatin-independent.   
1.2.3.3  N/C interaction in other nuclear receptors 
  Using a mammalian two-hybrid system, N/C interaction has been found for the rat AR, 
indicating a universal mechanism of AR function in different species 
442
.  
  An N/C interaction has also been described for other NRs. The ERα displays a ligand-
dependent N/C interaction, which is disrupted by amino acid substitutions that affect receptor 
function 
42, 443
. The ERα N/C interaction is claimed to be direct and can be induced by the 
agonist estradiol (E2) and the antagonist hydroxytamoxifen, but not by the antagonist 
ICI164,384. It was found that the N/C interaction of ERα was required for SRC-1 mediated 
synergism between AF-1 and AF-2 function 
41, 42
. The coactivator TIF2 was also found to 
synergize AF-1 and AF-2 functions in ERα 41. Recently, FRET experiments have shown that 
ERα N/C interaction can occur intramolecularly 435, 444. Although ERβ AF-1 is able to bind to 
SRC1 and to TIF2, it is not known whether AF-1 and AF-2 synergize and, so far, a direct N/C 
interaction has not been reported for this receptor 
179, 445
.  
  For both PR isoforms, PR-A and PR-B, an N/C interaction was reported in the presence of an 
agonist, but not in the presence of an antagonist 
446
. This interaction was much stronger for PR-
B, which is the strongest transcriptional activator. This activating capacity is attributed to its N-
terminal 164 amino acids, which are lacking in the PR-A. An AF-3 function has been mapped to 
this region and it contains two LXXLL motifs 
447, 448
. These motifs are essential for PR-B 
transcriptional activity. However, they are thought to bind sites in the PR-LBD which are 
different from the coactivator binding groove.       
  For a number of other NRs there are indications of communication between their NTD and 
LBD. Addition of the MR NTD does not restore the diminished ligand induced activity of an 
NTD-deleted GR
449
. This suggests a GR N/C interaction. For PPARγ communication between 
its NTD and LBD has been supposed to regulate ligand binding 
450
. However, experiments with 
CFP-PPARγ2 and PPARγ2-YFP did not result in a detectable FRET signal 
435
. For TRβ, it has 
been observed that its NTD can bind p160 coactivators in a ligand-independent manner. 
Because its LBD binds ligand-dependently to those coactivators, this suggests an indirect N/C 
interaction bridged by a p160 coactivator 
451-453
. Also the NTD and LBD of RARα1 were found 
to be bridged by SRC-1, which resulted in synergistic transcription activity 
109
.  
  So, NTD-LBD communication has been proposed for other NRs, but a direct N/C interaction is 
most clearly established for AR and might even be unique for this receptor.  
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1.2.3.4  AR LBD specifically binds to FXXLF motifs in AR NTD and AR 
coactivators 
   Overexpression of coactivator TIF2 can enhance AR LBD AF-2 function, but less efficiently 
full length AR activity 
284
. SRC1 does not need its LXXLL motifs for enhancement of full 
length AR activity 
108
. AR NTD can, through its FXXLF motif, compete with p160 coactivators 
for binding to AR LBD 
440
. These findings indicated that coactivation through LXXLL-AR LBD 
interaction is not essential in AR function. However, the AR candidate cofactors ARA54, 
ARA55, ARA70, and RAD9 have been identified to enhance AR activity by binding to its LBD 
302, 306, 333, 365
. Importantly, these coregulators mediate this function by FXXLF motifs, which 
bind to the AR LBD 
289
. Random peptide phage display experiments using the AR LBD as well 
as the full-length AR revealed almost exclusively FXXLF or related motifs, as high affinity 
interaction motifs 
292, 429
. Although some LXXLL motifs, i.g. TIF2 motifs 1 and 3, do have 
affinity for AR LBD that might equal that of the AR FXXLF motif, most LXXLL motifs tested 
have a low affinity for AR LBD 
289, 291, 292, 428, 432-434, 454
. So, FXXLF motifs in cofactors seem to 
be specifically involved in AR function.  
1.2.3.4.1 Structural background of the preference for FXXLF motifs of the AR coactivator 
groove 
  The question of high affinity of AR LBD to FXXLF motifs compared to LXXLL motifs has 
been addressed by elucidation of the structure of AR LBD complexed with FXXLF motifs. Like 
reported for LXXLL motifs, the FXXLF motif has a short α-helical structure, of which the 
phenylalanines fit in the hydrophobic coactivator groove 
32, 33
. The +1 phenylalanine binds a 
hydrophobic part of the AR coactivator groove that is formed by L712 (H3), V716 (H3), M734 
(H5), I737 (H5), Gln738 (H5), M894 (H12), and I898 (H12). The +5 phenylalanine binding site 
is formed by V716 (H3), K720 (H3), F725 (H4), V730 (H5), Gln 733 (H5), M734 (H5), and 
I737 (H5). The +4 leucine contacts L712 (H3) and V716 (H3) 
292, 434
. The AR coactivator 
binding groove is much deeper than that on the surface of ERα LBD (Figure 10) 
291, 292, 433
. This 
space allows phenylalanine residues, which have bulkier side chains than leucine residues, to 
enter the groove. In turn, although LXXLL motifs can enter the AR groove, they might lack 
sufficient hydrogen bonding and hydrophobic interaction necessary for tight interaction. F to L 
substitutions in FXXLF motifs abolished AR LBD interaction, whereas L/F swaps increased 
interaction with peptide motifs or even induced AR LBD interaction capacity in non-binding 
LXXLL motifs 
432, 454
. 
  The specificity of the AR groove for FXXLF-like motifs is further substantiated by the prostate 
cancer AR mutant V730M, which showed an increase in binding of LXXLL motifs , whereas it 
slightly decreased FXXLF binding 
455
. The methionine might provide additional interactions to 
the +5 leucine of an LXXLL motif without condiserably changing the interaction with the 
corresponding phenylalanine in FXXLF motifs. So, V730 seems important in FXXLF 
specificity of the AR LBD. 
  It was expected that, like for LXXLL motifs, the FXXLF motif is stabilized by interaction with 
the charged clamp lining the AR LBD coactivator groove 
32, 33
. Indeed, structural analysis of an 
FXXLF peptide-AR coactivator groove complex indicated E897 binding to the +1 
phenylalanine of the FXXLF motif, and K720 binding to the +5 phenylalanine 
291, 292, 433, 434
. In 
contrast, LXXLL motif binding to the AR LBD needs K720, but E897 is not involved (Figure 
11) 
270, 292, 433
. This may, together with the larger size of the coactivator groove, explain the 
lower binding affinity of LXXLL motifs for the AR LBD if compared to FXXLF motifs. 
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Figure 10. Side views of the coactivator binding grooves/peptide motifs of A, the ER LBD/LXXLL and B, AR 
LBD/FXXLF. Meshes represent the extent of the ER LBD and AR LBD molecular surfaces, respectively. The 
LXXLL and FXXLF motifs are represented in green coils. Side chains at positions +1 and +5 are in space-filling 
representation and colored in yellow. The positions of the charge clamp Lys and Glu are indicated. From ref. 291.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 11. Model of  FXXLF (green) and LXXLL (yellow) binding modes to DHT bound AR LBD. +1, +4, and 
+5 positions as well as the X positions in the motifs are indicated. This picture was kindly provided by H.J. 
Dubbink.   
 
  Like observed for LXXLL motifs, residues flanking FXXLF motifs underlie AR LBD binding 
specificity 
291, 429, 430, 432, 433, 456
. Electrostatic interactions between residues flanking the motif 
and the charged clamp are supposed to affect this specificity 
428
. For example, in addition to 
binding to the +5 phenylalanine of the AR FXXLF motif, K720 also makes contact with the +8 
valine 
434
. At the N-terminal side of the motif, E897 binds not only to the +1 phenylalanine, but 
also to the -1 alanine. This is consistent with a study described in chapter 3, showing that 
mutations of residues flanking the AR FXXLF motif affected interaction with the AR LBD 
427
. 
The peptides found in phage display studies mostly have positively charged residues N-terminal 
and negatively charged residues C-terminal to the peptide motif enabling electrostatic 
interaction with AR LBD 
292, 429
. A G21E mutation, N-terminal to the FXXLF motif in AR 
NTD, impaired the AR N/C interaction 
290
. A crystal structure of AR LBD in complex with the 
A B 
K720 
E897 
X 
X
+
+ +
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third LXXLL motif of TIF2 has shown that four negatively charged amino acid residues 
following this motif (DKDD) interact with positively charged patches on the receptor surface. 
This might explain the selective binding of AR LBD to this TIF2 motif and indicates that certain 
LXXLL motifs are appreciated by the AR LBD 
433
. 
  Residues at positions +2 and +3 in FXXLF motifs may also play a role in affinity for AR LBD. 
Phage display studies have shown a variety of residues on these positions, which are compatible 
with strong AR LBD interaction. However, at position +2 E and S residues were found more 
often, and for position +3 preference for K was reported 
432, 457
. Peptides containing the FXXLF 
motifs of TAFII250 (FLRLF) or TFIIEα (FEDLF) interacted weakly with AR LBD. FXXLF 
motifs found in CBP (FGSLF) and p300 (FGSLF) could not interact with AR LBD possibly due 
to a glycine at position +2 
289
. The FETLF motif found in the AR coactivator FHL2 (see also 
section 1.2.2.1) was also not capable to bind AR LBD 
289
. This might be due to the T residue at 
position +3, but also to sequences flanking the motif. Obviously, not all FXXLF motifs can bind 
to AR LBD. 
  Taken together, AR LBD binding preference for FXXLF motifs compared to LXXLL motifs is 
mainly determined by the hydrophobic phenylalanines, but specific flanking residues may play a 
role as well.  
1.2.3.4.2  Variations of the FXXLF motif 
  In order to elucidate the mechanism and relevance of FXXLF motifs in AR function and to 
identify AR specific peptide antagonists, phage display studies and screening of randomized 
peptide libraries have been carried out using AR LBD or full-length AR as a bait. These 
experiments have revealed many FXXLF motif variants containing exclusively hydrophobic 
amino acid substitutions at positions +1, +4, and +5, including F/WXXLF/W, FXXLY/MW, 
WXXVW, FXXFF, FXXFY, FXXYF, FXXVF, and sporadically LXXLL 
291, 292, 429, 457
. Many 
of these motifs showed a weaker interaction with AR LBD than the AR FXXLF motif. 
However, like AR FXXLF, many FXXFF, FXXYF, and FXXFY motifs had a high affinity for 
AR LBD 
292, 457
. Crystallographic experiments have revealed that the conformation of FXXYF 
mimicked closest that of  FXXLF if bound to the AR LBD coactivator groove, by making direct 
backbone interactions with E897. Binding of an FXXFF motif resembled binding of the FXXYF 
and FXXFY motifs by interaction with its -2 serine residue to E897 
292
. Substitution of the 
leucine of AR and ARA54 FXXLF motifs by phenylalanine or methionine did not decrease their 
AR specificity, and the same variants of the less AR-selective ARA70 FXXLF motif even 
increased its AR specificity 
322
. 
  Some FXXLF or related motifs found in the phage display and peptide screening studies have 
also been found in AR LBD binding proteins. In addition to its FXXLF motif, the AR 
coactivator FHL2 also contains an FXXLY motif. Although a peptide with its FXXLF motif 
cannot bind AR LBD on its own (see also section 1.2.4.4.1), both motifs are supposed to be 
necessary for FHL2 to bind AR LBD 
289, 429
. As mentioned before in section 1.2.5.1, the 
WXXLF motif in the AR NTD only weakly contributes to the AR N/C interaction 
289, 428
. An 
FXXFF and FXXMF motif found in the AR binding proteins gelsolin and PAK6, respectively, 
showed direct, efficient and specific interaction with AR LBD 
322
.  
  Several of the peptides containing FXXLF variant motifs that bind to the AR LBD were able to 
suppress AR N/C interaction. However, this did not always result in inhibition of AR 
transactivation 
429, 457
. Putative implications of such motifs in inhibiting AR function in order to 
treat prostate cancer is further discussed in Chapter 5. 
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1.2.4  Androgen-specific gene transcription 
 
1.2.4.1  General mechanism of androgen regulated gene transcription  
  For an increasing number of androgen regulated genes, the mechanism of androgen action has 
been at least partially elucidated 
52, 458-497
. Identification of novel androgen regulated genes has 
been accelerated during the last 5 years, because techniques have evoluated from subtractive 
hybridization and differential display to the high-throughput expression microarrays. Array 
technology has been used for gene expression profiling of prostatic tissue and different prostate 
cancer cell lines in the presence and absence of androgens 
498-504
 (reviewed in ref. 505). This has 
resulted in an extensive and still growing catalogue of genes being up- or down-regulated by 
androgens. Bioinformatics assisted analysis of the transcription regulation mechanisms of this 
huge number of genes will help to further elucidate the mechanism of action of androgens. In 
the near future whole genome identification of androgen regulated genes is to be expected, as 
now already started for ER regulated genes 
506
. 
  Basically, androgen induced transcriptional regulation occurs through ligand-activated AR 
dimers that bind to AREs in the regulatory regions of target genes. AREs have been found in 
promoters and in enhancers upstream or downstream of the promoter. Many AREs deviate 
considerably from the inverted repeat high affinity ARE consensus sequence 5'-
AGAACAnnnTGTTCT-3' and, in many cases, have a relatively low affinity for the AR. In 
transfection experiments, those AREs are individually not able to show detectable androgen 
inducibility, but together act synergistically, thereby conferring very effective androgen induced 
transcriptional regulation. Cooperatively acting AREs can be located in close vicinity of each 
other, but can also be separated by long distances.  
  An illustrative example of androgen regulated transcription is that of the extensively studied 
prostate specific antigen (PSA) gene. Its proximal core promoter contains two AREs, ARE-I at -
170 (AGAACAgcaAGTGCT) and ARE-II at -394 (GGATCAgggAGTCTC) 
463, 491
. These 
AREs act cooperatively, albeit that their total activity is still weak 
463
. A third ARE, ARE-III 
(GGAACAtatTGTATC), which is present in an enhancer region at -4.2 kbp of the PSA gene, is 
able to confer considerable androgen induced transcriptional activation of a reporter gene. 
Combination of the enhancer region and the core promoter synergistically results in a strong 
androgen inducibility 
462
. In the vicinity of ARE-III, five additional candidate AREs have been 
reported: ARE-IIIA, ARE-IIIB, ARE-IV and ARE-VI, which have a low affinity for the AR, 
and ARE-V with moderate affinity to the AR. These AREs might increase PSA enhancer 
activity.  
1.2.4.2  Androgen-specifically regulated genes 
  Many androgen regulated genes, like the PSA gene, have been found to be also regulated by 
other steroids, because GR, MR, PR and AR recognize the same sequences in the DNA. 
However, during the last decade, genes have also been found that can be specifically regulated 
by androgens. As mentioned in section 1.1.2, this specificity can be caused by different 
mechanisms, including tissue specific AR expression, specific coactivator/corepressor 
expression, ligand availability and local chromatin structure 
4, 7, 51, 53-55, 59
.  
  A mechanism leading to receptor specificity can also be found in the hormone response elements. 
Deviations from the HRE consensus sequence have been found to lead to receptor specific 
transcriptional regulation by AR, PR, GR, and MR. Flanking sequences can also contribute to 
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receptor preference 
507
. However, for the AR a clear specificity appears to exist. For several genes 
identified as specifically regulated by androgens, a distinct class of HREs has been found to be 
highly androgen specific. Most of these AREs deviate considerably in one half-site from a standard 
ARE 
52, 494, 496, 508-512
.  
  Up to date, five genes harboring androgen specific AREs have been identified. Features of 
these genes and their androgen responsiveness are described below. An overview of their 
androgen specific AREs is presented in Table 3. 
Probasin 
  The rat probasin gene encodes a nuclear and secreted protein, which is expressed in epithelial 
cells of the dorsolateral prostate 
513
. Its transcription can be induced by both androgens and 
glucocorticoids, but its androgen inducibility is much stronger than its regulation by 
glucocorticoids 
481, 514-516
. The probasin gene was the first gene described to be preferentially 
regulated by androgens. Its promoter contains two cooperative AREs, PbAREI and PbAREII, 
which were initially found not to function individually, but if duplicated in front of a 
heterologous minimal thymidine kinase promoter, androgen inducibility for PbAREII was 
observed 
52, 481, 490
. PB-ARE1 shows a classical inverted repeat sequence and has a low affinity 
for the AR. PB-ARE2 (see Table 3) is specifically responsive to androgens 
52
. PbAREII can 
bind to the AR, but not to the GR, and it has a higher AR binding affinity than PbAREI 
52, 517
. 
The left hand half-site of PbAREII, 5'-GGTTCT-3', determines its AR specificity by excluding 
GR binding, as was deduced from experiments using chimeric response elements with swapped 
half-sites 
52
. In an upstream enhancer fragment of the probasin gene two additional AREs were 
identified, ARBS3 and ARBS4. Like PbAREII, ARBS3 is also androgen specific and has also 
one half-site that deviates considerably from a consensus half site (see Table 3) 
518
. Two 
additional low affinity AREs with atypical half-site sequences, G-1 and G-2, are located near 
ARBS1 and ARBS2. These were postulated to stabilize AR binding to ARBS1 and ARBS2 and 
result in synergistic transcriptional activity and increased hormone sensitivity 
519
. All AREs 
found in the probasin gene appeared to be necessary for full androgen induction of probasin 
transcription 
518
. 
Secretory component 
  The rat Secretory component (Sc) is the transepithelial transporter of immunoglobulins A and 
M 
520
. In many tissues, expression of the Sc gene is constitutive. In the prostate and the lacrimal 
gland its expression is modulated by androgens 
521, 522
. In the -3.5 kbp enhancer region of the Sc 
gene, an androgen specific ARE, designated ScARE1.2, has been found, which has a relatively 
high affinity for the AR (see Table 3) 
496
. Exon 1 of the Sc gene contains a second androgen 
specific ARE, ScARE (see Table 3), which is responsive to glucocorticoids, but, despite of a 
low AR affinity, its androgen response is much stronger 
475
. Mutational analysis of ScARE1.2 
and ScARE showed that their left half-sites excluded or decreased GR binding. AR selectivity 
disappeared by mutating these half-sites to more consensus-like sequences 
496, 508, 511
.  
Slp 
  The mouse sex-limited protein (Slp) gene is a duplicated C4 gene encoding a liver-specific 
protein. Its transcription is regulated by androgens. The Slp gene contains an enhancer region at 
-2 kbp, which was introduced by insertion of an ancient provirus 
523
. A fragment of this 
enhancer is specifically responsive to androgens 
524
. It contains three candidate AREs. One is 
not functional, a second one is active with both AR and GR, and the third one, SlpHRE2 (see 
Table 3), is androgen specific 
511, 525
. The SlpHRE2 was initially considered as an ARE of which 
the flanking sequences could bind other transcription factors, thereby allowing AR binding, but 
excluding GR binding. However, although additional factors do contribute to its specific 
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androgen regulation, the SlpHRE2 was proven to confer androgen specificity autonomously 
with a relatively high AR affinity 
511, 525-529
. Like in the probasin and Sc androgen-specific 
AREs, the left half-site of the SlpHRE2 determines the exclusion of the GR to function via this 
HRE 
511
. 
Pem 
  The Pem homeobox transcription factor gene is highly conserved between rat and mouse, and 
is expressed in reproductive organs as well as in muscle and placenta 
530
. For its expression the 
rat Pem gene was shown to use two different promoters. A distal promoter is independent of 
androgens and active in testis, ovary, muscle, and placenta. A proximal promoter is located in 
intron 2, close to exon 3 which harbors the translation start codon. This proximal Pem promoter 
is androgen-dependent and controls expression in testis and epididymis 
530
. Analysis of the 
mouse Pem proximal promoter revealed that this promoter contains two androgen specific 
AREs, PemI and PemII (see Table 3), which act cooperatively and are both selectively 
responsive to androgens 
458
. The Pem AREs have a preference for the AR, but are also 
responsive to GR and PR, albeit to a lesser extent. Both PemI and PemII show a low relative 
affinity for the AR. In contrast with standard AREs, PemI contains a 5 bp spacing. This does not 
prevent responsiveness to androgens, but reducing the spacing to three nucleotides increases its 
activity 
458
.  
SARG 
  The specifically androgen regulated gene (SARG) was identified in the human LNCaP subline 
LNCaP-1F5, which expresses AR and GR in comparable amounts. In this cell line, transcription 
of SARG can be up-regulated by androgens but not by glucocorticoids, whereas PSA 
transcription is stimulated by both hormones 
531
. In intron 1 of the SARG gene, at +4.6 kbp, an 
androgen specific ARE, designated SARG+4.6ARE (see Table 3) is present 
494
. SARG+4.6ARE 
has a lower affinity for AR, compared to probasin PB-ARE2. SARG+4.6ARE cannot bind GR, 
and in transfection it is not responsive to glucocorticoids. The identification and a detailed 
analysis of the SARG gene is described in Chapter 4 of this thesis. 
 
 
Table 3. Androgen-specific androgen response elements. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  ARE name       ARE sequence 
       -6  -5  -4  -3  -2  -1                            +1 +2 +3 +4 +5 +6    References 
   PbAREII  GGTTCT tgg AGTACT 52 
   ARBS3   AGAACC tcc AGTTCC 518 
   ScARE1.2  GGCTCT ttc AGTTCT 496 
   ScARE   AGCAGG ctg TGTCCC 475 
   SlpHRE2  TGGTCA gcc AGTTCT 511 
   PemI  AGATCTcattcTGTTCC 458 
   PemII  AGCACA tcg TGCTCA 458 
   SARG+4.6ARE  TGTGCT aac TGTTCT 494 
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1.2.4.3  Mechanism of AR binding to androgen-specific AREs 
  Like for non-specific AREs, androgen-specific AREs with different AR affinities have been 
found 
52
. SARG+4.6ARE and SC-ARE weakly bind the AR, but are both highly androgen-
specific, they cannot bind to the GR. However, the low AR affinity Pem ARE1 and Pem ARE2 
show weak glucocorticoid responses. PB-ARE2, Slp HRE2 and SC-ARE1.2 have relatively 
high affinities for the AR, but also show differences in androgen specificity. PB-ARE2 and Slp 
HRE2 are not responsive to glucocorticoids, but SC-ARE1.2 can confer weak glucocorticoid 
induced transcriptional activation. So, it is not their relative affinity for the AR, but their 
preferential binding to the AR over the GR that may contribute to the androgen specific 
responsiveness of AREs. Additional indications for this hypothesis were provided by AR-GR 
chimeric receptor studies which revealed a crucial role for the AR DBD in androgen-specific 
activation of the Slp HRE2 
532
. 
  For most androgen-specific AREs it has been established that the left half-sites diminish GR 
binding (see Table 3). It has been postulated that in this half-site a T at position -4 is responsible 
for GR exclusion 
511
. However, Pem-ARE2 and SC-ARE have an A at this position and 
SARG+4.6ARE a G. In addition, the G at position -3 of the SC-ARE is indispensable for 
androgen specificity, but no other androgen-specific ARE has a G at this position 
508
. A T at 
position -2 was also supposed to contribute to androgen specificity, but is also not present in all 
androgen-specific AREs 
511
. So, specific nucleotides in the androgen-specific AREs seem not to 
be individually responsible for androgen specificity. 
  Since androgen specificity of AREs could not be explained by their relative affinity for the AR 
or specific nucleotide composition, it was proposed that another characteristic of androgen 
specific AREs is the determining factor. Most of the natural and synthetic androgen-specific 
AREs investigated so far can be considered as (im)perfect direct repeats rather than inverted 
repeats. Several crystallographic studies have shown a head-to-head orientation of NR DBD 
dimers binding to an inverted repeat response element and a head-to-tail orientation for direct 
repeat elements (reviewed in ref. 21). Therefore, it was suggested that an AR dimer binds to an 
androgen specific ARE in a head-to-tail orientation 
508, 510, 511
. This would imply an alternative 
dimerization of the AR DBD when bound to an androgen-specific ARE. In this way, the GR 
would be more or less excluded from binding to the androgen specific AREs, because it could 
not form head-to-tail DBD dimers. Unlike the first zinc cluster, the second zinc cluster of a 
DBD does not contact the DNA, but is an important part of the dimerization interface. Indeed, 
the second zinc cluster and a C-terminal extension of the AR DBD were previously found to be 
involved in DNA-specificity 
509
. This was substantiated by mutation to GR homologues of 
second zinc cluster residues Thr585, Gly610, and Leu617, which caused a lower affinity of the 
AR for PB-ARE2 
510
. Although these findings indicate that specific AR DBD dimerization plays 
a role in AR binding to androgen specific AREs, AR DBD dimer orientation on these AREs 
could not be determined from those experiments. 
  Ultimately, the orientation of AR DBD dimers on androgen-specific AREs was elucidated by a 
crystallographic study that showed that AR DBDs dimerize in a head-to-head fashion to a 
synthetic androgen-specific ARE (ADR3) (Figure 8 in section 1.2.1.2) 
24
. This head-to-head 
oriented DBD dimer indicated that an important part of the mechanism underlying androgen-
specific transcriptional regulation indeed could be found in the AR protein itself. So, the 
previously proposed head-to-tail dimerization of AR DBD, compared to that of the GR-DBD, is 
related to the non-standard ARE character of androgen-specific AREs. All androgen-specific 
AREs (Table 3) are comprised of one half-site with a complete or almost complete consensus 
sequence, which is known to bind AR as well as GR with high affinity. The specific half-site 
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can be designated as non-consensus, and will have a very low affinity for both AR and GR. It is 
thought that one DBD binds to the consensus half-site and that the second DBD can 
cooperatively bind to the non-consensus half-site only when there is a strong interaction 
between the DBDs. Indeed, crystallographic data revealed three extra hydrogen bonds between 
the second zinc clusters in the AR DBD dimer if compared to the GR DBD dimer (Figure 12) 
24, 
510
. A hydrogen bond can be formed between S580 of both AR DBD monomers, and T585 of 
each AR DBD monomer can hydrogen bond to A579 of the opposite monomer. So, the 
dimerization of AR DBDs is supposed to be strong enough to overcome a low affinity half-site, 
and as also previously proposed, the GR tends to be excluded from the non-consensus half-site 
of an androgen specific ARE because of a much weaker dimerization interface.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12.  Molecular mechanisms of  AR and GR dimer interfaces A) The AR DBD dimer interface. The 
molecular surfaces of the AR subunits are shown in red and blue. Dashed black lines are hydrogen bonds. (B) A 
similar view of the GR DBD dimer interface. A “glycine hole” is noted by the dashed circle. Adapted from ref. 24. 
1.2.4.4  Role of androgen-specific AREs  
  Recently, several studies have revealed possible roles for the androgen-specific AREs. 
Androgen specific AREs seem to reduce the need for the AR N/C interaction for transcription 
regulation (see section 1.2.5.1) 
290
. The non-specific AREs TAT-GRE, slp-HRE3, and C3 (1)-
ARE, are responsive to wild type AR, but not to a N/C interaction defective mutant, whereas the 
androgen specific Slp HRE2 and sc-ARE1.2 (see section 1.2.6.2) are equally responsive to the 
wild type and mutant AR. Mutation of the latter AREs to non-specific ones decreased their 
responses to the AR mutant. However, the androgen-specific Pb-ARE2 required the AR N/C 
interaction for its androgen responsiveness. The better resemblance of its left half-site to high 
affinity binding sites may play a role in this regard (see section 1.2.6.3). The N/C interaction-
dependent AREs were no longer dependent on the interaction if they were present in their 
natural enhancer/promoter regions. It was suggested that the higher complexity of these regions 
might overcome the need for AR N/C interaction in androgen responsiveness.  
  A second study also described the requirement of N/C interaction for AR activity on non-
specific elements 
533
. These AREs were all tested in the context of their corresponding 
enhancer/promoter sequences, like the PSA enhancer/promoter and the probasin enhancer, 
which is in conflict with the first report in which N/C interaction requirement was only found 
Ala 
Ala 
Ala 
Ala 
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for isolated non-specific AREs. In contrast, the same study reported that for the MMTV-
promoter, the AR N/C interaction was dispensable, although it contains non-specific AREs. 
  The function of several AR associated proteins could be differentially influenced by androgen-
specific and non-specific AREs. Overexpression of the AR coactivators TIF2 and ARA55 was 
reported to increase AR activation on androgen specific AREs rather than on non-specific AREs 
534
. Two proteins involved in mediating AR SUMO-ylation, (PIAS)xα and Ubc9 (see section 
1.2.2), had, if overexpressed, different effects on non-specific and androgen specific AREs 
534
. 
(PIAS)xα repressed AR activity much more on androgen-specific ARE driven genes than on 
genes regulated by non-specific AREs. Ubc9 showed little effect on androgen-specific AREs, 
whereas it enhanced AR activity on non-specific elements. Additionally, mutational analysis of 
an AR SUMO-ylation site revealed that overexpression of SUMO-1 repressed AR-mediated 
transcription only on non-specific elements 
535
. 
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1.2.5  The AR in disease 
  The AR is, next to its central role in normal development and maintenance of the male 
phenotype, also an important player in several diseases. AR associated diseases are androgen 
insensitivity syndrome (AIS), spinal and bulbar muscular atrophy (SBMA) or Kennedy’s 
disease, and prostate cancer.  
  AIS is a rare inherited defect of male development in which 46, XY individuals have a partial 
or complete lack of virilization, referred to as partial AIS (PAIS) or complete AIS (CAIS) 
536, 
537
. In this disorder, over one hundred different amino acid substitutions in the AR in different 
individuals or families have been documented 
263
. These substitutions partially or completely 
inactivate AR function by affecting its ligand or DNA binding. AIS can also be caused by 
coactivator defects 
538
.  
  SBMA or Kennedy’s disease is a spinobulbar motor neuropathy with an adult-onset and 
associated with mild PAIS 
539, 540
. This disease is caused by an expanded CAG repeat in the AR 
NTD, which results in a longer poly-glutamine stretch 
541
. AR containing aggregates are formed 
in the cytoplasm of motorneurons, but the exact molecular mechanism of this disease is still 
unknown 
542, 543
. 
  In Western countries prostate cancer forms a significant health problem as it is the most 
frequently diagnosed male cancer and second leading cause of cancer deaths in men 
544
. The role 
of AR in prostate cancer is discussed in the 1.2.5.1 subsection below. 
1.2.5.1  The AR in prostate cancer 
1.2.5.1.1  Prostate cancer development and progression 
  The prostate is a walnut-sized gland located below the bladder and surrounding the urethra. It 
produces approximately 30% of the seminal fluid, which contains secreted proteins like 
prostatic acid phosphatase (PAP) and the semen liquefying serine protease PSA 
545, 546
. 
Measurement of PSA serum levels is a well known diagnostic tool of prostate cancer. Benign 
prostatic hyperplasia (BPH), which is a common disorder in men over age 50, arises in the 
transitional zone of the prostate, whereas most prostate cancers originate in the peripheral zone 
(see for review ref.  547). 
  The glandular acini of the prostate are lined by a double-layer of epithelial cells. A basal layer 
of cuboidal cells is attached to the basal lamina. The basal layer is covered by a layer of 
columnar mucus-secreting cells lining the lumen of the gland. The luminal epithelial cells 
express cytokeratins 8 and 18, AR, PAP, and PSA 
548
. The basal cells express cytokeratins 5 and 
14, p63, and bcl-2 
434, 548, 549
. Most prostate cancers have a predominantly luminal phenotype 
with expression of keratins 8 and 18, and AR. However, a small percentage of the cells in a 
prostate tumor might express keratins 5 and 14 indicating a basal cell type. Like in normal 
tissues, in several cancers tumor-initiating cells have been found, which are called cancer stem 
cells (CSCs) 
550-556
. The keratin 5 and 14 positive prostate tumor cells were suggested to be 
prostate CSCs (PCSCs). Additionally, cells with an intermediate phenotype have been found to 
express either keratin 17 or 19, and low levels of keratin 8 and 18 
557-559
. These cells are 
considered to form an androgen-independent transit amplifying (TA) population. This led to the 
hypothesis of keratin 5 positive and AR negative PCSCs, which are androgen-independent and 
give rise to androgen-dependent, fully differentiated luminal cells via a TA population 
560
. 
PCSCs are supposed to arise from normal stem cells, which are believed to reside in the basal 
layer 
561
. Evidence for this is provided by the finding of CD133 and α2β1-integrin, which have 
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been identified as normal prostate epithelial stem cell markers, in 0.1% of prostate tumor cells, 
regardless of Gleason grade and metastatic states 
562-565
. In vitro these cells can, like normal 
stem cells, give rise to a mixed population of CD133
+ 
and AR
-
 cells, and more differentiated 
CD133
-
 and AR
+
 cells 
563, 564
. The more differentiated cells develop through subsequent TA and 
intermediate stages into non-proliferating mature cells 
566
. Whether the CD133+ cells indeed can 
form tumors remains to be established. 
  Like normal development and maintenance of the prostate, prostate tumor growth depends on 
continuous stimulation by androgens 
567
. Because of this androgen dependence, prostate cancer 
therapy is generally based on androgen withdrawal, which is achieved by inhibition of testicular 
androgen production using LHRH agonists, and/or blockade of AR function by antiandrogens 
such as BCA or OH-Fl. However, after an initial regression, essentially all prostate tumors 
continue to grow and become androgen-independent, which means independent of androgenic 
stimulation. Although loss of AR expression has been found in some tumors, studies of prostate 
tumors of various clinical stages have revealed that most androgen-independent prostate cancers 
retain AR expression 
558
. In androgen-ablated progressive prostate cancer the AR is still 
primarily located in the nucleus and androgen-regulated genes are expressed 
568-571
. That the AR 
indeed still is playing an important role in androgen-independent prostate cancer is further 
substantiated by RNAi driven AR inhibiton in androgen-independent prostate cell lines, which 
decreased PSA expression, cell proliferation and survival 
572-576
. 
  Important and challenging questions in prostate cancer research are how prostate tumors 
develop and how transition from androgen-dependent to androgen-independent prostate cancer 
occurs and which role the AR plays in these processes.  
1.2.5.1.2 Androgen-dependent prostate cancer 
  Because early stages of prostate tumor growth are dependent on androgens, the underlying 
mechanisms are expected to involve AR function. Although a large number of androgen 
regulated genes has been identified in expression array experiments, until recently none of these 
was specifically identified to play a direct role in the androgen-dependent tumor stage. 
However, recently, the androgen regulated TMPRSS2 gene was found to be highly relevant in 
androgen-dependent prostate cancer 
577, 578
. Fusions of the promoter and first exon(s) of the 
TMPRSS2 gene with members of the ETS transcription factor family, ERG or ETV1, have been 
found in the majority (estimate of 60%) of primary prostate tumors. These gene fusions are 
caused by interstitial deletions and translocations 
577-581
. The fusion genes are androgen-
responsive and highly expressed in tumor tissue, and therefore ETS factors are overexpressed if 
compared to normal prostate tissue 
582, 583
. Expression of the TMPRSS2:ERG fusion genes was 
found to correlate with a higher recurrence rate 
584
. In addition, different isoforms seem to be 
associated with clinical and pathological variables of aggressive disease, and therefore might 
serve as prognostic factors for tumor progression 
585, 586
. 
1.2.5.1.3 Mechanisms of AR activation in androgen-independent prostate cancer  
  For androgen-independent prostate tumor growth G. Jenster (personal communication) has 
proposed several mechanisms in which, despite of androgen withdrawal, the AR is still able to 
stimulate tumor growth (Figure 13). These mechanisms include: AR amplification and/or 
overexpression, AR mutations,  intraprostatic conversion of adrenal androgens to DHT, ligand-
independent AR activation, and aberrant AR coregulator expression and function. In addition, 
several cellular pathways that by-pass the AR have been found to influence prostate tumor 
growth (See for reviews refs 505, 587-591). 
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Figure 13.  Schematic overview of the role of the AR in prostate tumor growth. Proposed and designed 
first by G.Jenster 
 
1.2.5.1.3.1  AR amplification and overexpression 
  AR overexpression, as found in a subset of prostate cancers, can be caused by several 
mechanisms of which gene amplification is the best studied. In approximately 30% of androgen-
independent prostate tumors, AR gene amplification has been detected, whereas this is a rare 
event in untreated primary tumors 
592-597
. In a study of matched paired androgen-sensitive and 
androgen-independent tumors, 80% of androgen-independent tumors with AR gene 
amplification showed an increase in AR protein 
598
. Although AR amplification is not always 
accompanied by increased AR levels, it was found to correlate with a shorter life expectancy 
after relapse of prostate cancer 
598
. Of androgen-independent tumors without AR amplification, 
35% showed increased AR levels 
598
. Comparable observations were done in a study of seven 
paired androgen sensitive and androgen independent prostate cancer xenografts 
599
. Increased 
AR expression was suggested to enable the tumor cells to respond to low androgen levels 
present during androgen withdrawal therapy. This finding was substantiated by experiments in 
which overexpression of AR in LNCaP cells by transfection led to a higher sensitivity of these 
cells to low androgen levels followed by more rapidly progress to hormone-refractoriness 
599
.  
  Because not all cases of increased AR expression can be explained by gene amplification, also 
other mechanisms that regulate AR levels are supposed to be involved in androgen-
independence of prostate tumors. These include increased AR transcription, stabilization of AR 
mRNA, and stabilization of the AR protein (reviewed in ref. 588). 
1.2.5.1.3.2  AR mutations 
  AR mutations are rare in primary and locally progressive untreated prostate tumors, but are 
more common in high grade androgen-independent prostate cancer and distant metastases of 
patients following endocrine therapy. The relative prevalence of AR mutations found in 
androgen-independent prostate cancer varies between different studies, but is estimated to be 
approximately 10% 
600
. A proportion of the prostate cancer related AR mutations enhance AR 
activity, although there are also examples of AR inactivating mutations. Most AR mutations 
lead to gain-of-function by altering the ligand specificity of the AR allowing adrenal androgens, 
non-androgen steroids, and even antiandrogens to activate the receptor. The majority of AR 
mutations found in prostate cancer are confined to 8% of the coding region dispersed over 
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distinct regions of the receptor, but they are most common in the LBD 
601
. AR mutations 
identified in prostate cancer are deposited in the Androgen Receptor Mutations Database 
(http://www.mcgill.ca/androgendb)
263
. 
  Mutations in the NTD are rare, but they might affect AR interaction with coregulators 
602
. A 
E236G mutant is thought to increase AR activity through reduced binding of CHIP (see 1.2.2.1) 
and concomitantly increased responsiveness to coactivators ARA160 and ARA70 
370
. This 
mutation caused rapid development of intraepithelial neoplasia that progressed to invasive and 
metastatic prostate carcinoma in a mouse model 
370
. Several mutations in the hinge region affect 
AR activity. S646F substitution was detected in a high grade tumor and increased AR activity 
603
. A Q640Stop nonsense mutant, which appears as a truncated AR, is constitutively active in 
the absence of ligand 
604
. A C619Y substitution is thought to inactivate and change localization 
of the AR 
605
. AR mutations at the boundary of the hinge region and LBD show an enhanced 
response to androgens, but also to other steroidal and nonsteroidal ligands 
606
. A748T 
substitution in the LBD caused rapid degradation, has a higher ligand dissociation rate and a low 
expression level, if compared to the wild-type AR 
607
. 
  Best studied are the mutations in the AR LBD. Often, these mutations considerably alter the 
ligand-specificity, which includes responsiveness to adrenal androgens, glucocorticoids, 
progesterone, estrogens, and even antiandrogens. The first AR mutation identified was T877A 
in the LNCaP cell line, which was derived from a orchidectomized and E2 treated patient 
608, 609
. 
Subsequently, this mutation was repeatedly found in prostate cancer tissue specimens of patients 
with advanced disease and treated with OH-Fl 
280, 610-614
. Less frequently found mutations are 
H874Y in the androgen-independent  prostate cancer xenograft CWR22 and in a few androgen-
independent OH-Fl treated prostate cancer specimens, and T877S, which is found twice in 
androgen-independent OH-Fl treated tumors 
281, 615, 616
. The T877A substitution rendered the AR 
responsive to progesterone, E2, DHEA, cortisol, OH-Fl, and cyproterone acetate. Both H874Y 
and T877S induce, albeit to a lesser extent, similar properties to the AR (see Chapter 4) 
280, 281, 
494, 613, 615-618
. A double AR mutant, L701H/T877A, found in the MDA PCa 2a cell line, which 
was derived from a bone metastasis of a orchiectomized prostate cancer patient, has properties 
similar to that of the T877A mutant, but it binds cortisol with a higher affinity 
614, 619, 620
. 
Incubation of MDA PCa 2a cells with cortisol is associated with PSA expression and 
stimulation of growth 
620
. AR V715M was found in a OH-Fl treated metastasis and V730M was 
from an organ-confined untreated prostate cancer. Both mutants can be activated by adrenal 
androgens 
621-623
. In a BCA treated prostate cancer, a W741C mutation was found. The same 
mutation and another one at the same position, W741L, were detected in an LNCaP subline 
chronically treated with BCA 
624, 625
. This mutant could not be activated by OH-Fl 
626
. 
  AR T877A mutation seems a hot spot in androgen-independent prostate cancer 
280, 610-613
. It is 
believed that it has arisen by selection of an AR mutant that could be activated by E2 or OH-FL 
that have been used as treatment. This selection process was mimicked by screening of AR 
expression libraries with random mutations at codons 874 or 877 in a yeast read out system in 
the presence of Pg. This hormone was chosen because it is the best activating non-cognate 
ligand of the AR H874Y and T877A mutants found sofar. The T877A mutant was obtained 
most frequently, followed by the T877S and H874Y mutants (see Chapter 4) 
494
. When tested in 
mammalian cells, these mutants showed broadened ligand responses, including responsiveness 
to OH-FL. This indicates that the mutants found in prostate cancer could be selected with non-
cognate ligands that can activate the mutant ARs and therefore prostate tumor growth. It is 
assumed that therapeutic anti-androgen levels are sufficiently high to confer growth advantage 
to cells harboring those mutants and thus favor tumor growth.    
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  Homology modeling and crystallographic analysis of wild-type and mutant AR LBD bound to 
agonists or non-cognate ligands have revealed possible structural mechanisms of the broadened 
ligand responsiveness of AR mutants identified in prostate cancer 
277, 278, 626-630
. The ligand 
binding pocket of the AR is lined by 18 amino acid residues, of which most are hydrophobic, 
except N705, Q711, R752, and T877 
278, 630
. N705 and T877 form hydrogen bonds to the 17β 
hydroxyl group of the D-ring of R1881, R752 forms a hydrogen bond to O-3 in the A-ring of 
R1881. Q711 binds to O-3 through a H2O molecule. T877 is a very important amino acid in 
determining ligand specificity, because substitution by a less bulkier amino acid, like in the 
frequently found T877A mutant, enables binding of other ligands like progesterone, estrogens, 
adrenal androgens, antiandrogens, and even glucocorticoids 
277, 278
. The alanine residue in 
T877A is not able to form a hydrogen bond to the 17β hydroxyl group of the ligand, either DHT 
or R1881, but N705 binding is still sufficient for ligand binding (see Figure 14) 
277, 278
. In 
addition, L880 makes van der Waals contact with the 17β oxygen atom of R1881. On its 
corresponding position, the PR has a threonine (T894), which has a less bulkier side chain. This 
amino acid is supposed to be responsible for binding of progesterone to the PR and not to the 
wild-type AR 
278
. 
   Homology modeling has predicted that binding of the wild-type AR to non-steroidal 
antagonists like OH-Fl includes N705, Q711, and R752 
629
. Crystallographic analysis of the 
wild-type AR LBD bound to agonists that resemble the OH-Fl structure, has shown that 
hydrogen bonding to T877 is not involved, and that the side chain of this amino acid is rotated 
180˚ compared to its position in the receptor bound to steroidal ligands 
627
. This leaves some 
space between T877 and the non-steroidal ligand, which is increased in the T877A mutant and 
becomes occupied then by a water molecule that bridges the ketone group of the non-steroidal 
ligand to the backbone oxygen of L873 
627
. This interaction is thought to increase the agonistic 
activity of such a ligand. Similarly, crystallographic data on the T877A mutant bound to the 
partial agonist CPA have shown that this ligand induces movement of the L701 side-chain. This 
leads to an expansion of the ligand binding pocket that is supposed to enable the bulky CPA 
molecule to act as a full agonist 
628
.  
  Compared to the T877A mutant, in the AR double mutant L701H/T877A there is even more 
space to accomodate non-cognate ligands with bulkier substituents at position 17. The crystal 
structure of this mutant complexed with 9α-fluorocortisol showed favorable hydrogen bonding 
between the C17 and C21 of this synthetic ligand with the mutant protein 
631
. This might explain 
its activation by cortisol. 
  H874 is not directly lining the ligand binding pocket. In fact, it projects away from it, and is 
not able to bind the ligand 
630, 632
. This suggests a conformational change induced by the H874Y 
substitution that indirectly affects ligand binding. 
  In the W741L AR mutant the bulky tryptophan residue is replaced by leucine, which allows 
accomodation of large molecules like BCA, thereby maintaining the agonist bound LBD 
structure. In the wild-type AR, M895 is displaced by BCA, whereas in the W741L mutant this 
residue can be accomodated near L741 
626
. This may explain the presence of this mutation in 
BCA treated prostate cancer patients and in BCA treated LNCaP cells 
624, 625
. Why the W741L 
mutant can not be activated by OH-Fl is not clear yet, but it is thought that a water-mediated 
interaction does not occur between OH-Fl and L873 as was found for the T877A mutant 
627
. 
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Figure 14.  Comparison of (A) binding of DHT to AR LBD with (B) binding of DHT to the AR LBD T877A 
mutant. From ref. 277. 
 
 
  In vitro time-resolved FRET analysis of the wild-type and T877A mutant AR LBD revealed 
that DHT, R1881, E2, spironolactone, Pg, and cortisol, conferred recruitment of the peptide 
D11FXXLF and the SRC-3 LXXLL motif 1 in a way that correlated with the rank order potency 
of these ligands to induce receptor transactivation 
633
. These findings indicate that ligand 
binding and NTD or coactivator binding can be conformationally associated. Also, the extent of 
partial antagonistic activity of antiandrogen might be reflected by differential motif binding. For 
example, the usually antagonistic OH-Fl conferred a better binding of the FXXLF and LXXLL 
peptides to AR T877A LBD than to wild-type AR LBD, whereas the partial antagonist CPA 
conferred recruitment of the LXXLL motif, but not of the FXXLF motif to the mutant LBD 
633
.  
V715M and AR H874Y showed an increase in both FXXLF and LXXLL motif binding as 
compared to the wild-type AR 
634
. The V730M mutant showed an increase in LXXLL motif 
binding, and slightly decreases FXXLF binding 
455
. Androgen dissociation was not altered for 
this mutant 
634
. These findings suggest that several AR LBD mutations found in prostate cancer 
could confer aberrant AR activity through conformational changes that influence coactivator 
recruitment by the non-cognate ligand bound LBD.  
1.2.5.1.3.3  Intraprostatic conversion of adrenal androgens to T and DHT 
  The most common (90%) circulating androgen is T, which is synthesized by the Leydig cells in 
the testes. The remaining 10% are produced by the adrenals and include androgens like 
dehydroepiandrosterone (DHEA), androstenediol, and androstenedione. Upon entrance in target 
cells T can be converted to more potent DHT by 5α-reductase. LHRH agonists used as prostate 
cancer therapy inhibit production of T, thereby leaving adrenal androgen production unchanged. 
In normal and prostate cancer tissues, adrenal androgens have been found to be converted in 
vitro and in vivo to several different androgens among which T and DHT 
635-638
. This might be 
caused by increased expression of aldo-keto reductase family 1, member C3 (AKR1C3) 
639
. This 
enzyme, also called 17-β hydroxysteroiddehydrogenase type 5, converts androstenedione into T, 
which in turn can be converted to DHT. An additional mechanism could be that the conversion 
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of prostatic DHT to 5α-androstane-3α,17β-diol is reversed by a 11-cis retinol dehydrogenase 
like oxidative 3α-hydroxysteroid dehydrogenase (RL-HSD) and/or L-3-hydroxyacyl coenzyme 
A dehydrogenase. These two enzymes were found to be highly expressed in normal prostate 
tissue and are suggested to contribute to castrate prostatic DHT levels 
636
. Whatever the 
mechanism after LHRH induced castration there is an intraprostatic reduction of DHT levels by 
only 50-70%, while serum castrate levels of T are reduced by 90-95% 
640-643
. As described in 
1.2.5.1.3.2, adrenal androgen levels are thought to be able to activate particular AR mutants 
found in a subset of prostate cancers, but not wild-type AR. Moreover, prostatic castrate DHT 
levels are supposed to be sufficient for wild-type AR activation. Therefore a combination of a 
LHRH agonist and an antiandrogen is often used as prostate cancer therapy. 
1.2.5.1.3.4  Ligand-independent activation of the AR through cross-talk with other 
signaling pathways  
  An increasing number of manuscripts describes modulation of AR activity by complex cross 
talk with other signal transduction pathways. Cross-talk with other signaling pathways might be 
both ligand-dependent or -independent. Here several relevant examples of “alternative 
activation” of AR are presented. 
  Overexpression of the epidermal growth factor (EGF) receptor related human epidermal 
growth factor receptor-2 (HER-2) has been found in a subpopulation of prostate cancer patients. 
It has been described that HER-2 activates the AR via the MAPK pathway 
180
. Use of a MAPK 
inhibitor reduced PSA levels in prostate cells and the antagonistic action of antiandrogens is 
decreased in the presence of activated MAPK 
644
. Constitutively expressed active Ras stimulates 
MAPK activity and sensitizes prostate cells to low androgen levels, as examplified in the 
androgen independent C4-2 LNCaP subline where dominant-negative Ras restored sensitivity to 
BCA 
645, 646
. MAPK activity was found to increase during androgen ablation. Its 
phosphorylation, which is thought to be due to TGF-β action, correlates with prostate tumor 
metastatic potential 
647-650
.  
  Interleukin-6 (IL-6) activates the AR in a ligand-independent manner through p300 and SRC-1 
651
. It also activates signal transducers and activators of transcription (STAT3), MAPK, and 
phosphatidylinositol 3-kinase (PI3K), which all might activate the AR 
652,653
. 
  Recently, it was found that AR can be phosphorylated on Y534 by Src 
654, 655
. This 
phosphorylation increased AR activity at low androgen levels and stimulated prostate tumor 
growth in castrated mice 
655
. Src in turn can be activated by growth factors including EGF, 
heregulin, and IL-6 
655, 656
. Src is constitutively expressed in an androgen-independent LNCaP 
subline with a high passage number 
657
. Tyrosine phosphorylation of the AR is increased in 
androgen-independent clinical prostate cancer and correlates with a high Gleason score 
655
.   
  Contradictory reports have been published on the effect of the protein kinase Akt on AR 
activity. It has been described that activation of Akt is associated with advanced prostate cancer 
and that Akt enhances AR activity 
658
. However, inhibition AR activity by Akt has also been 
described 
659
. Possibly, differential phosphorylation of  AR by Akt in different cell lines might 
explain these discrepancies. For example Ser phosphorylated AR was found in LAPC-4 cells, 
but not in LNCaP cells 
660
. HER-2 might activate AR not only through MAPK but also by Akt 
stimulated phosphorylation of S213 and S791 
198
. The Akt downstream target Forkhead box O 1 
(FoxO1) transcription factor activates AR by interaction with the receptor, thereby inhibiting 
apoptosis 
661
.  
  Elevated serum levels of insulin-like growth factor-1 (IFG-1) have been associated with an 
increased prostate cancer risk and with the transition of prostate cancer xenografts to an 
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androgen-independent state 
662
. IGF-1 can activate the AR by inducing the PI3K/Akt or 
Ras/MAPK pathways, which results in AR phosphorylation and sensitization to low androgen 
levels 
271
. IGF-1 receptor (IGF-1R) expression in LNCaP cells can be induced by androgens, 
however, this seems independent of binding of AR to DNA,  but dependent on the Src/MAPK 
pathway 
663
. Increased levels of IGF binding proteins IGFBP-2 and IGFBP-5 have been found in 
prostate cancer patients. These proteins bind to the extracellular matrix thereby maintaining a 
relatively high IGF-1 concentration in the vicinity of the IGF-1R 
664-666
. Taken together, several 
lines of evidence indicate that the IGF signaling pathway can be involved in androgen-induced 
cell proliferation causing androgen-dependent prostate tumor growth, moreover it is a good 
candidate to subsequently promote progression to androgen-independent prostate cancer.   
1.2.5.1.3.5  Aberrant AR coregulator expression and function 
  Although the relative contributions of coregulators to AR function have not been fully 
determined as yet, several are considered to contribute to the development of androgen-
independent prostate cancer.  Aberrant expression of coregulators has been described in prostate 
tumor samples and cell lines, which could lead to stimulation of AR activity in the presence of 
low androgen levels, or, like some AR mutations do (see section 1.2.5.2.2), alter ligand 
specificity of the AR (reviewed in ref. 667). Below several examples are described in more 
detail. It has to be realized, however, that this still is a controversial subject, and that not all data 
are conclusive. 
 For all members of the SRC family, SRC-1, TIF2, and SRC-3, overexpression has been 
reported in subsets of androgen-independent tumors 
668, 669
. Microarray analysis of a large 
patient cohort has revealed that increased SRC-1 expression in prostate cancer is correlated with 
more aggressive disease 
670
. Another important finding is that phosphorylation of SRC-1 by 
MAPK can activate the AR in the absence of androgens to the same extent as physiological 
levels of DHT 
671, 672
. TIF2 expression and phosphorylation were found to be increased in an 
androgen-independent xenograft model by EGF stimulation 
668, 673
. The partial antagonist CPA 
and the antagonist OH-FL are agonists for AR mutant T877A (see section 1.2.5.2.2), and these 
activities were hardly affected by small amounts of the corepressor NCoR. However, TIF2 
strongly enhanced antagonist-induced AR activity 
359
. This indicates that the antagonist-bound 
T877A mutant prefers to bind a coactivator. So, AR activity will not only be determined by the 
ligand (agonist or antagonists), but also by the ratio of coactivator to corepressor ratio in a cell. 
Some prostate tumors show SRC-3 overexpression 
674, 675
. SCR-3 increases PSA levels in the 
presence of very low adrenal androgen levels 
395
. Furthermore there is a correlation between 
SRC-3 expression and a decreased time of prostate cancer relapse 
669
.  
  CBP expression in LNCaP cells is down-regulated by androgens, and seems overexpressed in 
androgen-independent clinical prostate cancer, possibly due to androgen withdrawal 
676
. In 
addition, the agonistic action of the AR antagonist OH-FL is increased by transiently transfected 
CBP in prostate cancer cells containing either wild-type or antiandrogen sensitive mutant AR 
677
. Increased level of CBP-related p300 also correlated with prostate cancer progression 
678
. 
  ARA55 expression was found to be increased in primary prostate tumors, and even more in 
androgen-independent tumors 
679
. It is also associated with shorter recurrence free survival and 
overall survival in androgen-independent prostate cancer patients 
680
. ARA55 is phosphorylated 
by proline-rich tyrosine kinase-2 (PYK-2), which inhibits its binding to AR. In progressive 
prostate cancers PYK-2 expression was found to be reduced, which increases AR-ARA55 
binding and therefore AR activity 
307
. 
  ARA70 is overexpressed in prostate tumors and androgen independent CWR22 xenografts, and 
enables OH-Fl and BCA to function as AR agonists 
569, 681-683
. E2 levels in the stroma of benign 
prostatic hypertrophy and in some prostate cancer samples were found to be relatively high by 
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an increased level of aromatase, which converts T to E2 
684-687
. In vitro increased ARA70 
expression was found to activate AR in the presence of low adrenal androgen or E2 levels 
304
. In 
addition, expression of ARA70 itself is induced by E2, which can further enhance the AR 
response to E2 
688
. Because of these effects of ARA70 on the ligand response of the AR, use of 
E2 or antiandrogens as therapy may be disadvantageous in prostate cancers with elevated 
ARA70. 
  Like ARA70, other AR coactivators were also found to allow AR activation by adrenal 
androgens. β-Catenin is mutated in 5% of prostate cancers 
689
. This seems to increase AR 
activation by androstenedione at the physiological nanomolar level 
319
. Supervillin is able to 
enhance AR activity in the presence of 10 nM androstenediol 
690
.  
  Upon androgen withdrawal, expression and nuclear localization of Tip60 are increased in 
LNCaP cells and CWR22 xenografts. In androgen-independent tumors Tip60 was exclusively 
localized in the nucleus 
691
. However, another study revealed that Tip60 is down-regulated in 
prostate cancer metastases, which indicates that it can have different roles in different tumor 
stages 
692
. Tip60 is also related to PSA expression in androgen-independent cell lines, probably 
by modulating AR acetylation 
300
.  
  Gelsolin, which is up-regulated upon androgen withdrawal in LNCaP cells, LNCaP xenografts, 
and human prostate tumors, was shown to enhance OH-Fl induced AR activity 
321
.  
  ART-27 is supposed to be differentiation-related and is expressed at low or negligible levels in 
prostate cancer specimens compared to well differentiated normal prostate tissue 
326
. However, 
the AR mutant P340L in prostate cancer showed an increased interaction with ART-27. This 
indicates that the role of ART-27 switches during prostate cancer progression. 
  Overexpression of CARM1 has been detected in both early stage prostate carcinoma and in 
androgen-independent prostate carcinoma 
355
.   
1.2.5.1.3.6  Signaling pathways in prostate cancer cells bypassing the AR  
  Several cellular signaling pathways that show cross-talk with AR function might also play a 
role in prostate tumor growth without involvement of AR. These bypass pathways include 
MAPK, Akt, and PKC signaling. 
  Members of the MAPK cascade were found amplified in androgen-independent prostate cancer 
693
. Transfection experiments have indicated that Ras may induce androgen-independence by 
increasing MAPK expression and activation 
646
. AP1, a c-Jun/c-Fos heterodimer, activated by 
the MAPK cascade, can increase expression of androgen-regulated genes by binding to its 
recognition site present in the promoters of some of these genes 
694
. In PC3 cells, which are 
androgen-independent, the levels of c-Jun and c-Fos showed a seven-fold increase as compared 
to androgen-dependent LNCaP cells 
695
. 
  Akt was found to play a role in apoptosis and proliferation of prostate cancer cell lines by 
suppressing pro-apoptotic processes and stimulating G1 cell-cycle progression. It inactivates the 
FoxO transcription factors, which has been claimed to decrease p27kip, a cell-cycle regulator 
661, 696, 697
.   
  Increased PKC expression is correlated with decreased survival time after development of 
androgen-independence 
695
. PKC has at least 12 isoforms, which activate different pathways, 
and since it is not known which isoforms are higher expressed in androgen independent prostate 
cancer it is not possible to determine which PKC induced mechanism is involved 
698
.     
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1.3  AIM AND SCOPE OF THIS THESIS 
 
 The AR, which is the target protein of androgens, is essential in development and maintenance 
of the male phenotype, and therefore plays a key role in diseases like AIS, SBMA or Kennedy's 
disease, and prostate cancer.  
  Androgens stimulate prostate tumor growth, and a generally applied therapy is androgen 
ablation and in case of metastatic prostate cancer anti-androgens are subscribed. This treatment 
initially causes a decrease of tumor size. However, unfortunately, almost all tumors ultimately 
relapse and have started to grow independent of androgens. In a number of patients the AR 
seems still involved in androgen-independent prostate tumor growth through an alternative 
mechanism for activation of the receptor which would not require binding of an androgenic 
ligand to the AR. Therefore, a thorough knowledge of the mechanisms underlying normal and 
aberrant AR function is essential for development and improvement of prostate cancer therapies.  
  Investigation of the molecular mechanisms of AR functions was done at the level of the AR 
protein itself, AR regulated gene transcription and AR mutations. The study 'Molecular 
mechanisms of androgen receptor functions' described in this thesis can be subdivided in three 
topics:  
1) interactions between AR subdomains,  
2) androgen specific transcriptional gene regulation, 
3) aberrant AR function caused by AR mutations found in prostate cancer. 
  Ad 1) A ligand-dependent functional interaction can occur between the AR NTD and AR 
LBD. Deletion mapping of the AR NTD has revealed an important interaction domain. This 
domain contains an interaction motif that is essential in the interaction with the AR LBD. A 
detailed study of this motif is described in Chapter 2.  
  Ad 2) The specifically androgen regulated gene SARG has been identified in the AR and GR 
positive LNCaP-1F5 subline. Its transcription can be up-regulated by androgens, but not by 
glucocorticoids. Chapter 3 describes the characterization of the SARG gene, and the 
bioinformatics-based identification and functional analysis of an androgen specific response 
element in intron 1.  
  Ad 3) Chapter 4 describes a random mutagenesis screening and the subsequent isolation of AR 
mutants, which are not only responsive to androgens, but also to other non-cognate steroids and 
even antiandrogens and cortisol. This broadened ligand specificity might have implications for 
prostate cancer patients carrying such AR mutations.  
  Chapter 5 summarizes the findings described in Chapters 2, 3, and 4, and places these in the 
context of recently published studies and indicates directions of future research. 
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SUMMARY 
 
  The NH2-terminal domain (NTD) and the ligand-binding domain (LBD) of the androgen 
receptor (AR) exhibit a ligand-dependent interaction (N/C interaction). Amino acids 3 to 36 in 
the NTD (AR3-36) play a dominant role in this interaction. Previously, it has been shown that a 
ΦxxΦΦ motif in AR3-36, 
23
FxxLF
27
, is essential for LBD interaction. We demonstrate in the 
current study that AR3-36 can be subdivided into two functionally distinct fragments: AR3-13 and 
AR16-36.  AR3-13 does not directly interact with the AR LBD, but rather contributes to the 
transactivation function of the AR.NTD-AR.LBD complex. AR16-36, encompassing the 
23
FxxLF
27
 motif, is predicted to fold into a long amphipathic α-helix. A second ΦxxΦΦ 
candidate protein interaction motif within the helical structure, 
30
VREVI
34
, shows no affinity to 
the LBD.
 
Within AR16-36, amino acid residues in and flanking the 
23
FxxLF
27 
motif are 
demonstrated to modulate N/C interaction. Substitution of Q24 and N25 by alanine residues 
enhances N/C interaction. Substitution of amino acids flanking the 
23
FxxLF
27 
motif by alanines 
are inhibitory  to LBD interaction.  
 
 
INTRODUCTION 
 
  The androgen receptor (AR) is a member of the steroid receptor subgroup of the nuclear 
receptor family of transcription factors. Nuclear receptors have a modular structure, composed 
of a moderately conserved carboxy-terminal ligand-binding domain (LBD) folded in 12 α-
helices, a highly conserved central DNA-binding domain (DBD) and a non-conserved amino-
terminal domain (NTD). Most nuclear receptors contain two transactivation functions: AF-1 in 
the NTD, and AF-2 in the LBD. Ligand-activated nuclear receptors bind as homo- or 
heterodimers to hormone response elements in the regulatory regions of their target genes. 
Together with coactivators, general transcription factors and RNA polymerase II they form a 
stable transcription initiation complex (see for recent reviews [1-4]). 
  Upon ligand binding the LBD acquires a conformation that facilitates the interaction with 
coactivators. Best studied in this regard are the interactions with the p160 coactivators SRC1, 
TIF2/GRIP1 and ACTR/RAC3. The nuclear receptor interaction domains of p160 coactivators 
contain LxxLL motifs (NR boxes), which bind to a hydrophobic cleft in the agonist-activated 
LBD. Antagonists induce a different LBD conformation, which inhibits the interaction with 
coactivators and enables the binding of corepressors [5] (see for review [3]).  
  P160 coactivators not only bind to the LBD, but also to the NTD [6,7]. This interaction is 
independent of the NR boxes. As shown for the estrogen receptor α (ERα), simultaneous NTD 
and LBD binding by one coactivator can confer synergism of AF-1 and AF-2 activities, which 
might be necessary for optimal functioning [8].  
  Like shown for other nuclear receptors, p160 coactivators can bind the AR LBD by their 
LxxLL motifs, and they interact with the AR NTD, independent of these motifs [9-11]. In 
contrast to AR AF1, which is strong, AF-2 needs overexpression of a p160 coactivator to 
become manifest [9,10,12-15]. Many other proteins with known or unknown functions have 
been found to interact with the AR. An overview of AR-interacting proteins is presented in the 
AR mutations database (http://www.mcgill.ca/androgendb) [16]. 
  Previously, a ligand-dependent functional interaction between the AR subdomains NTD and 
LBD, has been described [17-19]. This N/C interaction might be intra- or intermolecular [15,17-
19]. In vitro pull down experiments indicated that AR N/C interaction is direct [11]. The AF-2 
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core domain in helix 12 of the AR LBD was shown to be involved this interaction [11,15]. In 
the AR NTD two regions are involved in the functional interaction with the AR LBD: AR3-36, 
including the 
23
FxxLF
27
 motif, and AR370-494, which encompasses a transactivation function and 
a presumed supplementary protein interaction domain [15,20]. In the present study, AR3-36 is 
subdivided into two fragments: AR3-13  and AR16-36, which are further characterized. 
 
 
EXPERIMENTAL PROCEDURES  
 
Materials and plasmid construction 
  Dihydrotestosterone (DHT) was purchased from Steraloids (Wilton, NH), R1881 
(methyltrienolone) was from NEN (Boston, MA). 
  Standard procedures were utilized for PCR and molecular cloning [21]. PCR products were 
inserted in pGEM-T Easy (Promega, Madison, WI). All plasmids were sequenced to verify their 
correct construction. Primer sequences are shown in Table 1. AR numbering corresponds to a 
length of 919 amino acids, as employed by The Androgen Receptor Gene Mutations Database 
(http://www.mcgill.ca/androgendb). 
 
 
Table 1. Primers for construction of plasmids   
Primer name Primer sequence 
pr14 5’-TCTAGATTCCCGGGTCCGCCGTCCAAGACCTACCGAGG-3’ 
pr1B 5’-CAGCAGCAGCAAACTGGC-3’ 
pr23/27RR 5’-CTGGGGCCCGGGTTCTGGATCACTTCGCGGACGCTCTGGCGCAGATTCTGGCGAGCTCCT-3’ 
pr30/33RR 5’-CTGGGGCCCGGGTTCTGGATCCGTTCGCGGCGGCTCTGGAACAGATTCTGGAA-3’ 
pr24/25AA 5’-CTGGGGCCCGGGTTCTGGATCACTTCGCGGACGCTCTGGAACAGAGCCGCGAAAGCTCC-3’ 
pr26/27AA 5’-CTGGGGCCCGGGTTCTGGATCACTTCGCGGACGCTCTGGGCCGCATTCTGGAAAGCTCC-3’ 
pr2-36sense 5’-AATTGGGGATCCGAGAAGTGCAGTTAGGGCTGGGAAGG-3’ 
pr2-36anti-sense 5’-GATCGAATTCGTTCTGGATCACTTCGCGCACGCTC-3’ 
pr1-14sense 5’-GATCGAAGTGCAGTTAGGGCTGGGAAGGGTCTACCCTCGGCCGG-3’ 
pr1-14anti-sense 5’-AATTCCGGCCGAGGGTAGACCCTTCCCAGCCCTAACTGCACTTC-3’ 
pr16-36sense 
5’-GATCTCCAAGACCTACCGAGGAGCTTTCCAGAATCTGTTCCAGAGCGTGCGCGAAGTGATC 
CAGAACG-3’ 
pr16-36anti-sense 
5’-AATTCGTTCTGGATCACTTCGCGCACGCTCTGGAACAGATTCTGGAAAGCTCCTCGGTAGG 
TCTTGGA-3’ 
pr17-32sense 5’-GATCAAGACCTACCGAGGAGCTTTCCAGAATCTGTTCCAGAGCGTGCGCG-3’ 
pr17-32anti-sense 5’-AATTCGCGCACGCTCTGGAACAGATTCTGGAAAGCTCCTCGGTAGGTCTT-3’ 
pr24-39sense 5’-GATCCAGAATCTGTTCCAGAGCGTGCGCGAAGTGATCCAGAACCCGGGCCCCG-3’ 
pr24-39anti-sense 5’-AATTCGGGGCCCGGGTTCTGGATCACTTCGCGCACGCTCTGGAACAGATTCTG-3’ 
pr172B 5’-CGGAGCAGCTGCTTAAGCCGGGG-3’ 
pr-242 5’-AAGCTTCTGCAGGTCGACTCTAGG-3’ 
PDsense 5’-GATCCATATCGATAAGCTTAGATCTGAATTCA-3’   
PDanti-sense 5’-AATTCAGATCTAAGCTTATCGATATG-3’ 
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Yeast expression constructs  
  pGalAD-AR.NTDwt (AR3-503), originally derived from the yeast expression vector pACT2 
(Clontech, Palo Alto, CA), and pGalDBD-AR.LBD (AR661-919), originally derived from the 
yeast expression vector pGBT9 (Clontech), were previously described as AR.N8(high) and 
pGAL4(DBD)AR(LBD), respectively [15,18]. pGalAD-AR.NTD∆1-13 was obtained by 
exchange of a 75 bp SmaI fragment of pGalAD-AR.NTDwt with a corresponding fragment 
derived from a PCR product synthesized with primers pr14 and pr1B, utilizing pSVAR0 [22] as 
template. pGalAD-AR.NTD∆3-36 was obtained by excision of a 117 bp SmaI fragment from 
pGalAD-AR.NTDwt. For generation of pGalAD-AR.NTD23/27RR, pGalAD-
AR.NTD30/33RR, pGalAD-AR.NTD24/25AA and pGalAD-AR.NTD26/27AA, a 117 bp SmaI 
fragment of pGalAD-AR.NTDwt was exchanged with corresponding fragments containing the 
indicated mutations, which were obtained by PCR on the template pGalAD-AR.NTDwt 
utilizing primer G4AD1 (Clontech) in combination with one of the following oligonucleotides: 
pr23/27RR, pr30/33RR, pr24/25AA, and pr26/27AA (mutated codons are underlined in Table1). 
  The AR peptide construct pGalAD-AR2-36 was obtained by insertion of a 117 bp  
BamHI/EcoRI fragment, which was synthesized by PCR on the template pSVAR3 [23], utilizing 
primers pr2-36sense and pr2-36anti-sense, into the corresponding sites of pACT2 (Clontech). 
All other pGalAD-ARpeptide constructs were generated by BamHI/EcoRI in frame insertion of 
double-stranded oligonucleotides into the corresponding sites of pACT2 (Clontech), yielding 
pGalAD-AR1-14, pGalAD-AR16-36, pGalAD-AR17-32, pGalAD-AR24-39, pGalAD-AR17-
32(18/19AA), pGalAD-AR17-32(20/21AA), pGalAD-AR17-32(23A), pGalAD-AR17-32(24/25AA), 
pGalAD-AR17-32(26/27AA), pGalAD-AR17-32(28/29AA) and pGalAD-AR17-32(30/31AA). 
Oligonucleotides for these AR peptide expression constructs were: pr1-14sense, pr1-14anti-
sense, pr16-36sense, pr16-36anti-sense, pr17-32sense,  pr17-32anti-sense, pr24-39sense, and 
pr24-39anti-sense. Primers pr18/19AA, pr20/21AA, pr22A, pr24/25AA, pr26/27AA, 
pr28/29AA, and pr30/31AA sense and anti-sense oligonucleotides were modified pr17-32 sense 
and anti-sense oligonucleotides, containing GCTGCA (sense) and TGCAGC (anti-sense) as two 
adjacent alanine codons at the indicated positions. 
 
 Mammalian cell expression constructs 
  pMMTV-LUC, pSVAR.NTDwt (AR1-503) (originally described as pSVAR(TAD1-494)) and 
pSVAR.DBD.LBD (AR537-919) (originally described as pSVAR-104) were previously published 
[18,23,24]. Insertion of a 1.9 kb HindIII fragment from pSVAR3 in HindIII digested pGAD424 
(Clontech) yielded pGAD3. pGAD3.NTD∆3-13 was obtained by insertion of a 75 bp SmaI 
fragment synthesized by PCR on the pSVAR0 template, utilizing primers pr14 and pr172B, into 
the XbaI(Klenow-filled)/SmaI sites of pGAD3. Exchange of a 1.5 kb HindIII/BstEII fragment of 
pSVAR.NTDwt with the corresponding fragment of pGAD3.NTD∆3-13 yielded 
pSVAR.NTD∆3-13. pGAD3∆3-37 was obtained by excision of a 108 bp fragment from pGAD3 
by XbaI(Klenow-filled)/SmaI digestion. pSVAR8 was obtained by exchange of a 1.8 kb HindIII 
fragment of pSVAR3 with the corresponding fragment of pGAD3∆3-37. For construction of 
pSVAR.NTD∆3-37, a 1.7 kb HindIII/Asp718 fragment of pSVAR.NTDwt was exchanged with 
the corresponding fragment of pSVAR8. pSVAR.NTD23/27RR, pSVAR.NTD30/33RR, 
pSVAR.NTD24/25AA and pSVAR.NTD26/27AA were obtained by exchange of a 348 bp 
HindIII/SmaI fragment of pSVAR.NTDwt with corresponding fragments synthesized by PCR 
on the pSVAR0 template, utilizing primer pr-242 and one of the mutant primers pr23/27RR, 
pr30/33RR, pr24/25AA or pr26/27AA. 
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Pull-down constructs  
  For pSVAR.NTDwt and pSVAR.NTDmutant see Mammalian cell expression constructs. 
pCMV-GST-AR.LBD (AR664-919) was generated as follows: pGEX-2TK-CHB was obtained by 
BamHI/EcoRI in frame insertion of a double-stranded oligonucleotide in the corresponding sites 
of pGEX-2TK (Amersham Biosciences, Uppsala, Sweden). Oligonucleotides were PDsense and 
PDanti-sense. Insertion of the AR.LBD ClaI/BglII fragment from pAR34 [23] into the 
corresponding sites of pGEX-2TK-CHB yielded pGST-AR.LBD. Insertion of the AR LBD 
BamHI/SalI fragment of pGST-AR.LBD into the corresponding sites of pCMV-GST [25] 
yielded pCMV-GST-AR.LBD. 
 
Yeast growth, transformation and β-galactosidase assay 
  Yeast strain Y190 (Clontech), containing an integrated Gal4 driven UASGAL1-lacZ reporter 
gene, was utilized for two-hybrid experiments. Yeast cells were grown in the appropriate 
selective medium (0.67% w/v yeast nitrogen base without amino acids, 2% w/v glucose, pH5.8), 
supplemented with the required amino acids. Yeast transformation was carried out according to 
the lithium acetate method [26]. A yeast liquid β-galactosidase assay was performed to quantify 
the interaction of GalAD-AR.NTDwt, GalAD-AR.NTDmutant and GalAD-ARpeptide proteins 
with GalDBD-AR.LBD. In short, stationary phase cultures of Y190 yeast transformants grown 
in selective medium were diluted in the same medium supplemented with 1 µM DHT or without 
hormone, and grown until an OD600 between 0.7 and 1.2. Next, β-galactosidase activity was 
determined as described previously [18].  
 
Mammalian cell culture, transfection, and luciferase assay 
  CHO cells were maintained in DMEM/F12 culture medium, supplemented with 5% dextran-
coated charcoal-treated FCS (Life Technologies, Gaithersburg, MD). Cells were plated in 24 
wells-plates at a density of 2 x 10
4
 cells per well, in a total volume of 0.5 ml. Cells were 
transfected with MMTV-LUC reporter plasmid (50 ng/well) and pSVAR.DBD.LBD (10 
ng/well) together with increasing amounts of pSVAR.NTDwt or pSVAR.NTDmutant (10, 30, 
100, 300 ng/well), supplemented with pTZ19 as carrier DNA to a total amount of 300 ng/well, 
utilizing 0.5 µl FuGENE transfection reagent (Roche Inc, Mannheim, Germany) per well. After 
overnight incubation with or without 1 nM R1881, cells were harvested and luciferase 
measurement was performed as described previously [27]. 
 
Protein extraction and Western blot analysis 
  Yeast protein extracts were obtained by direct lysis of yeast cells in 2x SDS gel-loading buffer 
by a freeze/thawing cycle and boiling, according to Sambrook and Russell (2001) [21]. Western 
blot analysis for detection of GalAD fusion proteins was performed as previously described, 
utilizing a GAL4AD monoclonal antibody (Clontech) [18]. 
  CHO cells were plated at a density of 1.5 x 10
6
 cells per 80 cm
2
 flask and the next day 
transfected with 1 µg pSVAR.NTDwt or pSVAR.NTDmutant, utilizing 12 µl FuGENE 
transfection reagent. After overnight incubation, cells were harvested by scraping in 1 ml PBS 
and centrifugation (5 min. 800xg). Protein extracts were obtained by lysis of the pelleted cells 
in 60 µl lysis buffer A (20  mM Tris, 1 mM EDTA, 0.1% Nonidet P40, 25% glycerol, 20 mM 
Na-molybdate, pH 6.8), with addition of 0.3 M NaCl, followed by three cycles of 
freeze/thawing and centrifugation (10 min. at 400,000xg). Western blot analysis for detection 
of AR.NTD proteins was performed as previously described, utilizing AR antibody SP061 
[18,28].  
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Pull-down assay  
  CHO cell plating, transfection, harvesting, and protein extraction were done as described in 
the previous section, except that 3 µg pCMVGST-AR.LBD and 1 µg pSVAR.NTDwt or 
pSVAR.NTDmutant were utilized, and that transfection and cell lysis were in the absence or 
presence of 100 nM R1881. 5 µl protein lysate was directly applied on a 10% SDS-PAGE gel 
(10% input). 50 µl lysate was mixed with 150 µl buffer A, with or without 100 nM R1881, 
and rotated for 5 h at 4°C with 25 µl glutathione-agarose beads (Sigma-Aldrich, Deisenhofen, 
Germany). Next, agarose beads were washed 5 times with buffer A supplemented with 0.1 M 
NaCl with or without 100 nM R1881, boiled in 30 µl Laemmli sample buffer and 25 µl 
supernatant was separated over a 10% SDS-PAGE gel. After Western blotting, visualization of 
input and precipitated AR.NTD proteins was done as described above. 
 
 
RESULTS 
 
Systems for detection of androgen receptor N/C interaction  
  The ligand-dependent interaction between AR NTD and AR LBD, N/C interaction, was 
studied in yeast and mammalian in vivo protein interaction systems, and in pull down assays. In 
the yeast two-hybrid system, vectors encoding the Gal4 transactivating domain (GalAD) fused 
to AR NTDwt, AR NTDmutant or ARpeptides derived from AR NTD, were transfected to a 
yeast strain, which expressed the Gal4 DNA-binding domain (GalDBD) linked to AR.LBD 
(Figure 1A). Upon incubation with DHT, N/C interaction mediated the expression of an 
integrated UASGAL1-lacZ reporter gene, which was assessed in a β-galactosidase assay. Note 
that in this assay the transactivating function is provided by both AR NTD and GalAD.  
  In the mammalian protein interaction system, vectors encoding wild type or mutated AR NTD, 
and AR DBD-LBD were cotransfected to CHO cells (Figure 1B). R1881-induced activity of a 
transiently transfected androgen-inducible MMTV promoter was assessed in a luciferase assay. 
Note that in this assay the transactivating function is solely contributed by AR NTD.  
  In pull down assays the fusion protein GST-AR.LBD and wild type or mutated AR.NTD 
proteins were transiently expressed in CHO cells.  
 
AR 3-13 modulates the androgen receptor N/C interaction 
  As assayed in the yeast protein interaction system, deletion of AR3-36 (GalAD-AR.NTD∆3-36) 
completely abolished the ligand-dependent functional N/C interaction (Figure 2A). Deletion of 
the amino-terminal 13 amino acids (GalAD-AR.NTD∆1-13) resulted in a slightly diminished 
(approximately 20%) N/C interaction. Because GalAD-AR.NTD∆1-13 was expressed at a 
higher level than GalAD-AR.NTDwt (Figure 2C), the decrease of AR N/C interaction caused by 
AR1-13 deletion might actually be more than observed.  
  Similar to the yeast assay, in the mammalian protein interaction assay, deletion of AR3-37 
completely prevented N/C interaction (Figure 2B). A much more pronounced effect of AR3-13 
deletion on N/C interaction was observed as compared to the yeast assay. The approximately 
90% drop in activity is indicative of an important role of AR3-13 in N/C interaction. The 
diminished interaction was not due to a lower expression level of AR.NTD∆3-13. In fact, 
AR.NTD∆3-13 expression was higher than AR.NTDwt expression (Figure 2C). 
To investigate whether AR3-13 directly binds to AR LBD, pull down experiments were carried 
out. The results are presented in Figure 3. In the absence of ligand, none of the AR NTD 
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proteins showed LBD interaction. However, in the presence of ligand, both AR.NTDwt and 
AR.NTD∆3-13 bound to AR LBD with similar affinity (Figure 3). In contrast, AR.NTD∆3-37 
did not interact.  
 
AR2-14 cannot autonomously interact with the androgen receptor LBD   
  To substantiate the modulating role of AR2-14 in N/C interaction, as suggested by the 
experiments described above, the individual peptides AR2-36, AR2-14 and AR16-36 coupled to 
GalAD (Figure 4A) were assayed in the yeast protein interaction system (Figure 4B). No 
substantial interaction with AR.LBD was found for GalAD-AR2-14. Activity was retained for 
approximately 60% in the GalAD-AR16-36/AR.LBD complex. Because the GalAD-AR2-36 
expression level was lower than that of GalAD-AR16-36 (Figure 4C), the actual difference in 
activity between GalAD-AR2-36 and GalAD-AR16-36, might be larger.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.   Schematic representation of in vivo protein interaction systems utilized in this study. 
(A) Yeast protein interaction (two-hybrid) system. DHT dependent interaction between GalAD-AR.NTD and 
GalDBD-AR.LBD induces expression of the UASGAL1 regulated lacZ reporter gene. Cotransfection of pGBT9 and 
pACT2, which encode GalDBD and GalAD, respectively, does not induce reporter gene expression (data not 
shown). Similarly, individually expressed GalDBD-AR.LBD and GalAD-AR.NTD are not active in this assay. (B) 
Mammalian (CHO cells) protein interaction system. R1881 dependent interaction between AR.NTD and 
AR.DBD.LBD induces MMTV-promoter driven luciferase expression. Separately expressed AR.DBD.LBD and 
AR.NTD are unable to activate the MMTV promoter (data not shown). 
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Figure 2.   AR3-13 modulates androgen receptor N/C interaction. 
(A) Interaction of AR.NTDwt and NH2-terminal deletion mutants with AR.LBD in the presence of 1 µM DHT in 
the yeast protein interaction system. In each experiment the activity of GalAD-AR.NTDwt was set at 100%. Each 
bar represents the mean (±sem) β-galactosidase activity of three independent experiments. (B) Interaction of 
AR.NTDwt and deletion mutants with AR.LBD in the presence of 1 nM R1881 in the mammalian protein 
interaction system. pSVAR.DBD.LBD was cotransfected with increasing amounts of pSVAR.NTDwt or mutant 
(see Experimental Procedures). In each experiment, carried out in triplicate, the mean of the highest AR.NTDwt 
value was set at 100%. Each bar represents the mean (±sem) luciferase activity of three independent experiments. 
Fold induction is shown to the right of each bar and represents the ratio of activities determined in the presence and 
absence of R1881. (C) Western analysis of indicated GalAD-AR.NTD proteins in the yeast protein interaction 
system (left panel) and of indicated AR.NTD proteins in the mammalian protein interaction system (right panel). 
See Experimental Procedures for details. 
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Figure 3.   AR3-13 is not involved in direct binding of AR NTD to AR LBD. 
Interaction of AR.NTDwt and NH2-terminal deletion mutants with GST-AR.LBD as studied by pull down assays. 
Proteins were produced in CHO cells by cotransfection of pCMVAR.LBD and pSVAR.NTDwt or indicated 
deletion constructs. CHO cells were cultured in the absence (-) or presence (+) of 100 nM R1881. Input is 1/10 of 
the lysate utilized in a pull down experiment. See Experimental Procedures for details. 
 
 
Analysis of 
30
VREVI
34
 in androgen receptor N/C interaction  
  Prediction programs of protein secondary structures (see http://npsa-pbil.ibcp.fr) indicated a 
long α-helical structure for AR20-34. A helical wheel drawing of this region predicted an 
amphipathic character of this helical structure (Figure 5A) [29]. At positions 15 and 37, the 
putative α-helix is flanked by proline residues. Within the helix, two candidate ΦxxΦΦ protein 
interaction motifs (Φ is any hydrophobic amino acid residue; x is any amino acid residue) are 
present: 
30
VREVI
34
 and the previously identified 
23
FQNLF
27
 motif (Figure 5B) [20,30,31]. To 
investigate whether like 
23
FQNLF
27
, 
30
VREVI
34
 could contribute to N/C interaction, two 
constructs were generated, expressing either the complete 
30
VREVI
34
 or the complete 
23
FQNLF
27
 motif linked to GalAD (Figure 5B). As expected, in the yeast protein interaction 
system, ligand-dependent interaction with AR LBD could easily be detected for GalAD-AR17-32. 
However, the interaction was weak for GalAD-AR24-39 (Figure 5C). Low activity was not due to 
decreased protein expression (Figure 5D).  
  In a complementary yeast protein interaction experiment, the 
30
VREVI
34
 motif in GalAD-
AR.NTDwt was modified by substitution of two hydrophobic amino acids by arginine residues, 
resulting in GalAD-AR.NTD30/33RR. These substitutions might cause sterical hindrance in the 
interaction with the AR LBD surface, change the charge and disrupt the proposed amphipathic 
α-helical structure of AR16-36. GalAD-AR.NTD23/27RR was utilized as control. Substitution of 
V30 and V33 partially reduced the interaction, whereas the F23R,F27R mutation completely 
abolished the interaction (Figure 6A). Expression levels of GalAD-AR.NTDwt and GalAD-
AR.NTD30/33RR were similar (Figure 6C).  
  Results obtained in the mammalian protein interaction system, utilizing the AR.NTD30/33RR 
mutant and AR.NTD23/27RR, were essentially identical to the observations made in the yeast 
input pull-down
- + - +
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D
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system (Figure 6B). A partial inhibition of AR N/C interaction was observed for 
AR.NTD30/33RR, and an almost complete inhibition for AR.NTD23/27RR. 
  Pull down experiments confirmed and extended the in vivo protein interaction experiments 
(Figure 6D). AR N/C interaction was diminished due to 30/33RR substitutions, and completely 
abolished by 23/27RR substitutions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.   AR2-14 cannot autonomously interact with AR LBD.  
(A) AR peptides utilized in GalAD-ARpeptide fusion proteins in the yeast protein interaction system. (B) 
Interaction of indicated GalAD-ARpeptides with GalDBD-AR.LBD in yeast in the presence of 1 µM DHT. In each 
experiment the activity of GalAD-AR2-36 was set at 100% (see also legend to Figure 2A). (C) Western analysis of 
indicated GalAD-ARpeptide proteins in yeast. For details, see Experimental Procedures.  
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Figure 5.   Analysis of a predicted long amphipathic α-helix of  AR18-35 in AR N/C interaction.  
(A) A helical wheel drawing of AR18-35 predicts a long amphipathic α-helical structure. Grey circles represent 
hydrophobic amino acids. (B) ) GalAD-ARpeptide fusion proteins utilized in the yeast protein interaction system. 
The ΦxxΦΦ motifs 23FQNLF27 and 30VREVI34 are underlined. (C) Interaction of GalAD-ARpeptides with 
GalDBD-AR.LBD in yeast in the presence of 1 µM DHT. In each experiment the activity of GalAD-AR16-36 was 
set at 100% (see also legend to Figure 2A). (D) Western analysis of indicated GalAD-ARpeptide proteins in the 
yeast system. For details, see Experimental Procedures. 
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Figure 6.   
30
VREVI
34
 is not essential for AR N/C interaction. 
(A) Interaction of GalAD-AR.NTDwt and mutants with AR.LBD in the presence of 1 µM DHT in the yeast protein 
interaction system. In each experiment GalAD-AR.NTDwt activity was set at 100% (see legend to Figure 2A). (B) 
Interaction of AR.NTDwt and mutants with AR.LBD in the presence of 1 nM R1881 in the mammalian protein 
interaction system. pSVAR.DBD.LBD was cotransfected with increasing amounts  of pSVAR.NTDwt or indicated 
mutants (see Experimental Procedures and legend to Figure 2B). (C) Western analysis of indicated GalAD-
AR.NTD proteins in the yeast system (left panel) and indicated AR.NTD proteins in the mammalian system (right 
panel). See also Experimental Procedures. (D) Pull down assays showing interaction of AR.NTDwt and mutants 
with GST-AR.LBD (see also legend to Figure 3).  
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Amino acid residues flanking F23, L26 and F27 modulate androgen receptor N/C interaction 
  To study in more detail the role of 24/25QN in  the 
23
FQNLF
27
 motif in AR N/C interaction, 
these amino acids were substituted by 24/25AA. In both the yeast and mammalian protein 
interaction assay, GalAD-AR.NTD24/25AA and AR.NTD24/25AA formed even more active 
complexes with AR LBD than wild-type AR NTD (Figures 7A and 7B) (note the low 
expression levels of the 24/25AA mutants in both systems; Figure 7C). As expected, 
AR.NTD26/27AA was incapable to interact with AR.LBD.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.   Alanine substitutions of Q24 and N25 stimulate AR N/C interaction. 
(A) Interaction of GalAD-AR.NTDwt and mutants with GalDBD-AR.LBD in the presence of 1 µM DHT in the 
yeast protein interaction system. In each experiment GalAD-AR.NTDwt activity was set at 100%. See also legend 
to Figure 2A. (B) Interaction of AR.NTDwt and mutants with AR.LBD in the presence of 1 nM R1881 in the 
mammalian protein interaction system. pSVAR.DBD.LBD was cotransfected with increasing amounts of 
pSVAR.NTDwt or mutants (see Experimental Procedures and legend to Figure 2B). (C) Western analysis of 
indicated GalAD-AR.NTD proteins in the yeast protein system (left panel) and indicated AR.NTD proteins in the 
mammalian system (right panel). For details, see Experimental Procedures. 
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  To extend these findings, an alanine scan was carried out for peptide GalAD-AR17-32 (Figure 
8A). Results of the yeast protein interaction assay are shown in Figure 8B. Substitution of amino 
acids 23, 26 and 27 completely abolished interaction with GalDBD-AR.LBD and alanines at 
positions 24 and 25 increased the interaction capacity. All alanine substitutions of amino acids 
flanking 
23
FQNLF
27
 reduced the binding to AR LBD. Most prominent inhibitory effects were 
found for amino acid residues directly flanking 
23
FQNLF
27
. Note that expression levels of the 
peptide constructs were similar (Figure 8C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.  Alanine scanning of AR17-32: amino acids flanking F23, L26 and F27 modulate AR N/C 
interaction.  
(A) GalAD-ARpeptide fusion proteins in the yeast protein interaction system. (B) Interaction of GalAD-
ARpeptides with AR.LBD in the presence of 1 µM DHT in the yeast protein interaction system. In each experiment 
the activity of GalAD-AR17-32 was set at 100%. See also legend to Figure 2A. (C) Western analysis of indicated 
GalAD-ARpeptide proteins in the yeast assay. For details, see Experimental Procedures. 
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DISCUSSION 
 
  Previously, we and others demonstrated a ligand-dependent functional interaction between AR 
NTD and AR LBD. Amino acids 3-36 in the NTD (AR3-36), including the 
23
FxxLF
27
 motif, play 
a pivotal role in N/C interaction [15,20]. Here we studied the function of the AR3-36 subdomain 
AR3-13 in N/C interaction and the role of individual amino acid residues in and flanking the 
23
FQNLF
27
motif in AR16-36 in N/C interaction.  
  Yeast protein interaction assays indicated that AR3-13 contributed to the ligand-induced 
transactivation function of the AR.NTD/AR.LBD complex (Figures 2 and 4). Pull down 
experiments provided evidence that AR3-13 does not directly interact with AR LBD (Figure 3). 
On first sight, conflicting results were obtained in the yeast and mammalian protein interaction 
assays (Figure 2). In the yeast assay, reporter gene activity, which monitored the N/C 
interaction, was partly reduced by AR3-13  deletion, whereas in the mammalian assay almost all 
reporter gene activity was lost. The most obvious difference between both assays is the coupling 
of AR.NTD to GalAD in the yeast assay, and the absence of a second transactivation domain 
linked to AR NTD in the mammalian assay. The latter assay completely depends on the intrinsic 
transactivating function of AR NTD and thus does not allow discrimination between loss of 
AR.NTD-AR.LBD binding and loss of AR.NTD transactivating function. In the yeast assay, 
loss of transactivation function of AR NTD mutants, which retain AR LBD interacting capacity, 
like AR.NTD∆3-13, will be masked by the GalAD transactivating function. So, AR3-13 is not 
essential, but rather modulates N/C interaction, most likely by affecting the transactivation 
function of AR.NTD. Alternative explanations might be induction of a more favorable NTD 
conformation or stabilization of the in vivo N/C interaction, which are not reflected in the pull 
down assays and peptide interaction experiments. Unfortunately, the primary structure and the 
predicted secondary structure of AR3-13 do not give a clue to a more precise description of its 
function (data not shown). However, the fact that, between species, AR3-13 is one of the most 
conserved regions of AR NTD, underscores a presumed important role in AR function [32]. 
  The second domain that was studied, AR16-36, is essential in N/C interaction. The predicted 
structure indicated that AR16-36 can fold in a remarkably long amphipathic α-helical structure, 
suggesting an important protein interaction interface [29]. AR16-36 contains two ΦxxΦΦ putative 
protein interaction motifs: 
23
FxxLF
27
, which was found to be pivotal for direct N/C interaction 
[20, this study], and 
30
VxxVI
34
 (Figures 5 and 6). The latter sequence modulates N/C 
interaction. Amino acid residues in this sequence might contribute to the stability of the 
predicted α-helix. Alternatively, they might make additional contacts to the LBD surface. This 
is also true for other amino acid residues flanking the 
23
FxxLF
27 
motif  (Figure 8). Remarkably, 
substitution of Q24 and N25 by alanines increased N/C interaction (Figures 7 and 8). 
  The AR FxxLF motif shows similarities to LxxLL motifs [5,33,34] present in nuclear receptor 
interaction domains (NR boxes) of p160 coactivators. LxxLL motifs are essential in the 
interaction with LBDs [33]. They bind to a hydrophobic cleft in nuclear receptor LBDs, which 
is marked by a charged clamp composed of a highly conserved lysine and glutamate residue in 
helix 3 and helix 12 of the LBD, respectively (K720 and E897 in AR) [35-37]. AR K720 and 
E897 are both involved in the ligand-dependent interaction between AR LBD and the 
coactivator TIF2 [9,11,15]. However, in the FxxLF-mediated AR N/C interaction, E897 is 
essential, but K720 can be replaced by many other amino acids, without affecting N/C 
interaction [9,11,15,38]. So, the AR N/C interaction is comparable, but not identical to LxxLL-
mediated coactivator-LBD interaction.  
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  The 3D structures of agonist bound LBD/LxxLL peptide complexes of several nuclear 
receptors have been elucidated, and interactions of the peptide backbone and its amino acid side 
chains with the LBD surface have been identified [5,36,37,39]. It is presumed that upon binding 
to the LBD surface, the LxxLL motif adapts a short α-helical structure, which is stabilized by 
interaction with the charged clamp [5,36,37]. The first and last leucine residue in the LxxLL 
motif enter the hydrophobic cleft in the LBD, and directly contact amino acid residues within 
the cleft. The variable amino acids (xx) in the LxxLL motif point away from the cleft and seem 
not to interact directly with the LBD surface. Structural data for AR.LBD/LxxLL peptides are 
not available, but, because AR.LBD/coactivator interaction also depends on K720 and E897, it 
might be predicted that they will be similar to LBD/LxxLL peptide complexes studied so far 
[9,11,15]. Because K720 is not essential for AR
23
FxxLF
27
/AR.LBD interaction, the structure of 
this complex might be different. A different complex would also explain the stimulation of 
AR
23
FxxLF
27
/AR.LBD interaction by substitution of Q24 and N25 by alanine residues. 
Structural analyses of AR.LBD/AR16-36 complexes have to reveal the function of amino acid 
residues flanking F23, L26 and F27 and answer the question whether or not the entire long 
amphipathic AR16-36 α-helix is required for a stable AR NTD/LBD complex. 
  The LxxLL-like motifs LxxIL, FxxLL, and L/IxxI/VI, have been found in LBD binding 
coactivators or corepressors [40-43]. FxxLF motifs that are able to contact AR LBD, have only 
been found in AR NTD and most recently in the AR coactivators ARA54 and ARA70, 
suggesting a specific role of these motifs in AR function [44-47]. The increasing number of 
proteins found to interact with the AR LBD raises the question of the physiological relevance of 
the many interactions. It remains to be established whether all interactions take place in living 
cells under physiological conditions, whether interactions with different proteins are 
simultaneous or consecutive events, and which interactions are most stable and most specific. 
Recently, a start has been made to the identification of factors, including the AR, present in the 
transcription initiation complex of the prostate specific antigen enhancer/promoter, using 
chromatin immunoprecipitation (ChIP) [48].  
  Another question concerns the interaction of AR16-36 with other proteins. One candidate might 
be the TFIID TATA box-binding protein associated factor 31, TAFII31, which has been found to 
interact with FxxΦΦ motifs in acidic transcription activation domains of p65 (NF-κB), VP16, 
p53 and related proteins [31,49-51]. 
  AR NTD has previously been proposed to accommodate more than one AR LBD interacting 
domain [9,15,20]. A candidate second domain is 
433
WHTLF
437
, which was found to modulate 
23
FxxLF
27
 function [20]. Another candidate motif is 
179
LxxIL
183
 [9]. However, peptides 
containing these motifs were unable to interact with AR LBD in the yeast protein interaction 
assay, excluding their role as a second autonomous interaction motif in AR NTD (data not 
shown).   
  N/C interaction is not unique for the AR, but has also been described for other nuclear 
receptors. ERα ligand-dependent direct N/C interaction has been demonstrated, which was 
disrupted by amino acid substitutions that affect receptor function [52,53]. The ERα N/C 
interaction could be induced by the agonist estradiol (E2), but not by the antagonist ICI164,384 
[53]. Recently, it was found that the ERα N/C interaction was required for SRC-1 mediated 
synergism between AF-1 and AF-2 function [8,53]. The progesterone receptor (PR) showed 
direct N/C interaction in the presence of agonist R5020, but not in the presence of antagonist 
RU486 [54]. LxxLL motifs in the PR-B form were most likely not involved, because the shorter 
PR-A form, lacking these motifs, also showed N/C interaction [55].  
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  The role of N/C interaction in full-length AR function is not well understood. Ligand-
dependent AR N/C interaction affects ligand dissociation [11,20,56]. Whether this is a direct or 
an indirect effect is unknown. Disruption of the N/C interaction by mutation of the 
23
FxxLF
27
 
motif has a limited effect on full length AR transactivation function [20, Steketee unpublished]. 
However, several AR LBD mutants with reduced or completely abolished N/C interaction have 
been found in androgen insensitivity patients [11,56,57]. Additionally, both N/C interaction and 
transactivating function of the AR prostate cancer mutant T877A can be induced by natural low 
affinity ligands like progesterone or E2 or the AR antagonist cyproterone acetate [18].  
  In conclusion, we propose that AR3-36 is involved in a dynamic sequence of protein interaction 
events, including N/C interaction, in regulation of AR function. Detailed knowledge on the role 
of the AR N/C interaction would require the elucidation of its function under more physiological 
conditions, including the study of mouse models carrying AR mutants defective in N/C 
interaction. 
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ABSTRACT 
 
  We characterized the specifically androgen-regulated gene SARG, which is expressed in the 
androgen receptor and glucocorticoid receptor positive cell line LNCaP-1F5. SARG mRNA 
expression can be up-regulated by androgens, but not by glucocorticoids. SARG mRNA 
expression is high in prostate tissue. SARG is composed of 4 exons and spans a region of 14.5 
kbp on chromosome 1q32.2. Transcripts of 5.5, 3.3 and 2.3 kb are the result of alternative 
polyadenylation. SARG mRNA splice variants lack exon 2 and vary in length of exon 1. The 
SARG protein has a length of 601 amino acids and is located in the cytoplasm. By screening 18 
kbp genomic sequence flanking the transcription start site we identified the imperfect direct 
repeat 5’-TGTGCTaacTGTTCT-3’ in intron 1 as an active androgen response element (ARE-
SARG+4.6). A 569 bp genomic DNA fragment, containing this element functioned as an 
androgen-specific enhancer in transiently transfected LNCaP-1F5 cells. ARE-SARG+4.6 
cooperated with flanking sequences for optimal activity. Inactivation of ARE-SARG+4.6 
completely abolished the androgen response of the enhancer. ChIP experiments showed 
chromatin structural changes of the enhancer in the presence of R1881. ARE-SARG+4.6 was 
able to bind to the androgen receptor, but not to the glucocorticoid receptor, correlating with its 
androgen-specific activity in transfections. 
 
 
INTRODUCTION 
 
  Androgens are essential in the development and maintenance of the male phenotype. They 
mediate their function by activation of the androgen receptor (AR), which is a member of the 
nuclear receptor family of ligand-activated transcription factors. Nuclear receptors have a 
modular structure composed of a moderately conserved carboxyl-terminal ligand-binding 
domain (LBD), a highly conserved central DNA-binding domain (DBD) and a non-conserved 
amino-terminal domain (NTD). Most ligand-activated nuclear receptors bind as homodimers or 
heterodimers to hormone response elements (HREs) in the regulatory regions of their target 
genes. HREs are composed of an inverted or direct repeat of two 6 bp half-sites separated by a 
spacer of variable size (Khorasanizadeh and Rastinejad 2001). Together with coactivators, 
chromatin remodelling complexes, general transcription factors and RNA polymerase II, nuclear 
receptors initiate the transcription of target genes in a tightly controlled fashion (Glass and 
Rosenfeld 2000, Lee and Lee Kraus 2001, McKenna and O'Malley 2002). 
  An important class of nuclear receptors is the family of steroid hormone receptors, which is 
composed of AR, glucocorticoid receptor (GR), mineralocorticoid receptor (MR), progesterone 
receptor (PR) and estrogen receptors alpha and beta (ERα and ERβ) (Thornton 2001). Steroid 
hormone receptors display distinct physiological functions, reflected in their tissue-specific 
expression pattern and to some extent in their spectrum of target genes. However, AR, GR, MR 
and PR all bind with high affinity to the same inverted repeat consensus sequence 5’-
AGAACAnnnTGTTCT-3’ (Nordeen et al. 1990, Roche et al. 1992, Lieberman et al. 1993, 
Lombes et al. 1993). As a result, the activity of several promoters can be regulated by more than 
one of these receptors. Examples are the MMTV promoter, and the promoters of the C3, the CRP 
and the PSA gene (Ham et al. 1988, Claessens et al. 1989, De Vos et al. 1994, Cleutjens et al. 
1997, Devos et al. 1997). The consensus high affinity binding site of ERα and ERβ is slightly 
different, 5’-AGGTCAnnnTGACCT-3’ (Klein-Hitpass et al. 1989). Therefore, ERα and ERβ 
direct the expression of a different panel of target genes. Because GR, MR, PR and AR recognize 
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the same DNA sequence, it has been postulated that additional mechanisms are necessary to 
explain their specificity. These include differences in expression levels of the various receptors in 
specific cell types (Strahle et al. 1989), selective interaction with specific transcription factors, 
coactivators and corepressors, and ligand availability (Glass and Rosenfeld 2000, Aranda and 
Pascual 2001, Heinlein and Chang 2002). 
  In spite of the identical high-affinity recognition sequence for AR, PR, GR and MR, steroid 
response elements can also direct receptor specificity. In natural promoters steroid receptor binding 
sites can deviate considerably from the consensus high-affinity binding site. These sequences might 
have a different affinity to the various receptors. Additionally, sequences directly flanking the 
response element can contribute to receptor affinity and preference (Nelson et al. 1999, Haelens et 
al. 2003). On top of this, the AR seems to have adopted an exclusive mechanism of specificity. A 
few genes are known to be preferentially regulated by AR (Claessens et al. 2001). The structures of 
the androgen response elements (AREs) that direct androgen-specificity to these genes more 
resemble direct repeats of the sequence 5’-TGTTCT-3’ than classic inverted repeats of this 
sequence.  
  The androgen-sensitive human prostate carcinoma cell line LNCaP expresses AR, but lacks GR 
and PR (Horoszewicz et al. 1983, Berns et al. 1986). It was previously shown that growth of 
LNCaP cells, and PSA mRNA expression in these cells can be stimulated by androgens 
(Schuurmans et al. 1988, Riegman et al. 1991, Young et al. 1991). In order to compare directly the 
molecular and biological function of AR and GR, the LNCaP-1F5 subline, containing a stably 
integrated GR expression vector, was generated (Cleutjens et al. 1997). PSA mRNA expression in 
LNCaP-1F5 can be induced by both androgens and glucocorticoids, but cell growth is selectively 
induced by androgens. We identified in LNCaP-1F5 cells a novel gene that is specifically 
regulated by androgens (Cleutjens et al. 1997). In the present study an integrated experimental 
and bioinformatics-based approach was applied to characterize the gene, designated SARG, and 
to decipher the molecular mechanism of androgen-specific regulation of the gene.  
 
 
MATERIALS AND METHODS 
 
Materials 
  Methyltrienolone (R1881) was purchased from NEN (Boston, MA), dexamethasone (Dex) was 
obtained from Steraloids (Wilton, NH). Cell culture media were from Bio Whittaker (Verviers, 
Belgium), fetal calf serum (FCS) was from Roche Diagnostics (Almere, The Netherlands). 
 
Plasmid construction 
  pLUC and pPSA-4-LUC have been described previously (Cleutjens et al. 1996). pHisXpress-
cSARG, expressing (His)6-Xpress-SARG protein, contains the SARG cDNA fragment 209-
2579 (SARG ORF is from 251 to 2053) inserted in the eukaryotic expression vector 
pcDNA3.1His (Invitrogen, Carlsbad, CA). 
  The SARG genomic fragments SARG-8.5, SARG-7.3 and SARG+4.6, with sizes of 510 bp, 
476 bp and 569 bp, respectively, were obtained by PCR on PAC90L18 DNA (GenomeSystems, 
St Louis, MO) as template with the primer sets:  
-8.5F: 5'-GATCAGCTGGATCCCAGGGACATGGATGAAGCTG-3' 
-8.5R: 5'-GATCAGCTGGATCCTGCCTCAACCTCCCAAGTAG-3' 
-7.3F: 5'-GATCAGCTGGATCCGTCATAATGACTTGGCCATG-3' 
-7.3R: 5'-GATCAGCTGGATCCTGTCCAACATTTGAGGCCAG-3' 
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+4.6F: 5'-GATCAGCTGGATCCGTATCGTAGCGGTGGTTGTG-3' 
+4.6R: 5'-GATCAGCTGGATCCTGGAGAGGCAGTCTAGTCAG-3' 
The resulting amplified fragments were inserted in pGEM-T Easy (Promega, Madison, WI), 
sequenced and subsequently inserted as BamHI/BamH1 fragments in pPSA-4-LUC, yielding 
pSARG-8.5-PSA-LUC, pSARG-7.3-PSA-LUC and pSARG+4.6-PSA-LUC, respectively. 
  The -55 to +168 genomic fragment SARG-S was obtained by PCR on PAC90L18 DNA, 
utilizing the primers SARG-A: 5'-GCTAAGAGGGAACAGCACCAC-3' and SARG-B: 5'-
CCCGGGAGATCTACTAGTCCACTGGGTTG-3'. The PCR product was inserted in pGEM-T 
Easy, verified by sequencing and inserted as a 240 bp PvuII/BglII fragment in pLUC, yielding 
pSARG-S-LUC. To generate pSARG-L-LUC, the –3012 to -1559 HindIII/PvuII SARG genomic 
fragment was isolated from PAC90L18 and inserted in the corresponding sites of pSARG-S-
LUC, yielding pSARG-L∆-LUC. Subsequently, the -1559 to –55 PvuII/PvuII genomic SARG 
fragment was inserted into the PvuII site of pSARG-L∆-LUC. The resulting construct pSARG-
L-LUC contains SARG bp -3012 to +168. 
  SARG+4.6 was inserted as a BamHI/BamH1 fragment upstream of the SARG-S promoter or 
SARG-L promoter in pSARG-S-LUC and pSARG-L-LUC, respectively, yielding pSARG+4.6-
SARG-S-LUC and pSARG+4.6-SARG-L-LUC. pSARG+4.6m-SARG-S-LUC was generated 
by mutagenesis utilizing the QuikChange Site Directed Mutagenesis Kit (Stratagene, LaJolla, 
CA) on pSARG+4.6-SARG-S-LUC as template. Primers: mut-4603S: 5’-
CAACTAAACTATGATAACTATTATCTCATTTAATC-3’ and its complementary strand: 
mut-4603AS. 
  SARG+4.6-(+4447/+4659)-S-LUC and SARG+4.6-(+4548/4659)-S-LUC were constructed by 
insertion of the respective BamH1/BamH1 fragments upstream of the S promoter in pSARG-S-
LUC. The fragments SARG+4.6-(+4447/+4659) and SARG+4.6(+4548/+4659) were generated 
by PCR utilizing the primers 
  S+4.6-A (5’-GATCAGCTGGATCCCCTTCTTTTCTGAGATCCTG-3’) and 
 S+4.6-B (5’-GATCAGCTGGATCCCTCATGAGGTCTTAGGGTAT-3’) as respective 
forward primers, and S+4.6-C (5’-GATCAGATGGATCCGGCAAATTACTCTGAGTCTG-3’) 
as reverse primer. Amplified fragments were sequenced prior to insertion into pSARG-S-LUC 
as BamH1/BamH1 fragments.  
  pRIT2TAR, encoding rat AR DBD, was described previously (De Vos et al. 1991). prGR-
DBD-PRIT2T, encoding rat GR DBD, was constructed by BamHI/SalI insertion of a PCR 
fragment, synthesized with primers rGR-DBD-1: 5'-
CAGCGGATCCGCAGCCACGGGACCACCTCCC-3' and rGR-DBD-2: 5'-
CTATTGTCGACTAAGGATTTTCCGAAGTGTCTTG-3' on pSTC-GR3-795 (Rusconi and 
Yamamoto 1987) as template, in pRIT2T (Amersham Biosciences, Bucks, UK). 
 
Screening of a prostate cDNA library 
  Screening of a λgt10 human prostate cDNA library (BD Biosciences Clontech, Palo Alto, CA) 
was performed according to the manufacturer's protocol. Hybridization probes were the SARG 
differential display PCR (DD-PCR) fragment (GenBank Accession Number AF007835) and 
SARG cDNA fragment 855-1957 (see GenBank Accession Number AY352640)
 
. 
 
RACE-PCR 
  For RACE-PCR we applied the Marathon-Ready prostate cDNA cloning kit (BD Biosciences 
Clontech). Primers: SARG-RACE: 5'-CCTGAAGTTCTGGCTTCTGGCAATGTG-3' and the 
standard AP1 primer of the  
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kit. Amplified cDNA fragments were inserted in pGEM-T Easy and sequenced.  
 
Analysis of alternative splicing of mRNA by RT-PCR  
  cDNA was synthesized from 1 µg total RNA isolated from LNCaP cells incubated for 24 h in 
RPMI 1640 supplemented with 5% (v/v) dextran-coated charcoal treated FCS (FCS-DCC), 
antibiotics and 1 nM R1881. cDNA synthesis was performed at 55°C utilizing M-MuLV reverse 
transcriptase and an oligo-dT primer. Subsequently, PCR was carried out under standard 
conditions on the LNCaP cDNA template utilizing either forward primer SARG-F1A: 5’-
CCAGGCAGCACAGATGAAGC-3’ or SARG-F1B: 5’-AGCCTCTGTCTCCATCTCTGC-3’ 
in combination with the reverse primer SARG-R: 5’-CTTCAGTGGACAGGAAGTCG-3’. RT-
PCR products were inserted in pGEM-T Easy and sequenced. 
 
RNA isolation and Northern analysis 
Total RNA from LNCaP and LNCaP-1F5 cells was isolated by the guanidinium thiocyanate 
method (Sambrook and Russell 2001). RNA (10 µg per lane) was separated by electrophoresis on a 
1% (w/v) agarose formaldehyde gel in TBE. Following electrophoresis RNA was transferred to a 
Hybond-N
+
 membrane (Amersham Biosciences). The blot was hybridized under standard 
conditions at 65°C utilizing the 32P-labelled HindIII/HindIII SARG cDNA fragment (854-1957) 
as a probe (Sambrook and Russell 2001). Actin cDNA was utilized as a hybridization control. 
Blots were exposed to X-ray film with intensifying screens at -80°C. 
 
Analysis of tissue specific expression of mRNA by PCR  
  Tissue specificity of SARG mRNA was assayed by semi-quantitative PCR on Human MTC Panel 
II cDNA (BD Biosciences, Clontech), containing cDNAs from spleen, thymus, prostate, testis, 
ovary, small intestine, colon and peripheral blood lymphocytes, essentially according to the 
procedure described in the User Manual. G3PDH primers from the cDNA kit were used as a 
control (30 amplification cycles). SARG primers utilized were 5’-
AGTCTGAGCCAGCCACAACT-3’ (F-ex3) and 5’-TGTGGATATTCCTAGGGAGG-3’ (R-ex4) 
(30 amplification cycles; primer annealing was at 55°C). 
 
Immunocytochemistry 
  LNCaP cells were seeded at a density of 3 x 10
5
 cells per well on sterile micro-slides in four-well 
tissue culture plates (Heraeus Instruments, Hanau, Germany), cultured until 50% confluence in 
RPMI 1640, supplemented with 5% (v/v) FCS and antibiotics, and subsequently transfected with 5 
µg pHisXpress-cSARG. After overnight incubation, cells were washed twice in phosphate buffered 
saline (PBS), and fixed in acetone for 10 min. Next, slides were rinsed twice in PBS, followed by 
overnight incubation in mouse anti-Xpress antibody solution (Invitrogen) diluted 1:500 in PBS at 
4°C. Incubation was stopped by four PBS washes. Next, slides were incubated for 30 min at room 
temperature in goat anti-mouse peroxidase conjugate antibody (DAKO, Glostrup, Denmark) 
solution (1:100 dilution in PBS). After four PBS washes, immunoreactivity was visualized by 
diaminobenzidine (DAB) staining. The reaction was stopped in water. Cells were counterstained 
with Mayers Hematoxylin.  
 
Isolation of genomic DNA fragments 
  The SARG DD-PCR fragment was randomly 
32
P-labelled and utilized to screen a genomic 
human PAC library on gridded filters (GenomeSystems, St. Louis, MO) according to the 
manufacturer's protocol. DNA was isolated from positive PACs by standard procedure 
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(Sambrook and Russell 2001). For Southern blot analysis 10 µg PAC90L18 DNA was HindIII, 
PstI or EcoRI digested, electrophoresed on a 0.8% TAE-agarose gel and subsequently transferred 
to a Hybond-N
+
 membrane. Filters were hybridized at high stringency with randomly 
32
P-labelled 
SARG probes under standard conditions (Sambrook and Russell 2001). HindIII, PstI or EcoRI 
digested PAC DNA was shot-gun cloned in the corresponding sites of pBSKS
+/-
 (Stratagene). 
Clones were utilized for isolation of genomic fragments by screening with randomly 
32
P-
labelled SARG cDNA fragments and for SARG gene walking with overlapping HindIII, PstI and 
EcoRI fragments. Hybridizing inserts were sequenced. 
 
Search for candidate androgen response elements 
  The MatInspector professional program (www.genomatix.de/mat_fam) (Quandt et al. 1995) was 
utilized for detection of candidate AREs with queries for the inverted repeat 5’-
RGWACANNNTGTTCT-3’ (R=A/G, W=G/T) and the direct repeat 5’-TGTTCTNNNTGTTCT-
3’. The threshold for candidate AREs was set at 9 out of 12 matches. The Matinspector program 
searched both the sense and anti-sense strand. Identified sequences were manually further selected 
according to additional criteria. Candidate inverted repeat AREs should contain G and C at the 
double-underlined positions in the sequence above, and at least one of either single underlined C or 
G. Candidate direct repeat AREs should contain three out of four single-underlined C and G 
residues.  
 
Cell culture, transfection and luciferase assay 
  LNCaP and LNCaP-1F5 cells were cultured in RPMI 1640 supplemented with 5% (v/v) FCS 
and antibiotics. Four hour prior to transfection, medium was substituted by Dulbecco's 
Modification of Eagle's Medium (DMEM) supplemented with 5% (v/v) FCS-DCC. Transient 
transfections were performed according to the calcium phosphate precipitation method 
(Sambrook and Russell 2001) utilizing 1 x 10
6
 cells per 25 cm
2
 flask and 5 µg of one of the 
pLUC-constructs. After 4 h the medium was removed and cells were incubated for 90 sec at 
room temperature in PBS containing 15% (v/v) glycerol. Next, transfected cells were cultured in 
DMEM-FCS-DCC medium for 24 h in the absence or presence of 1 nM R1881 or 10 nM Dex. 
Transfected cells were washed in PBS, and subsequently incubated in 300 µl lysis buffer (25 
mM Tris-phosphate, pH 7.8/ 8 mM MgCl2/ 1mM DTT/ 1% (v/v) Triton X-100/ 15% (v/v) 
glycerol). Next, 100 µl 0.25 mM luciferin (Sigma, St. Louis, MO)/ 0.25 mM ATP in lysis buffer 
was added to 150 µl lysate, and luciferase activity was measured in a LUMAC 2500 M 
Biocounter (LUMAC, Landgraaf, The Netherlands).  
 
Electrophoretic mobility shift assay 
  AR DBD and GR DBD were produced in Escherichia coli, and purified as described 
previously (De Vos et al. 1991). AR DBD and GR DBD were expressed from pRIT2TAR and 
pRIT2TrGR-DBD, respectively. 
Oligonucleotide electrophoresis mobility shift assay (EMSA) probes: 
PSA ARE I:     5'-GATCCTTGCAGAACAGCAAGTGCTAGCTG-3' 
              3'-GAACGTCTTGTCGTTCACGATCGACCTAG-5' 
Probasin ARE II: 5'-TCGACTAGGTTCTTGGAGTACTTTG-3' 
    3'-GATCCAAGAACCTCATGAAACAGCT-5' 
ARE-SARG+4.6: 5’-TCGACACTGTGCTAACTGTTCTCTG-3’ 
    3’-GTGACACGATTGACAAGAGACAGCT-5’ 
DR:   5’-TCGACACTGTTCTAACTGTTCTCTG-3’ 
    3’-GTGACAAGATTGACAAGAGACAGCT-5’ 
 115
ARE-mSARG+4.6: 5’-TCGACACTATGATAACTATTATCTG-3’ 
       3’-GTGATACTATTGATAATAGACAGCT-5’ 
Probes were filled in by standard M-MuLV-RT reaction in the presence of α-32P-dATP, and 
subsequently purified on a non-denaturing polyacrylamide gel. For EMSA, 50 x 10
3
 cpm probe 
was added to 20 µl reaction mixture, containing 2 µg poly dIdC, 2 µg BSA, 10 µM ZnCl2, 1 
mM DTT and 2 µl 10x binding buffer (100 mM Hepes, pH 7.6/ 300 mM KCl/ 62.5 mM MgCl2/ 
4% (v/v) ficoll 400), and 5 pmol AR DBD or GR DBD. Incubation was for 30 min on ice. 
Samples were electrophoresed on a 4% (w/v) polyacrylamide (19:1 mono/bis acryl ratio) gel in 
a 25 mM Tris.HCl/ 41.5 mM boric acid/ 0.5 mM EDTA buffer for 2 h at 150 V at room 
temperature. Subsequently, gels were fixed, dried and exposed to X-ray film. 
 
Chromatin immunoprecipitation  
  Chromatin immunoprecipitations (ChIP) were done essentially according to the method 
described in the Acetyl-Histone H3 ChIP assay kit (Upstate Biotechnology, Chicago, Il). In 
short, LNCaP cells were grown for at least 3 days on 5% FCS-DCC supplemented RPMI 1640 
medium. To half of the cultures R1881 was added to a final concentration of 10 nM. After 1 h 
cells were cross-linked with formaldehyde (1% final concentration) at 22
o
C for 10 min. Cross-
linking was stopped by addition of glycine to a final concentration of 125 mM. Next, cells were 
washed in ice-cold PBS and harvested in PBS supplemented with protease inhibitors (Roche 
Diagnostics). Cell pellets were resuspended in SDS lysis buffer and sonicated to shear the DNA. 
Sonicated samples were centrifuged, diluted in Chip Dilution Buffer and precleared by 
incubation with salmon sperm DNA/Protein A agarose slurry for 1 h at 4
o
C with rotation. After 
centrifugation, immunoprecipitation of the supernatant was performed overnight at 4 
o
C with 
Acetyl-Histone H3 antibody. Next, salmon sperm DNA/Protein A agarose slurry was added, and 
the incubation was continued for another hour. Agarose beads were washed according to the 
procedure described by the manufacturer. Eluates were heated overnight at 65
o
C to reverse the 
cross-linking. DNA fragments were purified with a QIAquick Spin Kit (QIAGEN, Hilden, 
Germany). One µl from 50 µl DNA solution was used in a standard PCR (35 amplification 
cycles). Primer sequences were: 
-8.5F: 5’-CAGGGACATGGATGAAGCTG-3’ 
-8.5R: 5’-GAACCCGTCATCTACATTAG-3’ 
-7.3F: 5’-GTAAGTCCAACACAGCTAGTC-3’ 
-7.3R: 5’-CTGAGATGCTGAGAGGCTGA-3’ 
+4.6F: 5’-CAAGTCTACAGTCTCCCATC-3’ 
+4.6R: 5’-CTCAAATCCCAGTTTAGCCA-3’. 
PCR fragments were separated over an agarose gel. 
 
 
RESULTS 
 
SARG mRNA expression in LNCaP-1F5 cells 
  Utilizing DD-PCR technology, we previously identified in LNCaP-1F5 prostate cancer cells, 
which express both AR and GR, a novel androgen-specific  regulated gene, denoted 21.1 in the 
initial study and SARG in the present study (Cleutjens et al. 1997). SARG mRNA expression 
was found to be up-regulated by the synthetic androgen R1881, but not by the synthetic 
glucocorticoid Dex. Utilizing the DD-PCR fragment as hybridization probe, a 5.5 kb transcript 
was identified in R1881-incubated LNCaP-1F5 cells. 
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Figure 1.  SARG cDNA, and androgen-regulated and prostate specific SARG mRNA expression. 
(A) Schematic overview of the isolation of the complete SARG cDNA. The start and stop codons are indicated. An 
asterisk indicates a polyadenylation signal. DD-PCR indicates the original differential display fragment (Cleutjens et al. 
1997). RACE1, RACE2 are two related 5' ends of SARG cDNA. (B) Northern blot of SARG mRNA expression in 
LNCaP-1F5 cells incubated for 24 h without hormone (-), with 1 nM R1881 or 10 nM Dex. Transcript sizes are 
indicated. Actin was utilized as a loading control. (C) RT-PCR analysis of SARG mRNA expression in spleen (1), 
thymus (2), prostate (3), testis (4), ovary (5), small intestine (6), colon (7) and lymphocytes (8). cDNAs were 
normalized for G3PDH expression as loading control. 
 
 
  For further characterization of SARG we first isolated full-length SARG mRNA. Overlapping 
SARG cDNA fragments were obtained by repeated screening of a human prostate cDNA library. 
In the first screen the DD-PCR fragment was utilized as hybridization probe (Figure 1A). The 
longest cDNA, containing a polyadenylation signal and a polyA tail, was 3.6 kbp. Screening of the 
cDNA library with a 5' fragment of this cDNA as a probe resulted in the detection of an 
overlapping 2.7 kbp cDNA with a second polyadenylation signal and a polyA tail. This cDNA 
fragment extended the cDNA sequence to approximately 4.9 kbp. Further 5' SARG cDNA 
sequence was obtained by RACE-PCR, utilizing a primer in the 2.7 kbp cDNA. Two related 5' 
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cDNA fragments of 665 bp and 537 bp, respectively, were found. The shorter fragment (RACE2) 
lacked nucleotides 42-169 of the longer fragment (RACE1) (Figure 1A). The longest SARG cDNA 
sequence of 5487 bp was deposited in GenBank under Accession Number AY352640. 
  A BLAST search of the EST database (www.ncbi.nlm.nih.gov/) identified two EST clusters 
overlapping the SARG cDNA sequence. The first group represented the 3’ parts of the 5.5 kb and 
3.3 kb transcripts, as detected in the cDNA library (Unigene cluster Hs.32417), the second cluster 
represented a 2.3 kb transcript, which contained SARG 5’ cDNA sequences, and a third 
polyadenylation sequence and polyA tail (Unigene cluster Hs.223394). We confirmed the presence 
of three polyadenylation signals in the 5.5 kbp SARG cDNA sequence (Figure 1A). A 1.1 kbp 
SARG cDNA fragment (nucleotides 854 to 1957) hybridized with all three predicted SARG 
mRNAs in a Northern blot of LNCaP-1F5 RNA (Figure 1B). The 3.3 kb transcript showed the 
highest expression. All SARG transcripts were up-regulated by R1881, but their expression could 
not be induced by Dex. Semi-quantitative RT-PCR indicated high SARG mRNA expression in 
prostate tissue (Figure 1C, lane 3) as compared to spleen, thymus, testis, ovary, small intestine, 
colon and lymphocytes.  
 
SARG protein 
  The SARG open reading frame (ORF) encodes a 601 amino acid protein (Figure 2A). This ORF 
is identical to that of the hypothetical protein MGC2742 (Genbank). Because Unigene cluster 
Hs.23417 encompasses the 3’ part of the two longest SARG transcripts, a predicted protein from 
this EST cluster (MGC4309) is unlikely.  
  To determine its cellular localization, SARG protein was Xpress-tagged and transiently expressed 
in LNCaP cells. Immunocytochemical staining with anti-Xpress antibody showed that SARG 
protein was exclusively present in the cytoplasm (Figure 2B). 
 
SARG gene structure and splice variants   
  The complete SARG gene was isolated in one PAC (90L18) by screening of a human genomic 
PAC library with the SARG DD-PCR fragment (see Figure 1A) as probe. To characterize SARG, 
subcloned overlapping HindIII, PstI and EcoRI fragments of PAC 90L18 were hybridized with 
appropriate cDNA fragments. Comparison with the cDNA sequence revealed that SARG was 
composed of 4 exons, and spanned 14.5 kbp (Figure 3A). The two cDNA fragments obtained by 
RACE-PCR represented two forms of exon 1, the short exon 1A, and the extended exon 1AB. All 
splice junctions were consistent with the GT/AG rule (Figure 3B). The SARG ORF started in exon 
2 and ended in the large exon 4 (Figure 3A). SARG is part of BAC RP11-564A8 (Genbank 
Accession Number AC098935.2). The transcription start site is at position 184,776 in this clone. 
SARG maps at chromosome band 1q32.2.  
  RACE-PCR and RT-PCR revealed four different SARG splice variants (Figure 3C). The largest 
variant contained all 4 exons, smaller variants lacked either part B of exon 1AB, exon 2 or both. 
The splice variants lacking exon 2, which formed a minority, are predicted to encode a protein of 
355 amino acids, starting at methionine 247 (Figure 2A). The corresponding ATG codon is in exon 
4, in frame with the long SARG ORF  (Figure 3C).    
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Figure 2.  The SARG open reading frame and the cellular localization of the SARG protein. 
(A) The SARG ORF encodes a protein of 601 amino acids. Methionine 247 (in bold) is the first amino acid residue 
of the shorter SARG protein translated from mRNA lacking exon 1B and/or exon 2 sequences. (B) The SARG 
protein is located in the cytoplasm. LNCaP cells were transfected with pcHisXpress-cSARG encoding Xpress-
tagged SARG protein. Xpress-SARG was visualized by immunostaining with anti-Xpress antibody. 
2 5 1        A T G C C C G A G A G G G A G C T G T G G C C A G C G G G G A C T G G C T C A G A A C C C G T G A C C C G T G T C G G C  
1           M   P   E   R   E   L   W   P   A   G   T   G   S   E   P   V   T   R   V   G    
 
3 1 1        A G C T G T G A C A G C A T G A T G A G C A G C A C C T C C A C C C G C T C T G G A T C T A G T G A T A G C A G C T A C  
2 1          S   C   D   S   M   M   S   S   T   S   T   R   S   G   S   S   D   S   S   Y    
 
3 7 1        G A C T T C C T G T C C A C T G A A G A G A A G G A G T G T C T G C T C T T C C T G G A G G A G A C C A T T G G C T C A  
4 1          D   F   L   S   T   E   E   K   E   C   L   L   F   L   E   E   T   I   G   S    
 
4 3 1        C T G G A C A C G G A G G C T G A C A G C G G A C T G T C C A C T G A C G A G T C T G A G C C A G C C A C A A C T C C C  
6 1          L   D   T   E   A   D   S   G   L   S   T   D   E   S   E   P   A   T   T   P    
 
4 9 1        A G A G G T T T C C G A G C A C T G C C C A T A A C C C A A C C C A C T C C C C G G G G A G G T C C A G A G G A G A C C  
8 1          R   G   F   R   A   L   P   I   T   Q   P   T   P   R   G   G   P   E   E   T    
 
5 5 1        A T C A C T C A G C A A G G A C G A A C G C C A A G G A C A G T A A C T G A G T C C A G C T C A T C C C A C C C T C C T  
1 0 1         I   T   Q   Q   G   R   T   P   R   T   V   T   E   S   S   S   S   H   P   P    
 
6 1 1        G A G C C C C A G G G C C T A G G C C T C A G G T C T G G C T C C T A C A G C C T C C C T A G G A A T A T C C A C A T T  
1 2 1         E   P   Q   G   L   G   L   R   S   G   S   Y   S   L   P   R   N   I   H   I    
 
6 7 1        G C C A G A A G C C A G A A C T T C A G G A A A A G C A C C A C C C A G G C T A G C A G T C A C A A C C C T G G A G A A  
1 4 1         A   R   S   Q   N   F   R   K   S   T   T   Q   A   S   S   H   N   P   G   E    
 
7 3 1        C C G G G G A G G C T T G C G C C A G A G C C T G A G A A A G A A C A G G T C A G C C A G A G C A G C C A A C C C A G G  
1 6 1         P   G   R   L   A   P   E   P   E   K   E   Q   V   S   Q   S   S   Q   P   R    
 
7 9 1        C A G G C A C C T G C C A G C C C C C A G G A G G C T G C C C T T G A C T T G G A C G T G G T G C T C A T C C C T C C G  
1 8 1         Q   A   P   A   S   P   Q   E   A   A   L   D   L   D   V   V   L   I   P   P    
 
8 5 1        C C A G A A G C T T T C C G G G A C A C C C A G C C A G A G C A G T G T A G G G A A G C C A G C C T G C C C G A G G G G  
2 0 1         P   E   A   F   R   D   T   Q   P   E   Q   C   R   E   A   S   L   P   E   G    
 
9 1 1        C C A G G A C A G C A G G G C C A C A C A C C C C A G C T C C A C A C A C C A T C C A G C T C C C A G G A A A G A G A G  
2 2 1         P   G   Q   Q   G   H   T   P   Q   L   H   T   P   S   S   S   Q   E   R   E    
 
9 7 1        C A G A C T C C T T C A G A A G C C A T G T C C C A A A A A G C C A A G G A A A C A G T C T C A A C C A G G T A C A C A  
2 4 1         Q   T   P   S   E   A   M   S   Q   K   A   K   E   T   V   S   T   R   Y   T    
 
1 0 3 1       C A A C C C C A G C C T C C T C C T G C A G G G T T G C C T C A G A A T G C A A G A G C T G A A G A T G C T C C C C T C  
2 6 1         Q   P   Q   P   P   P   A   G   L   P   Q   N   A   R   A   E   D   A   P   L    
 
1 0 9 1       T C A T C A G G G G A G G A C C C A A A C A G C C G A C T A G C T C C C C T C A C A A C C C C T A A G C C C C G G A A G  
2 8 1         S   S   G   E   D   P   N   S   R   L   A   P   L   T   T   P   K   P   R   K    
 
1 1 5 1       C T G C C A C C T A A T A T T G T T C T G A A G A G C A G C C G A A G C A G T T T C C A C A G T G A C C C C C A G C A C  
3 0 1         L   P   P   N   I   V   L   K   S   S   R   S   S   F   H   S   D   P   Q   H    
 
1 2 1 1        T G G C T G T C C C G C C A C A C T G A G G C T G C C C C T G G A G A T T C T G G C C T G A T C T C C T G T T C A C T G  
3 2 1         W   L   S   R   H   T   E   A   A   P   G   D   S   G   L   I   S   C   S   L    
 
1 2 7 1       C A A G A G C A G A G A A A A G C A C G T A A A G A A G C T C T A G A G A A G C T G G G G C T A C C C C A G G A T C A A  
3 4 1         Q   E   Q   R   K   A   R   K   E   A   L   E   K   L   G   L   P   Q   D   Q    
 
1 3 3 1       G A T G A G C C T G G A C T C C A C T T A A G T A A G C C C A C C A G C T C C A T C A G A C C C A A G G A G A C A C G G  
3 6 1         D   E   P   G   L   H   L   S   K   P   T   S   S   I   R   P   K   E   T   R    
 
1 3 9 1       G C C C A G C A T C T G T C C C C A G C T C C A G G T C T G G C T C A G C C T G C A G C T C C A G C C C A G G C C T C A  
3 8 1         A   Q   H   L   S   P   A   P   G   L   A   Q   P   A   A   P   A   Q   A   S    
 
1 4 5 1       G C A G C T A T T C C T G C T G C T G G G A A G G C T C T G G C T C A A G C T C C G G C T C C A G C T C C A G G T C C A  
4 0 1         A   A   I   P   A   A   G   K   A   L   A   Q   A   P   A   P   A   P   G   P    
 
1 5 1 1       G C T C A G G G A C C T T T G C C A A T G A A G T C T C C A G C T C C A G G C A A T G T T G C A G C T A G C A A A T C T  
4 2 1         A   Q   G   P   L   P   M   K   S   P   A   P   G   N   V   A   A   S   K   S    
 
1 5 7 1       A T G C C A A T T C C T A T C C C T A A G G C C C C A A G G G C A A A C A G T G C C C T G A C T C C A C C G A A G C C A  
4 4 1         M   P   I   P   I   P   K   A   P   R   A   N   S   A   L   T   P   P   K   P    
 
1 6 3 1       G A G T C A G G G C T G A C T C T C C A G G A G A G C A A C A C C C C T G G C C T G A G A C A G A T G A A C T T C A A G  
4 6 1         E   S   G   L   T   L   Q   E   S   N   T   P   G   L   R   Q   M   N   F   K    
 
1 6 9 1       T C C A A C A C T C T G G A G C G C T C A G G C G T G G G A C T G A G C A G C T A C C T T T C A A C T G A G A A A G A T  
4 8 1         S   N   T   L   E   R   S   G   V   G   L   S   S   Y   L   S   T   E   K   D    
 
1 7 5 1       G C C A G C C C C A A A A C C A G C A C T T C T C T G G G A A A G G G C T C C T T C T T G G A C A A G A T C T C G C C C  
5 0 1         A   S   P   K   T   S   T   S   L   G   K   G   S   F   L   D   K   I   S   P    
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5 6 1         Y   Q   G   Q   S   R   D   K   L   P   R   P   P   C   V   S   V   K   I   S    
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Figure 3.  SARG gene structure and splice variants.  
(A) Schematic presentation of the SARG gene. The ATG start codon in exon 2 and the TAG stop codon in exon 4 are 
indicated. The three asterisks indicate polyadenylation signals. (B) Splice donor and acceptor sites at the exon/intron 
boundaries in the SARG gene. Numbering is according to the genomic SARG sequence. (C) Four different splice 
variants of the SARG gene. Start and stop codons are indicated. 
 
 
Functional and bioinformatics-based selection of candidate androgen response elements 
  To establish androgen response of SARG, the promoter fragments SARG-L (-3012 to +168) and 
SARG-S (-55 to +168) were inserted in front of the luciferase reporter gene in the constructs 
pSARG-L-LUC and pSARG-S-LUC, respectively. Transient transfection of these constructs to 
LNCaP cells showed in both cases a very weak androgen response, indicative of the absence of 
strong AR binding sites (see Figure 4D).  This prompted us to screen for candidate AREs in a 
region of approximately 18 kbp, from 9 kbp upstream to 9 kbp downstream of the transcription 
start site, by a bioinformatics-based approach. This sequence is present in BACs AC098935.2 and 
AC023534. The MatInspector program was applied to search both DNA strands for sequences 
homologous to the direct repeat 5’-TGTTCTnnnTGTTCT-3’ or to the inverted repeat consensus 
ARE sequence 5’-A/GGA/TACAnnnTGTTCT-3’ (see Materials and Methods). We selected 
sequences that showed at least 9 out of 12 matches in the two half sites. Out of the sequences 
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least 3 out of 4 underlined C or G residues in the direct repeat, or presence of the double-underlined 
C and G residue, and at least one of the two single-underlined C and G residues in the inverted 
repeat. Utilizing this approach we identified 34 candidate AREs in the 18 kbp region, 12 inverted 
repeats and 22 direct repeats. None of these was completely identical to the consensus inverted 
repeat. One was a perfect direct repeat and two sequences deviated at one position from a perfect 
direct repeat. Four sequences matched the inverted or direct repeat at 10 out of 12 positions. 
Several candidate AREs clustered in the genome. At approximately –8.5 kbp a cluster of 4 
candidate AREs was present, including the imperfect direct repeat 5’-TGAACAatgAGAACA-3’ 
(11/12 matches); at +4.6 kbp a cluster of 5 candidate AREs was detected, including the imperfect 
direct repeat 5’-TGTGCTaacTGTTCT-3’ (11/12 matches). The latter cluster is located in SARG 
intron 1. The perfect direct repeat 5’-TGTTCTcctTGTTCT-3’ mapped at -7.3 kbp, one ARE-like 
sequence was close to this repeat (Figure 4 A,B). 
  Next, it was investigated whether three genomic fragments containing the indicated direct repeats 
and flanking candidate AREs could function as enhancer regions. Genomic fragments with a size 
of approximately 500 bp, SARG-8.5, SARG-7.3 and SARG+4.6, respectively, were coupled to 
PSA4-LUC, containing the 600 bp promoter of the PSA gene. This promoter was weakly 
responsive to androgens, but combination with an upstream PSA enhancer fragment resulted in a 
strong androgen-inducible promoter (Cleutjens et al. 1997). In transfected LNCaP cells, SARG-8.5 
and SARG-7.3 had no significant effect on the weak R1881 induction of the PSA4 promoter. In 
contrast, SARG+4.6 clearly increased R1881 induced PSA4 activity (Figure 4C). Next, SARG+4.6 
was linked to SARG-S (-55 to +168) and SARG-L (-3012 to +168), which both showed, as 
mentioned above, a very low androgen induction. Similar to the PSA promoter experiment, linkage 
of SARG+4.6 to both SARG-L and SARG-S showed androgen response in transfected LNCaP 
cells (Figure 4D).  
 
SARG intron 1 contains a functional direct repeat androgen response element 
  To determine whether the imperfect direct repeat 5’-TGTGCTaacTGTTCT-3’ in SARG+4.6 
was responsible for androgen induction, it was mutated to 5’-TATGATaacTATTAT-3’. The 
mutated fragment was coupled to SARG-S and tested in LNCaP cells for its response to R1881. 
As shown in Figure 5A, the androgen induction of SARG+4.6 was completely abolished by the 
mutations. 
  Next, the direct repeat 5’-TGTGCTaacTGTTCT-3’ in SARG+4.6, designated ARE-SARG+4.6, 
was tested in an EMSA for its ability to bind to AR DBD (Figure 5B). Control AREs were PSA 
ARE I (5’-AGAACAgcaAGTGCT-3’), which has been shown to bind strongly to the AR DBD, 
and rat probasin ARE II (5’-AGTACTccaAGAACC-3’), which is considered as a direct repeat, 
strongly interacting with AR DBD (Riegman et al. 1991, Rennie et al. 1993, Claessens et al. 1996, 
Cleutjens et al. 1996). ARE-SARG+4.6 bound to AR DBD, albeit weaker than the PSA and 
probasin AREs. The change of ARE-SARG+4.6 into the perfect direct repeat 5’-
TGTTCTaacTGTTCT-3’ (DR) did not affect its capacity to bind AR DBD. AR DBD was unable 
to bind inactive mutant ARE-mSARG+4.6 (5’-TATGATaacTATTAT-3’). 
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Figure 4.  Three direct repeat candidate androgen response elements in the SARG gene. 
 (A) Positions (kbp) of the 3 direct repeat candidate AREs (♦) in the SARG gene. (B) Sequences and location of the 
3 direct repeat candidate AREs in the SARG gene. Numbering is according to the genomic SARG sequence. 
Matching to the direct repeat 5’-TGTTCTnnnTGTTCT-3' is indicated below the sequences. (C) Androgen-induced 
activity of the SARG fragments, containing a direct repeat candidate ARE, coupled to the PSA4 promoter. LNCaP 
cells were transiently transfected with pPSA-4-LUC, pSARG-8.5-PSA-LUC, pSARG-7.3-PSA-LUC or 
pSARG+4.6-PSA-LUC. Luciferase activity was measured after 24 h incubation with or without 1 nM R1881. (D) 
Androgen-induced activity of SARG+4.6 coupled to SARG-S and SARG-L, respectively. LNCaP cells were 
transfected with pSARG-S-LUC, pSARG+4.6-SARG-S-LUC, pSARG-L-LUC or pSARG+4.6-SARG-L-LUC. 
After 24 h incubation with or without 1 nM R1881 luciferase activity was measured. Value +/- SEM in (C) and (D) 
are from two experiments carried out in duplicate. Fold induction is the ratio of luciferase activity measured in the 
presence and absence of R1881. 
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Figure 5  The direct repeat in SARG+4.6 is a functional androgen response element. 
(A) Effect of mutation of ARE-SARG+4.6 on the transcriptional activity of SARG+4.6. LNCaP cells were 
transfected with pSARG-S-LUC, pSARG+4.6-SARG-S-LUC or pSARG+4.6m-SARG-S-LUC and incubated for 
24 h with or without 1 nM R1881. Transcriptional activity was measured in a luciferase assay. Values +/- SEM are 
from two experiments carried out in duplicate. Fold induction is the ratio of luciferase activity measured in the 
presence and absence of R1881. (B) EMSA of indicated AREs and AR DBD. ARE sequences are shown below the 
figure. The arrowhead indicates the position of the AR DBD-ARE complex. 
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Characterization of enhancer SARG+4.6  
  To further decipher the role of the 569 bp enhancer SARG+4.6-(+4297/+4865) in androgen 
regulation, two deletion constructs of SARG+4.6-S-LUC were generated. Construct SARG+4.6-
(+4447/4659) lacked all four candidate weak ARE sequences present in the SARG+4.6 
enhancer, but contained the imperfect direct repeat ARE (ARE-SARG+4.6).  The 112 bp 
enhancer fragment SARG+4.6-(+4548/4659) lacked even more upstream sequences, but also 
still contained ARE-SARG+4.6. In transfection experiments the shortened enhancer SARG+4.6-
(4447/4659) was less active than the 569 bp fragment, suggesting that clustering of ARE-
SARG+4.6 with weak ARE-like sequences is important for full enhancer activity (Figure 6A). 
Interestingly, further shortening of the enhancer completely abolished its activity although ARE-
SARG+4.6 was still present. However, in the deleted region we could not detect an obvious 
ARE-like sequence. 
  We carried out ChIP assays in order to investigate the in vivo function of enhancer SARG+4.6. 
Utilizing an antibody directed against acetylated histone H3 we observed a difference in H3 
acetylation over SARG+4.6 between LNCaP cells grown in the presence and in the absence of 
R1881, showing a difference in chromatin structure on this part of the gene (Figure 6B). The higher 
signal with AcH3 antibody in the presence of R1881 indicated an active structure of the enhancer 
region. Such a difference was not detected for the genomic fragments SARG-8.5 and SARG-7.3. 
These findings were in accordance with the transient transfection studies, as shown in Figure 4C. 
Unfortunately, ChIP assays with a large series of different antibodies against the AR were not 
successful, probably due to the low affinity of AR for ARE-SARG+4.6. 
 
ARE-SARG+4.6 is androgen receptor specific 
  To address the question whether ARE-SARG+4.6 is involved in androgen specificity, 
SARG+4.6 coupled to both SARG-S-LUC and PSA4-LUC was tested for activation by Dex. 
The constructs were transfected to LNCaP-1F5 cells cultured in the presence of 1 nM R1881 or 
10 nM Dex, or in the absence of hormone  (Figure 7A,B).  SARG+4.6 did not significantly 
stimulate Dex induced activity of SARG-S and PSA4. In contrast, R1881 induced activity of 
these two promoters was clearly increased by SARG+4.6. 
  ARE-SARG+4.6 was also tested in an EMSA for its ability to bind to GR DBD (Figure 7C). 
Control PSA ARE I did bind to GR DBD, but rat probasin ARE II did not. Importantly, ARE-
SARG+4.6 was also not able to bind to GR DBD, which correlated with the R1881 specificity of 
SARG+4.6 in the transfection assay. 
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Figure 6. Characterization of enhancer SARG+4.6. 
(A) Deletion mapping of enhancer SARG+4.6 in transiently transfected LNCaP cells. See legend to Figure 5A and 
Materials and Methods for experimental details. (B) ChIP assay of the candidate –8.5 kb, -7.3 kb and +4.6 kb 
enhancer regions of SARG in the presence and absence of R1881. Acetyl-Histone H3 antibody was used for 
immunoprecipitation. Experimental details are described in Materials and Methods. Input: DNA prior to 
immunoprecipitation. 
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Figure 7.  ARE-SARG+4.6 is androgen receptor specific. 
LNCaP-1F5 cells were transfected with pSARG-S-LUC and pSARG+4.6-SARG-S-LUC (A) and pPSA4-LUC and 
pSARG+4.6-PSA-LUC (B). Luciferase activity was measured after 24 h incubation with 1 nM R1881 or 10 nM Dex 
or without hormone. R1881 and Dex induced activities of SARG-S-LUC (A) and PSA4-LUC (B) were set at 1. 
Relative inductions +/- SEM are from 2 experiments carried out in duplicate. (C)  EMSA of AREs with GR DBD. 
Sequences of the DNA fragments analysed are shown in figure 5 (B). GR DBD-ARE complexes are indicated by 
the arrowhead. 
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DISCUSSION 
  The androgen-specific regulated SARG gene was identified in the LNCaP-1F5 subline that 
expresses endogenous AR, and GR from a stable-integrated cDNA expression vector (Cleutjens et 
al. 1997). We showed that SARG mRNA expression could be up-regulated by androgens, but not 
by glucocorticoids. SARG is a 4 exon gene of 14.5 kbp mapping to chromosome band 1q32.2. 
Exon 1 can appear in a short or long form, 1A and 1AB, respectively. The 2.3, 3.3 and 5.5 kb 
transcripts result from alternative polyadenylation. Splice variants might lack either exon 2, part B 
of exon 1 or both. The predicted genes MGC2742 and MGC4309 are both part of SARG. SARG is 
preferentially expressed in the prostate (Figure 1C). Our findings are substantiated by data in the 
expression profile database GeneNote (http://bioinformatics/weizmann.ac.il/cards/). In this 
database high SARG expression was only documented for prostate and lung.  
  The SARG ORF encodes a protein of 601 amino acids; splice variants lacking exon 2 are 
expected to code for a carboxyl-terminal fragment of 355 amino acids of the full-length protein. 
Transient transfection experiments showed that the SARG protein is located in the cytoplasm. No 
homology to other proteins was found. Unfortunately, the amino acid composition of SARG does 
not indicate motifs that could predict its function. The Sarg mouse ortholog is 605 amino acids 
with a homology to human SARG of 65%. Highest homology is in the amino-terminal and 
carboxyl-terminal regions of the proteins (data not shown). 
  To explain androgen specificity of SARG expression we first studied a 3 kbp promoter region 
in transfection assays. Because these experiments were unsuccessful, we decided to carry out an 
in silico search for candidate AR binding sites in 18 kbp flanking the SARG transcription start 
site. The search criteria were based on three or less deviations from a perfect direct repeat or the 
consensus high affinity ARE inverted repeat. We identified 34 candidate AREs. Functional 
studies, based on clustering of candidate AREs indicated that an imperfect direct repeat in intron 
1, 5’-TGTGCTgcaTGTTCT-3’ (ARE-SARG+4.6) was active and AR-specific. Importantly, 
ARE-SARG+4.6 cooperated with surrounding sequences in a 569 bp enhancer region for full 
activity. Part of the cooperating sequences might be weak AR binding sites. However, others 
might be binding sites for prostate specific and more common transcription factors. The 
properties of these factors remain to be identified.   
  Mutation of ARE-SARG+4.6 to a perfect repeat did not affect AR DBD binding. However, 
SARG-7.3, which contains a perfect direct repeat, did not show any detectable androgen-
induction in transfections. Also, linkage of SARG-7.3 to SARG+4.6-SARG-S did not increase 
the activity of SARG+4.6-SARG-S in transfections (data not shown). In contrast to ARE-
SARG+4.6, ARE-SARG-7.3 might lack favourable modulating flanking sequences (Nelson et 
al. 1999) or binding sites for other transcription factors in its close vicinity. This might also be 
true for inactivity of ARE-SARG-8.5.   
  The present study shows that a bioinformatics-based search for AR binding sites followed by 
selected functional studies can successfully identify active regulatory elements. However, it 
shows also the limitations of such an approach, due to the complexity of the regulation 
mechanism of gene expression. The functional studies were limited to the two largest clusters of 
candidate AREs, and to a small cluster containing a perfect direct repeat in an 18 kbp region. 
Without clustering as a selection criterion, the bioinformatics approach would not have been 
selective, because of the high density of candidate AREs (1 per 500 bp). We realize that 
functional AREs in enhancers and promoters might also cluster with binding sites for other 
transcription factors. Moreover, although less likely, it cannot be excluded completely that some 
candidate ARE sequences did not pass the selection criteria. One such ARE should be in SARG-
S (-55 to +168), which is weakly androgen inducible. A candidate is the sequence 5’-
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GGGCCAggcAGCACA-3’ (+5 to +17) in exon 1, which deviates at 4 positions from a perfect 
direct repeat.  
  A complicating factor in direct repeat ARE search is the lack of a consensus sequence for high-
affinity, high-specificity AR binding, due to the limited number of this type of AREs identified 
so far. Rat probasin ARE II (5’-GGTTCTtggAGTACT-3’), which deviates from a perfect direct 
repeat at 3 positions, seems at present the specific ARE with highest AR affinity (Rennie et al. 
1993, Kasper et al. 1994, Claessens et al. 1996, Kasper et al. 1999, Claessens et al. 2001). 
However, a search of the 18 kbp SARG sequence did not detect candidate AREs closely 
resembling this sequence (data not shown). Our data provide the first evidence that an almost 
perfect direct 5’-TGTTCT-3’ repeat as present in SARG+4.6, can function as an AR-specific 
element in a natural enhancer. Other direct repeat-like functional AREs, with variable AR 
specificity, as detected in the SC (Secretory Component) gene, the mouse Slp (Sex limited 
protein) gene and the PEM (placenta and embryo) homeobox gene all deviate at least at three 
positions from a perfect direct repeat (Verrijdt et al. 1999, Verrijdt et al. 2000, Barbulescu et al. 
2001).   
  Comparison of functional AREs of a large series of preferentially androgen regulated genes 
should reveal the sequence of a consensus high-affinity, high-specificity AR binding site in a 
natural context. Such genes might be identified by expression profiling of the AR and GR 
positive LNCaP-1F5 cell line followed by an unbiased functional study of a large series of 
overlapping fragments flanking the transcription start sites of these genes. This should also give 
a better insight in selection criteria for a bioinformatics-based search for functional AR binding 
sites in novel genes. Such an approach might also include comparison with data from other 
species.  
  It may be possible that the composition of an ARE can influence receptor activity by 
transduction of a particular conformation via the DNA-bound DBD to other AR domains. 
Recent evidence indicates that binding to different AREs indeed induces different 
conformational changes (Geserick et al. 2003). A different DBD conformation might directly or 
indirectly affect the association with coactivators, as shown for ER (Wood et al. 2001, Hall et 
al. 2002). In addition, it remains to be elucidated whether the ARE sequence is the major 
molecular determinant of AR specificity, or whether AR protein-protein interactions, including 
interactions with other specific transcription factors can contribute significantly to receptor 
specificity (Karvonen et al. 1997, Scheller et al. 1998). 
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ABSTRACT 
 
  In a subset of endocrine therapy resistant prostate cancers, amino acid substitutions H874Y, 
T877A and T877S, which broaden ligand specificity of the ligand binding domain (LBD) of the 
androgen receptor (AR), have been detected. To increase our knowledge about the role of amino 
acid substitutions at these specific positions in prostate cancer, codons 874 and 877 were 
subjected to random mutagenesis. AR mutants were screened in a yeast read out system for 
responsiveness to 5α-dihydrotestosterone, progesterone and dehydroepiandrosterone. At 
position 874, only the histidine to tyrosine substitution could broaden AR ligand specificity. At 
position 877, four ligand specificity broadening substitutions were found: T877A, T877S, 
T877C and T877G. The latter two were not found in prostate cancer. The AR mutants were 
tested in mammalian (Hep3B) cells for responsiveness to thirteen different ligands. All mutants 
displayed their own ligand specificity spectrum. Importantly, AR(H874Y) and AR(T877A) 
could be activated by cortisol. According to the three-dimensional structure of the AR LBD, 
T877 interacts directly with the 17β-hydroxyl-group of androgens. All amino acid substitutions 
identified at position 877 had smaller side chains than the threonine in the wild-type receptor, 
indicating that increased space in the ligand binding pocket is important in broadened ligand 
specificity. Because H874 does not interact directly with the ligand, its substitution by a tyrosine 
is expected to change the ligand binding pocket conformation indirectly. For T877C and T877G 
substitutions two point mutations are required, and for H874Y, T877A and T877S substitutions, 
only one point mutation is sufficient. This most likely explains that the latter three have been 
found in prostate cancer.  
 
 
INTRODUCTION 
 
  Androgens (T and DHT) are essential for development and maintenance of the male 
phenotype. They mediate their function by activation of the AR, which is a member of the 
nuclear receptor family of transcription factors. The AR also plays a pivotal role in prostate 
tumor growth. Because growth of the majority of prostate cancers depends on continuous 
androgenic stimulation, therapy of metastatic disease is generally based on androgen withdrawal 
or blockade of AR function by antiandrogens. However, after an initial regression, essentially all 
tumors continue to grow.  
  Like other nuclear receptors, the AR displays a modular structure: a carboxy-terminal LBD, a 
central DBD, and an amino-terminal TAD. Upon ligand binding, the AR regulates transcription 
by binding to specific androgen response elements in regulatory regions of target genes. 
Together with coactivators, general transcription factors and RNA polymerase II, a stable 
transcription initiation complex is formed (see for reviews refs 
1-3
). The size of the AR can be 
variable, due to variation in the length of poly-glutamine and poly-glycine stretches in the TAD. 
Amino acid numbering in this manuscript corresponds to an AR with a length of 919 amino 
acids, which is employed by The Androgen Receptor Gene Mutations Database 
(http://www.mcgill.ca/androgendb). 
  One of the causes of transition from androgen-dependent to apparent androgen-independent 
prostate tumor growth is modification of AR functioning. In a proportion of endocrine therapy 
resistant tumors, AR gene amplification has been detected.
4-6
 This can lead to AR 
overexpression. Another mechanism, which directly affects AR function, can be activation of 
the AR by aberrant cross talk with other signal transduction pathways.
7-11
 A third mechanism is 
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modification of AR properties by missense mutations. In a subgroup of endocrine therapy 
resistant prostate cancers, amino acid substitutions in the AR LBD have been found, which 
result in a broadened ligand response spectrum. The most common substitution, T877A, has first 
been described in the LNCaP prostate cancer cell line.
12
 Subsequently, it was repeatedly found 
in prostate cancer tissue specimens of patients with advanced disease.
13-18
 The T877A 
substitution renders the AR responsive to natural low affinity ligands and antiandrogens; T877S 
and H874Y substitutions, which have also been found in prostate cancer, induce similar 
properties to the AR.
12,17,19-23
  
   During the last years, the three dimensional structures of many nuclear receptor LBDs have 
been elucidated.
24-33
 The crystallographic data revealed a three-layer structure composed of ten 
to twelve α-helices. Ligand binding induces a specific conformational change in the helical 
LBD structure, which makes it accessible to coactivators.
34,35
 Antagonists induce a different 
LBD conformation than agonists, indicatig the importance of the LBD conformation for 
activation or inhibition of nuclear receptor function.
27,31,34
  
  Knowledge of the LBD structure is invaluable for explanation of the molecular and the 
biological effects of specific amino acid substitutions in the AR in prostate cancer. 
Homology modeling predicted a three-dimensional structure of the AR LBD that is similar to 
other nuclear receptors.
36-38
 The crystal structures of the DHT and R1881 complexed wild-type 
AR LBDs and DHT complexed T877A mutant AR LBD have recently been elucidated and 
confirmed most of the earlier assumptions.
39,40
 
  In this study we investigated the biological effects of amino acid substitutions at positions 874 
and 877, which are both in helix 11 of the AR LBD.
36,37,39,41
 We addressed the question whether 
in addition to H874Y, T877A and T877S other, as yet unidentified, amino acid substitutions at 
these positions could give rise to similar functional alterations. Previously, we have shown that 
both wild-type AR and AR(T877A) retained their ligand specificity in yeast.
42
 Therefore, AR 
expression libraries with random mutations at codons 874 or 877 were screened for ligand 
specificity in a yeast read out system. AR mutants with an altered ligand specificity as identified 
in the yeast system, were analyzed in mammalian cells for their responsiveness to a large series 
of sex steroids, antiandrogens and adrenal steroids, including glucocorticoids.  
 
 
MATERIAL AND METHODS 
 
Hormones  
  DHT, ASD, Pg, E2, DHEA, DEX, cortisol, aldosterone and TAA were purchased from 
Steraloids (Wilton, NH), R1881 (methyltrienolone) was from NEN (Boston, MA). CPA was a 
gift from Schering AG (Berlin, Germany), OH-Fl from Schering USA (Bloomfield, NJ), and 
bicalutamide (Casodex) from Zeneca Pharmaceuticals (Macclesfield, UK).  
 
Construction of androgen receptor cDNA libraries with random mutation of codons 874 and 
877 
  The yeast AR cDNA expression vector pG1ARII
42
 was used to generate pG1ARII∆(863-919) 
as a cloning vector for the construction of the control AR expression vector pG1ARIII, and the 
AR expression libraries pG1ARIII(874X) and pG1ARIII(877X). All deletions and mutations 
were generated essentially as described.
43
 First, a PCR fragment was synthesized utilizing 
pG1ARII as a template, with the forward primer 5’-CACTGAGGAGACAACCCAGAAGCT-3’ 
and the reverse primer 5’-AAGACGTCGACTACGCGGCGCGCAATAGGCTGCACGG-3’. A 
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SalI restriction site in the reverse primer is boldfaced and underlined; a BssHII site in this 
primer is underlined. The amplified fragment was TthIII and SalI digested and exchanged with 
the corresponding AR fragment in pG1ARII, resulting in pG1ARII∆(863-919). To generate the 
pG1ARIII(874X) library, PCR mutagenesis was carried out on the pG1ARII template, utilizing 
the forward primer 874X: 5’-ATTGCGCGCGAGCTGNNNCAGTTCACTTTTGACCTG-3’ 
(BssHII boldfaced and underlined, codon 874 underlined) combined with the reverse primer RP 
5’-AAGACGTCGACCGGATCCGCTTCACTGGGTGTGG-3’ (SalI boldfaced and underlined; 
BamHI underlined; stop codon boldfaced). The amplified fragment was BssHII-SalI digested 
and inserted in the corresponding sites in pG1ARII∆(863-919). The pG1ARIII(877X) AR 
cDNA library was generated by the same procedure, utilizing the forward primer 877X 5’-
ATTGCGCGCGAGCTGCATCAGTTCNNNTTTGACCTGCTAATC-3’ and the RP reverse 
primer. Similarly, PG1ARIII was generated, utilizing forward primer 5’-
ATTGCGCGCGAGCTGCATCAGTTCAC-3’ and the reverse primer RP, resulting in an AR 
cDNA expression vector with an internal BssHII site and a BamHI site in the slightly shorter 3’-
UTR, as compared to pG1ARII. The internal BssHII site does not result in an altered AR amino 
acid composition. Random codon representation at codons 874 and 877 in the pG1ARIII(874X) 
and pG1ARIII(877X) libraries was verified by sequencing of fourteen clones of each library. In 
both libraries the sequenced clones were unique.  
 
Yeast LacZ-reporter plasmids 
  The androgen inducible yeast integration vector pGRE3LacZi was constructed by insertion of a 
100 bp HindIII-EcoRI fragment of pARE3tkCAT
44
, containing a triple arranged repeat of the -
174/-152 prostate specific antigen (PSA) promoter region, in the corresponding sites of pLacZi 
(Clontech, Palo Alto, CA). The androgen inducible yeast LacZ-reporter plasmid pUC∆SS-26X, 
containing a triple arranged 26 bp GRE oligonucleotide, was provided by Dr. Picard.
45
  
 
Construction of mammalian androgen receptor  expression plasmids  
  Mammalian AR expression plasmids pSVARIII, pSVARIII(H874Y), pSVARIII(T877A), 
pSVARIII(T877C), pSVARIII(T877G) and pSVARIII(T877S) were constructed by exchanging 
the TthIII-BamHI fragments of pG1ARIII(mutant) constructs with the corresponding fragment 
of pSVAR0.
46
 
 
Yeast strains, growth and transformation 
  Yeast strain YM4271(GRE3LacZ) was utilized for AR cDNA library screening. 
YM4271(GRE3LacZ) was derived from YM4271 (Clontech, Palo Alto, CA) by integration of 
NcoI linearized pGRE3LacZi into its non-functional ura locus. Yeast strain BJ2168, a gift from 
Dr. Picard, was used for quantitative measurement of AR activity.
42
 Yeast cells were grown in 
the appropriate selective media (0.67% w/v yeast nitrogen base without amino acids, 2% 
glucose, pH 5.8) supplemented with the required amino acids. Yeast transformation was carried 
out according to the lithium acetate method.
47
 
 
Yeast screening of androgen receptor mutants 
  Approximately four hundred clones of YM4271(GRE3LacZ) transformed with 
pG1ARIII(874X) or pG1ARIII(877X) were grown on a master plate with the appropriate 
selective medium. After replica plating on Hybond-N filters (Amersham, Buckinghamshire, 
UK), colonies were grown for 16 h on the same medium supplemented with different hormones: 
DHT (10
-8
 M), Pg (10
–7
 M) and DHEA (10
-6
 M) or in the absence of hormone. Yeast colonies 
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were made permeable by freezing the filters in liquid nitrogen. Next, LacZ expression was 
visualized by incubation on Whatmann paper soaked in Z-buffer (60 mM Na2HPO4, 40 mM 
NaH2PO4, 10 mM KCl, 1 mM MgSO4, pH 7.0) supplemented with 0.27% β-mercaptoethanol 
and 0.1% X-GAL.  
  AR expression plasmids were isolated from LacZ-positive yeast clones as described.
48
 
Plasmids were sequenced to identify specific mutations at codons 874 and 877 and to confirm 
proper PCR amplification of the inserted fragments in the pG1ARIII vectors. 
 
Quantitative analysis of androgen receptor mutants in yeast 
  A liquid β-galactosidase assay was performed to quantify the activity of selected AR mutants, 
utilizing yeast strain BJ2168 containing the pUC∆SS-26X LacZ-reporter plasmid. Overnight 
cultures of yeast transformants grown in selective medium were diluted to OD600 of 0.3 in the 
same medium supplemented with ligand (DHT, Pg or DHEA) or without hormone and grown 
until an OD600 of approximately 1.0. Next, β-galactosidase activity was determined as described 
previously.
42
  
 
Mammalian cell culture, transfection, and luciferase assay    
  Hep3B (human liver) cells were maintained in α minimal essential medium (α-MEM) 
supplemented with 5% fetal calf serum and antibiotics. Cells were seeded at a density of 5 x 10
4
 
cells/well (1.9 cm
2
) and grown for 24 h.. Four h. prior to transfection, the medium was replaced 
by 250 µl α-MEM, supplemented with 5% charcoal-stripped fetal calf serum, antibiotics and 
one of the following hormones: DHT, R1881, ASD, Pg, E2, OH-Fl, CPA, bicalutamide, DHEA, 
DEX, cortisol, aldosterone or TAA. For transfection, 25 µl α-MEM containing 1 µl Fugene 6 
(Boehringer Mannheim, Germany), 0.5 µg AR expression plasmid (pSVARIII constructs), and 1 
µg MMTV-LUC reporter plasmid were added per well. Following 24 h incubation, cells were 
lysed and luciferase activity was assayed as described previously.
49
 In the absence of ligand, 
wild-type and mutant ARs displayed comparable background activities. 
 
 
RESULTS 
 
Detection of androgen receptor H874 and T877 mutants in a yeast screening system 
  Using random mutagenesis, two AR cDNA libraries were generated in a yeast expression 
vector: one with mutations in codon 874, AR(874X), and one with mutations in codon 877, 
AR(877X). Approximately four hundred independent yeast colonies from each library were 
screened for activation of an AR-inducible LacZ reporter by DHT, Pg and DHEA (see Materials 
and Methods). Pg was tested because H874Y, and T877 mutant ARs showed an increased 
response to this hormone.
12,19-23,50
 DHEA was chosen because the H874Y and T877A mutant 
ARs were known to be responsive to this adrenal androgen.
21
 In each library, approximately two 
hundred out of the four hundred colonies were β-galactosidase positive upon incubation with 
DHT, indicating that the other half of the colonies contained inactivating AR mutations. 
  Screening of the AR(874X) library resulted in four yeast colonies, which were positive after 
DHT, Pg and DHEA incubation. Colonies positive with two tested hormones, or with Pg or 
DHEA alone were not found. Sequencing revealed that the DHT+/Pg+/DHEA+ colonies 
contained at codon 874 the sequences TAC or TAT, which both encode a tyrosine residue. From 
this finding it was concluded that a tyrosine residue at position 874 is unique in the generation 
of an AR, which can not only be activated by DHT, but also by Pg and by DHEA.     
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  Screening of the AR(877X) library resulted in sixty-three colonies, which were 
DHT+/Pg+/DHEA+; fourteen colonies were DHT+/Pg+/DHEA-. Sequencing of the 
DHT+/Pg+/DHEA+ colonies revealed three different amino acid substitutions at 877: T877A, 
T877G and T877S. The DHT+/Pg+/DHEA- colonies contained a cysteine residue at 877. 
Interestingly, as described above, H874Y, T877A and T877S have been found in prostate 
cancer, whereas T877C and T877G substitutions have not been detected in these tumors. 
 
Hormone induced transcriptional activity of the androgen receptor H874Y mutant  in yeast and 
in mammalian cells   
  Activation of AR(H874Y) by DHT, Pg and DHEA was quantified in a yeast liquid β-
galactosidase assay. The results are summarized in Figure 1. AR(H874Y) showed a decrease in 
AR activation by DHT, as compared to wild-type AR (Fig. 1a). At the highest hormone 
concentrations, Pg and DHEA responses of AR(H874Y) were clearly stronger than that of wild-
type AR (Fig. 1b,c).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  FIGURE 1 ─ Transcriptional activity of wild-type AR and AR(H874Y) in yeast. Yeast cells were 
cotransfected with the wild-type AR or AR(H874Y) yeast expression vector and the androgen inducible LacZ 
reporter pUC∆SS-26X. (a) DHT activation. (b) Pg activation. (c) DHEA activation. Values (±SEM) are the mean 
of three independent experiments each carried out in duplicate. 
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  For direct comparison with the yeast data, Hep3B mammalian cells were cotransfected with the 
AR(H874Y) mutant or wild-type AR expression plasmid and a MMTV-luciferase reporter 
plasmid. Transfected cells were incubated in the absence of hormone or in the presence of serial 
dilutions of a large set of different ligands: the androgens DHT, and R1881; the steroidal 
antiandrogen CPA, the non-steroidal antiandrogens OH-Fl and bicalutamide, and the steroids Pg 
and E2. R1881 activated wild-type AR and AR(H874Y) equally; bicalutamide was inactive on 
both wild-type AR and AR(H874Y) (data not shown). The activities of wild-type AR and 
AR(H874Y) induced by DHT, Pg, E2, OH-Fl and CPA are shown in Figures 2a and 2b, 
respectively. As expected, wild-type AR activation was DHT specific. Only at high 
concentrations, some agonistic activity of Pg, E2 and CPA was observed; OH-Fl was unable to 
activate the wild-type AR at all concentrations tested. Like in yeast, DHT was found to be a less 
potent activator of AR(H874Y) than of wild-type AR, which was not due to a lower expression 
level (data not shown). Both E2 and Pg induced AR(H874Y) activity to almost the same extent 
as DHT. At high concentrations, OH-Fl showed some agonistic activity; agonistic activity of 
CPA on AR(H874Y) was as low as on wild-type AR.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  FIGURE 2 ─ Transcriptional activity of wild-type AR and AR(H874Y) in mammalian cells. Hep3B 
cells were cotransfected with the wild-type AR or AR(H874Y) mammalian expression vector and a MMTV-LUC 
reporter, and activated by different hormones. (a) wild-type AR. (b) AR(H874Y). Ligands: () DHT, () Pg, () 
E2, () CPA, () OH-Fl. Values (±SEM) represent the mean of three independent experiments each carried out in 
duplicate.  
 
 
Hormone induced transcriptional activity of the androgen receptor T877 mutants in yeast and 
mammalian cells 
  Activation of the AR 877 mutants by DHT, Pg and DHEA was analyzed in the quantitative 
yeast assay as described above for AR(H874Y). The results are summarized in Figure 3. DHT 
activation of all mutants, AR(T877A), AR(T877S), AR(T877G) and AR(T877C), was 
comparable to wild-type AR (Fig. 3a). AR(T877A) and AR(T877S) displayed the most 
prominent altered ligand specificity at the two Pg and DHEA concentrations tested. Both 
showed increased activation by Pg and DHEA as compared to wild-type AR (Fig. 3b,c). 
AR(T877C) and AR(T877G) were activated by Pg (Fig. 3b), but only AR(T877G) was DHEA-
inducible (Fig. 3c), in agreement with the qualitative yeast screening.  
  Ligand specificity studies of the four AR 877 mutants were extended to mammalian Hep3B 
cells, using the same set of ligands as used for the wild-type AR and AR(H874Y) studies shown 
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in Figure 2. R1881 activation, which was identical for wild-type AR and the four 877 mutants, 
is not shown. Bicalutamide did not activate any of the 877 mutants (data not shown). The 
T877A and T877S substitutions introduced the most dramatic alterations in ligand specificity 
(Fig. 4; see for wild-type AR Fig. 2a). Both AR(T877A) and AR(T877S) exhibited a strong 
activation by Pg, E2 and the antiandrogen CPA (Fig. 4a,d). AR(T877A) was more responsive to 
OH-Fl than AR(T877S) (Fig. 4a,d). AR(T877C) and AR(T877G) ligand specificity was less 
altered. Although Pg activation could clearly be established, agonistic activity of other ligands 
was limited (Fig. 4b,c). Differences in ligand responses between the AR mutants were not due to 
different protein levels (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  FIGURE 3 ─ Transcriptional activity of wild-type AR and AR(T877) mutants in yeast. Yeast cells 
were cotransfected with wild-type AR yeast expression vector, or AR(T877A), or AR(T877C), or AR(T877G), or 
AR(T877S) mutant yeast expression vectors and the androgen inducible LacZ-reporter pUC∆SS-26X. (a) DHT 
activation. (b) Pg activation. (c) DHEA activation. Values (±SEM) represent the mean of three independent 
experiments each carried out in duplicate. 
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  FIGURE 4 ─ Transcriptional activity of AR(T877) mutants in mammalian cells. Hep3B cells were 
cotransfected with (a) AR(T877A), (b) AR(T877C), (c) AR(T877G), and (d) AR(T877S) mammalian expression 
vector and a MMTV-LUC reporter. Ligands: () DHT, () Pg, () E2, () CPA, () OH-Fl. Values (±SEM) 
represent the mean of three independent experiments each carried out in duplicate.  
 
 
Transcriptional activation of androgen receptor H874 and T877 mutants by adrenal steroids 
and synthetic glucocorticoids  
  The AR 874 and AR 877 mutants were also assayed in Hep3B cells for their activation by the 
adrenal steroids DHEA and ASD (androgens), cortisol (glucocorticoid) and aldosterone 
(mineralocorticoid), and the synthetic glucocorticoids DEX and TAA. Activation of wild-type 
AR and all mutant ARs by ASD was identical; TAA was unable to activate wild-type and 
mutant ARs (data not shown). For the other ligands a remarkable variation in activation patterns 
of the different mutants was observed. Figure 5a displays the activities of wild-type AR and all 
AR mutants induced by high concentrations DHEA, cortisol, DEX and aldosterone (10
-6
 M). In 
Figure 5b-e the ligand concentration dependent activation of selected mutants is shown. 
AR(H874Y), AR(T877A) and AR(T877S) were clearly responsive to DHEA (Fig. 5a,b). Also, a 
concentration dependent activation of AR(H874Y) and AR(T877A) by aldosterone, cortisol and 
DEX was observed (see Fig. 5a,c-e). In contrast, AR(T877S) and AR(T877G) could hardly be 
activated by these ligands (Fig. 5a). AR(T877C) did not respond to any of the ligands (Fig. 5a).  
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  FIGURE 5 ─ DHEA and corticoid induced transcriptional activity of wild-type AR and AR 
mutants. Hep3B cells were cotransfected with the wild-type AR, AR(H874Y) or AR(T877) mutant mammalian 
expression vector and a MMTV-LUC reporter. (a) incubation in the absence of hormone, or in the presence of 
DHEA, Cortisol, DEX or ALD (all at 10
-6
 M). (b) DHEA activation. (c) ALD activation. (d) Cortisol activation. (e) 
DEX activation. ()WT:  wild-type AR, ()Y: AR(T874Y), ()A: AR(T877A), and ()S: AR(T877S). Values 
(±SEM) represent the mean of three independent experiments each carried out in duplicate. 
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     TABLE 1 ─ LIGAND RESPONSIVENESS1 OF AR MUTANTS TO THIRTEEN DIFFERENT   
      HORMONES AS TESTED ON A MMTV-LUC REPORTER IN TRANSIENTLY TRANSFECTED  
      MAMMALIAN (HEP3B) CELLS  
 wild-type 
AR 
AR 
(H874Y) 
AR 
(T877A) 
AR 
(T877C) 
AR 
(T877G) 
AR 
(T877S) 
       androgens       
DHT +++ +++ +++ +++ +++ +++ 
R1881 +++ +++ +++ +++ +++ +++ 
sex steroids       
Pg + ++ +++ +++ ++ +++ 
E2 + ++ ++ + + ++ 
antiandrogens       
CPA + + +++ + + +++ 
OH-Fl - + ++ - + + 
Bicalutamide - - - - - - 
adrenal androgens       
DHEA - + + - ± + 
ASD ++ ++ ++ ++ ++ ++ 
glucocorticoids       
Cortisol - + + - - - 
DEX - + + - - - 
TAA - - - - - - 
mineralocorticoid       
Aldosterone - + + - - - 
            1
Degree of ligand responsiveness: - no activity; + low activity; ++ moderate acivity; +++ high activity,  
       comparable to wild-type AR responsiveness to DHT.  
 
 
DISCUSSION 
 
  Mutations in the AR have been described in several diseases. In androgen insensitivity, which 
is an inherited defect of male development, over one hundred amino acid substitutions in the AR 
LBD have been documented (http://www.mcgill.ca/androgendb).
1,51
 These mutations 
completely or partially inactivate AR function. In Kennedy’s disease or SBMA (spinal and 
bulbar muscular atrophy), an expanded (CAG)n repeat results in a longer glutamine-stretch in 
the AR TAD.
52
 In prostate cancer, AR mutants are rare in primary and locally progressive 
tumors, but more frequent in metastatic disease, following endocrine therapy.
16-18,22,53-57
 The 
relevance of most AR mutants in progressive prostate cancer remains to be established. The 
mutants investigated in more detail are functionally different from AR mutants in androgen 
insensitivity, and tend to cluster in different regions of the LBD.
57
   
  The most frequently described AR mutations in prostate cancer are substitutions of H874 and 
T877, which are both in helix 11 of the AR LBD.
36,37,39,41
 AR(T877A), which has originally 
been detected in the LNCaP cell line, seems to be the preferred amino acid substitution in 
endocrine therapy resistant prostate cancer.
12,14-17
 Like the less common H874Y and T877S 
amino acid substitutions, T877A broadens AR ligand specificity in such a manner, that not only 
androgens, but also other sex steroids, and antiandrogens can activate the AR.
12,19-23
 The 
recently identified T877A&L701H AR double mutant exhibited an even broader ligand 
specificity than the T877A single mutant,
58
 adding cortisol to the spectrum of strong activators. 
There is increasing evidence that the AR LBD mutants with less specific ligand responsiveness 
are of clinical relevance in a subset of endocrine therapy resistant prostate cancers.
16,17
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  In the present study two types of experiments were carried out. First, ARs randomly mutated at 
positions 874 or 877 were screened for broadened ligand specificity in a yeast read out system. 
Second, AR mutants with broadened ligand responsiveness were assayed in mammalian cells 
for activation by thirteen different ligands, including sex steroids, adrenal steroids and 
antiandrogens. From our findings, several important conclusions can be drawn. 
1. In the AR cDNA library randomly mutated at codon 874, AR(H874Y) was the only mutant 
able to broaden AR ligand specificity. In the 877 AR cDNA library, an alanine, serine, 
glycine or cysteine residue at position 877 broadened AR ligand response. As pointed out 
above, AR(H874Y), AR(T877A) and AR(T877S) are well known from prostate cancer; 
AR(T877G) and AR(T877C) have never been described in prostate cancer. The random 
mutagenesis system used in this study allowed the screening of all triplets possible for 
codons 874 and 877. As expected, among the identified AR mutants, one, two and three base 
deviations from the wild-type codon were detected. In nature, the chance of more than one 
point mutation within a codon is extremely low. Indeed, all amino acid substitutions found at 
AR codons 874 and 877 in prostate cancer are due to single point mutations: H874Y: 
CAT>TAT,
17,21,22
 T877A: ACT>GCT,
12-17,22
 T877S: ACT>TCT.
17,22
 For T877C or T877G 
substitutions, at least two bases need to be mutated. This can explain their absence in 
prostate cancer. In conclusion, the H874Y substitution is not only unique at this position in 
prostate cancer, but is also the only possibility at this position to broaden AR ligand-
specificity. The T877A and T877S substitutions in prostate cancer are not unique, in that 
they are not the only substitutions that can broaden AR ligand-specificity at this position, but 
seem to be sequence-driven selections of four possible amino acid substitutions.  
2. The results of the extensive series of transactivation experiments with wild-type and mutated 
ARs in mammalian cells are summarized in Table 1. Importantly, each mutant displayed its 
own characteristic spectrum of ligand responsiveness. Differences in ligand affinities, as 
well as differences in ligand-induced conformational changes may account for this variation. 
Most remarkable are the similarities between activation of AR(H874Y) and AR(T877A) by 
the various ligands. Although completely different, both show identical responses to the 
glucocorticoids cortisol and DEX, and the mineralocorticoid aldosterone. Zhao et al.
58
 
described activation of the AR double mutant T877A&L701H by cortisol, but they did not 
find cortisol responsiveness of the single mutant AR(T877A). The apparent discrepancy 
with our data might be due to a less sensitive assay, or different cell line used for 
transfection experiments. Our findings warrant a further investigation of the role of 
glucocorticoids in prostate cancer patients carrying a mutated AR. 
  Based on the crystal structures of closely related steroid hormone receptor LBDs, homology 
models of the AR LBD have been constructed.
36-38
 These models indicated that T877 is part of 
the ligand-binding pocket and directly interacts with the ligand, H874 does not participate 
directly in ligand binding. Recently, the predictions of AR LBD folding and ligand interaction 
were modified and extended by the elucidation of the crystal structures of the wild-type and 
T877A mutant AR LBD complexed with androgens.
39,40
 For the wild-type AR LBD, eighteen 
amino acids were found to contact the ligand directly. Importantly, T877 in helix 11 of the LBD, 
together with N705 in helix 3, form hydrogen bonds to the 17β-hydroxyl group of R1881, which 
is also present in DHT (Fig. 6). As predicted, H874, which is also in helix 11, projects away 
from the ligand binding pocket. 
  The crystal structure of the T877A mutant AR LBD complexed with DHT revealed an 
increased space in the ligand binding pocket.
40
 The amino acid residues serine, glycine and 
cysteine at position 877, have in common that, like alanine, they all are smaller than the  
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FIGURE 6 ─ Chemical structures of steroids used in this study. 
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threonine residue at this position in the wild-type AR.
59
 So, substitution of T877 by S, G or C 
will also increase the space of the ligand binding pocket. This larger space will facilitate 
appropriate entering by ligands with more bulky side chains at C17 like Pg, cortisol, DEX and 
aldosterone (Fig. 6). This may allow a conformational change in the LBD, which is favorable 
for the AR transactivation function. A larger binding pocket may also explain appropriate 
folding of the LBD induced by the antiandrogen CPA, resulting in agonistic activity. The 
synthetic glucocorticoid TAA might be too big for proper entering an enlarged AR ligand 
binding pocket (Fig. 6). Not only the size of the C17 side chain, but also slight differences in 
overall conformation of a steroid, as determined by the A- to D-ring moities, might contribute to 
positioning in the ligand binding pocket. Particularly in case of E2 and DHEA, which both have 
a small C17 side chain (Fig. 6), but not excluding other ligands, the larger binding pocket might 
be needed for appropriate binding of these different conformations. Elucidation of the crystal 
structures of the various AR mutants complexed with different ligands has to prove and extend 
these hypotheses.  
  Many other mutations have been described in the AR LBD in prostate cancer, but most of the 
mutants have not been characterized.
22,55,56,60,61
 In contrast to L701 and T877, none of the 
mutated amino acid residues can be predicted to contact directly the ligand.
39,40
 This is also true 
for mutant V715M, which clearly displays broadened ligand response.
23,61,62
 So, like for H874Y, 
for the V715M mutant a different mechanism of activation can be predicted. 
  One of the most important questions, which remain to be addressed, is the identification of the 
physiological ligand of the AR mutants in endocrine therapy resistant prostate cancer. Most AR 
LBD mutants with a broadened ligand response seem to be induced or selected during 
antiandrogen therapy.
17
 Our findings suggest that in androgen depleted patients following 
antiandrogen withdrawal, Pg or cortisol might be the physiological ligands for activation of a 
mutated AR. The concentration of circulating Pg in men (0.3-0.9 nM)
63
 seems sufficient for 
such a function, because of the strong response of especially AR(T877A) and AR(T877S) to this 
ligand (Fig. 4). Although cortisol is a less potent activator of the mutants (Fig. 5), its high 
concentration in the circulation (70-550 nM)
63
 warrants further investigation of its role in 
patients carrying a AR(H874Y) or AR(T877A) mutation. Activation of these mutants by cortisol 
would be in line with activation of the AR(L701H) single and AR(L701H/T877A) double 
mutant by cortisol.
58
 Circulating E2, DHEA and aldosterone concentrations (73-184 pM, 6-28 
nM and 83-832 pM, respectively),
63
 seem too low to account for such a function. However, 
inactive DHEA sulfate, with a serum level of 1-9 µM,63 can be converted into DHEA in the 
prostate, and resulting local DHEA concentrations may be sufficient for activation of the various 
AR mutants (Fig. 5, Table 1).
64
  
  To obtain relevant data on non-cognate ligands as activators of mutant ARs, extended studies 
with prostate cell lines containing mutated ARs are needed. In a previous study with DEX 
incubated LNCaP cells, applied hormone concentrations were too low to be able to observe an 
effect on the endogenous AR(T877A).
65
 Monitoring of the response of LNCaP (T877A) and 
CWR22 (H874Y)
12,21,66
 cells to physiological concentrations of different ligands, including 
glucocorticoids and DHEA, will give important supportive information about the role of 
mutated ARs in prostate cancer. 
 
 
 
 
 
 145
ACKNOWLEDGEMENTS 
   
We thank Didier Picard for supplying plasmid pUC∆SS-26X, Pascal Farla for help in 
preparation of the manuscript and Erik Jan Dubbink for fruitful discussions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: AR, androgen receptor; ASD, androstenedione; CPA, cyproterone acetate; DBD, DNA binding 
domain; DEX, dexamethasone; DHEA, dehydroepiandrosterone; DHT, 5α-dihydrotestosterone; E2, estradiol; LBD, 
ligand binding domain; OH-Fl, hydroxy-flutamide; Pg, progesterone; T, testosterone; TAA, triamcinolone 
acetonide; TAD, transactivation domain. 
 146
REFERENCES 
 
1. Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM, French FS. Androgen receptor 
defects: historical, clinical, and molecular perspectives [published erratum appears in Endocr Rev 1995 
Aug;16(4):546]. Endocr Rev 1995;16:271-321. 
2. Trapman J, Cleutjens KB. Androgen-regulated gene expression in prostate cancer. Semin Cancer Biol 
1997;8:29-36. 
3. Brinkmann AO, Blok LJ, de Ruiter PE, Doesburg P, Steketee K, Berrevoets CA, Trapman J. Mechanisms 
of androgen receptor activation and function. J Steroid Biochem Mol Biol 1999;69:307-13. 
4. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, 
Kallioniemi OP. In vivo amplification of the androgen receptor gene and progression of human prostate 
cancer. Nat Genet 1995;9:401-6. 
5. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij 
A, Visakorpi T, Kallioniemi OP. Androgen receptor gene amplification: a possible molecular mechanism 
for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997;57:314-9. 
6. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and 
overexpression of androgen receptor gene in hormone- refractory prostate cancer. Cancer Res 
2001;61:3550-5. 
7. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. Androgen 
receptor activation in prostatic tumor cell lines by insulin- like growth factor-I, keratinocyte growth factor, 
and epidermal growth factor. Cancer Res 1994;54:5474-8. 
8. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z. Interleukin-6 regulates 
prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. 
Cancer Res 1998;58:4640-5. 
9. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer 
through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 
1999;5:280-5. 
10. Abreu-Martin MT, Chari A, Palladino AA, Craft NA, Sawyers CL. Mitogen-activated protein kinase 
kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol 
Cell Biol 1999;19:5143-54. 
11. Peterziel H, Mink S, Schonert A, Becker M, Klocker H, Cato AC. Rapid signalling by androgen receptor 
in prostate cancer cells. Oncogene 1999;18:6322-9. 
12. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, 
Brinkmann AO, Mulder E. A mutation in the ligand binding domain of the androgen receptor of human 
LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res 
Commun 1990;173:534-40. 
13. Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J. Androgen receptor gene mutations in 
human prostate cancer. J Steroid Biochem Mol Biol 1993;46:759-65. 
14. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S. Frequent 
detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 
1994;54:2861-4. 
15. Kleinerman DI, Troncoso P, Pisters LL, Navone NM, Hsieh J-T, Logothetis CJ, Sleddens HFBM, Van der 
Kwast TH, Brinkmann AO, Schroder FH, Trapman J. Expression and structure of the androgen receptor in 
bone metastasis of hormone refractory prostate cancer. Proc. Am. Urol. Assoc. 1996;155:624A. 
16. Suzuki H, Akakura K, Komiya A, Aida S, Akimoto S, Shimazaki J. Codon 877 mutation in the androgen 
receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 
1996;29:153-8. 
17. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP. Selection for androgen 
receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999;59:2511-5. 
18. Zhao XY, Boyle B, Krishnan AV, Navone NM, Peehl DM, Feldman D. Two mutations identified in the 
androgen receptor of the new human prostate cancer cell line MDA PCa 2a. J Urol 1999;162:2192-9. 
19. Veldscholte J, Berrevoets CA, Brinkmann AO, Grootegoed JA, Mulder E. Anti-androgens and the mutated 
androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, 
and transcription activation. Biochemistry 1992;31:2393-9. 
20. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J, Brinkmann AO, Mulder 
E. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects 
steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 1992;41:665-9. 
21. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, deVere White RW, Pretlow 
TG, Harris SE, Wilson EM, Mohler JL, et al. Dehydroepiandrosterone activates mutant androgen receptors 
expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol 
Endocrinol 1997;11:450-9. 
22. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP. Mutation of 
the androgen-receptor gene in metastatic androgen- independent prostate cancer. N Engl J Med 
1995;332:1393-8. 
23. Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, Balk SP. Functional 
characterization of mutant androgen receptors from androgen- independent prostate cancer. Clin Cancer 
Res 1997;3:1383-8. 
24. Bourguet W, Ruff M, Chambon P, Gronemeyer H, Moras D. Crystal structure of the ligand-binding 
domain of the human nuclear receptor RXR-alpha. Nature 1995;375:377-82. 
 
 147
25. Renaud JP, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, Moras D. Crystal structure of the 
RAR-gamma ligand-binding domain bound to all- trans retinoic acid. Nature 1995;378:681-9. 
26. Wagner RL, Apriletti JW, McGrath ME, West BL, Baxter JD, Fletterick RJ. A structural role for hormone 
in the thyroid hormone receptor. Nature 1995;378:690-7. 
27. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, 
Gustafsson JA, Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 
1997;389:753-8. 
28. Williams SP, Sigler PB. Atomic structure of progesterone complexed with its receptor. Nature 
1998;393:392-6. 
29. Uppenberg J, Svensson C, Jaki M, Bertilsson G, Jendeberg L, Berkenstam A. Crystal structure of the 
ligand binding domain of the human nuclear receptor PPARgamma. J Biol Chem 1998;273:31108-12. 
30. Moras D, Gronemeyer H. The nuclear receptor ligand-binding domain: structure and function. Curr Opin 
Cell Biol 1998;10:384-91. 
31. Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engstrom O, Ljunggren J, Gustafsson JA, 
Carlquist M. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial 
agonist and a full antagonist. Embo J 1999;18:4608-18. 
32. Rochel N, Wurtz JM, Mitschler A, Klaholz B, Moras D. The crystal structure of the nuclear receptor for 
vitamin D bound to its natural ligand. Mol Cell 2000;5:173-9. 
33. Bourguet W, Germain P, Gronemeyer H. Nuclear receptor ligand-binding domains: three-dimensional 
structures, molecular interactions and pharmacological implications. Trends Pharmacol Sci 2000;21:381-
8. 
34. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL. The structural basis of 
estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 
1998;95:927-37. 
35. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass 
CK, Milburn MV. Ligand binding and co-activator assembly of the peroxisome proliferator- activated 
receptor-gamma. Nature 1998;395:137-43. 
36. McDonald S, Brive L, Agus DB, Scher HI, Ely KR. Ligand responsiveness in human prostate cancer: 
structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors. Cancer Res 
2000;60:2317-22. 
37. Poujol N, Wurtz JM, Tahiri B, Lumbroso S, Nicolas JC, Moras D, Sultan C. Specific recognition of 
androgens by their nuclear receptor. A structure-function study. J Biol Chem 2000;275:24022-31. 
38. Marhefka CA, Moore BM, 2nd, Bishop TC, Kirkovsky L, Mukherjee A, Dalton JT, Miller DD. Homology 
modeling using multiple molecular dynamics simulations and docking studies of the human androgen 
receptor ligand binding domain bound to testosterone and nonsteroidal ligands. J Med Chem 
2001;44:1729-40. 
39. Matias PM, Donner P, Coelho R, Thomaz M, Peixoto C, Macedo S, Otto N, Joschko S, Scholz P, Wegg A, 
Basler S, Schafer M, et al. Structural evidence for ligand specificity in the binding domain of the human 
androgen receptor. Implications for pathogenic gene mutations. J Biol Chem 2000;275:26164-71. 
40. Sack JS, Kish KF, Wang C, Attar RM, Kiefer SE, An Y, Wu GY, Scheffler JE, Salvati ME, Krystek SR, 
Jr., Weinmann R, Einspahr HM. Crystallographic structures of the ligand-binding domains of the androgen 
receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad 
Sci U S A 2001;98:4904-9. 
41. Brinkmann AO, Trapman J. Prostate cancer schemes for androgen escape. Nat Med 2000;6:628-9. 
42. Doesburg P, Kuil CW, Berrevoets CA, Steketee K, Faber PW, Mulder E, Brinkmann AO, Trapman J. 
Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding 
domain of the androgen receptor. Biochemistry 1997;36:1052-64. 
43. Higuchi R, Krummel B, Saiki RK. A general method of in vitro preparation and specific mutagenesis of 
DNA fragments: study of protein and DNA interactions. Nucleic Acids Res 1988;16:7351-67. 
44. Riegman PH, Vlietstra RJ, van der Korput JA, Brinkmann AO, Trapman J. The promoter of the prostate-
specific antigen gene contains a functional androgen responsive element. Mol Endocrinol 1991;5:1921-30. 
45. Schena M, Picard D, Yamamoto KR. Vectors for constitutive and inducible gene expression in yeast. 
Methods Enzymol 1991;194:389-98. 
46. Brinkmann AO, Faber PW, van Rooij HC, Kuiper GG, Ris C, Klaassen P, van der Korput JA, Voorhorst 
MM, van Laar JH, Mulder E, et al. The human androgen receptor: domain structure, genomic organization 
and regulation of expression. J Steroid Biochem 1989;34:307-10. 
47. Gietz D, St. Jean A, Woods RA, Schiestl RH. Improved method for high efficiency transformation of 
intact yeast cells. Nucleic Acids Res 1992;20:1425. 
48. Kaiser P, Auer B. Rapid shuttle plasmid preparation from yeast cells by transfer to E. coli. Biotechniques 
1993;14:552. 
49. Cleutjens KB, van Eekelen CC, van der Korput HA, Brinkmann AO, Trapman J. Two androgen response 
regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol 
Chem 1996;271:6379-88. 
50. Ris-Stalpers C, Verleun-Mooijman MC, Trapman J, Brinkmann AO. Threonine on amino acid position 
868 in the human androgen receptor is essential for androgen binding specificity and functional activity. 
Biochem Biophys Res Commun 1993;196:173-80. 
51. Brinkmann AO, Trapman J. Genetic analysis of androgen receptors in development and disease. Adv 
Pharmacol 2000;47:317-41. 
52. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in 
X-linked spinal and bulbar muscular atrophy. Nature 1991;352:77-9. 
 148
53. Ruizeveld de Winter JA, Janssen PJ, Sleddens HM, Verleun-Mooijman MC, Trapman J, Brinkmann AO, 
Santerse AB, Schroder FH, van der Kwast TH. Androgen receptor status in localized and locally 
progressive hormone refractory human prostate cancer. Am J Pathol 1994;144:735-46. 
54. Evans BA, Harper ME, Daniells CE, Watts CE, Matenhelia S, Green J, Griffiths K. Low incidence of 
androgen receptor gene mutations in human prostatic tumors using single strand conformation 
polymorphism analysis. Prostate 1996;28:162-71. 
55. Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated 
with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996;2:277-85. 
56. Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, Zhao Y, DiConcini D, Puxeddu E, 
Esen A, Eastham J, Weigel NL, et al. Androgen receptor mutations in prostate cancer. Cancer Res 
2000;60:944-9. 
57. Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR, Tilley WD. Collocation of androgen 
receptor gene mutations in prostate cancer. Clin Cancer Res 2001;7:1273-81. 
58. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D. Glucocorticoids can 
promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat 
Med 2000;6:703-6. 
59. Chothia C. Structural invariants in protein folding. Nature 1975;254:304-8. 
60. Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JI, Isaacs WB, Brown TR, Barrack ER. Androgen 
receptor gene mutations in human prostate cancer. Proc Natl Acad Sci U S A 1992;89:6319-23. 
61. Culig Z, Hobisch A, Cronauer MV, Cato AC, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H. 
Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal 
androgens and progesterone. Mol Endocrinol 1993;7:1541-50. 
62. Peterziel H, Culig Z, Stober J, Hobisch A, Radmayr C, Bartsch G, Klocker H, Cato AC. Mutant androgen 
receptors in prostatic tumors distinguish between amino- acid-sequence requirements for transactivation 
and ligand binding. Int J Cancer 1995;63:544-50. 
63. Greenspan FS, Strewler, G.J. Appendix: Table of normal hormone reference ranges, Basic and clinical 
endocrinology. London: Prentice-Hall International, 1997 
64. Harper ME, Pike A, Peeling WB, Griffiths K. Steroids of adrenal origin metabolized by human prostatic 
tissue both in vivo and in vitro. J Endocrinol 1974;60:117-25. 
65. Cleutjens CB, Steketee K, van Eekelen CC, van der Korput JA, Brinkmann AO, Trapman J. Both 
androgen receptor and glucocorticoid receptor are able to induce prostate-specific antigen expression, but 
differ in their growth- stimulating properties of LNCaP cells. Endocrinology 1997;138:5293-300. 
66. Schuurmans AL, Bolt J, Voorhorst MM, Blankenstein RA, Mulder E. Regulation of growth and epidermal 
growth factor receptor levels of LNCaP prostate tumor cells by different steroids. Int J Cancer 
1988;42:917-22. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 149
 
Chapter 5  General discussion and future perspectives 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
 
 
 
General discussion and future perspectives 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 150
5.1  Aim of AR research 
  The AR plays a prominent role in development of the male phenotype, and therefore also in 
diseases like Kennedy's disease, AIS, and prostate cancer. Prostate cancer is the second leading 
cause of cancer deaths in men in Western countries and therefore it is a major research topic. 
Normal growth, development, and maintenance of the prostate depends on androgens which act 
through AR mediated regulation of androgen target genes. Prostate tumor growth also depends 
on androgens. Androgen withdrawal therapy initially inhibits tumor growth and leads to a 
decrease of tumor size. However, eventually prostate tumors relapse and become apparantly 
androgen-independent. The tumor then appears to grow without androgen, although in most 
cases the AR is still present. In androgen-independent tumors, the receptor might be activated by 
other mechanisms, like overexpression, mutations, aberrant coactivator function, and cross-talk 
with other signaling pathways. Even intraprostatic conversion of adrenal androgens to DHT 
might occur. So, the AR is a key player in both androgen-dependent and -independent prostate 
cancer and therefore it is a major subject of research in this disease and an important target for 
therapy. 
  In this thesis research on several aspects of AR function have been described. These include: 1) 
the functional interaction between the AR NTD and LBD, also known as N/C interaction, 2) 
androgen specific regulation of gene expression, and 3) AR LBD mutations. In this Chapter 5 
the findings are placed in the general context of AR function, and directions of future research 
are discussed. 
 
5.2 Molecular mechanisms of AR functions 
5.2.1  N/C interaction 
  In Chapter 2, the androgen-dependent interaction between the amino-terminal AR NTD and 
the carboxy-terminal AR LBD, the N/C interaction, is described. In this interaction an FXXLF 
motif (
23
FQNFL
27
) in the AR NTD is essential. The phenylalanine and leucine residues are 
indispensible, but X can be any residue. Residues flanking the AR FXXLF motif have a 
modulating role in the interaction 
1, 2
. 
  Like LXXLL motifs, the FXXLF motif can form an α-helical structure that fits in the 
coactivator groove of the AR LBD. The groove in the AR LBD is relatively deep compared to 
that in other steroid receptors and therefore it can harbor phenylalanine residues, which are 
bulkier than leucines 
3, 4
. Several AR coregulators, like ARA54, ARA70, and Rad9, also contain 
an FXXLF motif that can interact with the AR LBD 
5-7
. However, not all FXXLF motifs found 
in AR coregulators can bind to the AR LBD. For example, the coactivator FHL2 contains an 
FXXLF motif, but this motif can not bind to the AR LBD 
5, 8
. So, residues flanking the motif 
might prevent interaction. 
  Indeed, hydrophylic residues surrounding the groove and forming a charged clamp are very 
important in binding of FXXLF motifs 
1
. Like was found for LXXLL motifs, this clamp can 
interact with the charged residues flanking the AR FXXLF motif 
1
. Structural data have revealed 
that in principle E897, but not K720, is necessary for LXXLL-AR LBD binding, whereas both 
residues are needed for the N/C interaction 
4, 9
. However, crystallographic analysis of various 
peptides containing either LXXLL or FXXLF motifs indicates a more differentiated induced-fit 
model in which other residues lining the coactivator groove, like K717 and R726, also can play 
an important role depending on the residues that flank the motif 
9, 10
. This can explain that in 
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some studies K720 was found to be indispensible for FXXLF motif binding, whereas in 
experiments whith other peptides, K720 appeared to be less important 
1, 4, 9-13
. Similar 
differences were found for E897. 
  So, binding of the FXXLF motif is similar, but not identical to LXXLL binding, and most 
LXXLL motifs bind to the AR LBD with less affinity than FXXLF motifs. However, the third 
LXXLL motif of TIF2 was found to have C-terminally flanking negatively charged residues that 
interact with positively charged patches on the AR LBD surface 
14
. This might explain the 
relatively strong binding of this motif to the AR LBD and AR preference for TIF2 over other 
p160 coactivators 
15
. So, AR coactivators that contain an FXXLF or LXXLL motif could 
compete with the N/C interaction and/or with each other. Therefore, it might also be possible 
that there is redundancy between p160 coactivators and FXXLF containing coactivators, like the 
redundancy between SRC-1 and TIF2, and between SRC-1 and SRC-3/p/CIP as observed in 
p160 coactivator knock-out mice 
15-19
. 
  Screening of peptide libraries has revealed that variations of the FXXLF motif are allowed. 
These include exclusively hydrophobic bulky residues at positions +1, +4, and +5 of the motif, 
with preference for F at +1, F, M or Y at +4, and F or Y at +5 for strong interaction with AR 
LBD 
20, 21
. However, although in some peptides a W was found at position +1 of the motif, these 
peptides showed a very weak interaction with the AR 
8, 9
. In addition, a peptide containing a 
WXXLF motif found in the AR NTD that was proposed to be involved in the N/C interaction, is 
not able to bind to the AR LBD (Steketee unpublished results) 
22
. A W residue might not 
properly fit in the coactivator groove, or does not make sufficient contacts to allow stable 
binding. Crystallographic analysis has provided evidence for the preference for bulky 
hydrophobic residues at the +1, +4, and +5 position of AR LBD interacting motifs 
9
. The 
structural observations correspond with the strength of the interaction between the AR LBD and 
the motifs identified with random screening. Illustrative of the prefered motif residues are an 
FXXFF motif in gelsolin and an FXXMF motif in PAK6, that show high affinity binding to AR 
LBD 
21
. It may be expected that more AR LBD binding proteins will be found that contain 
FXXLF or variant motifs that can interact with the AR LBD. 
  To further unravel the molecular mechanism of AR function it was investigated whether the 
FXXLF mediated N/C interaction is intra- or intermolecular or both. FRET experiments with 
CFP-AR-YFP, CFP-AR, and AR-YFP fusion proteins have indicated that the FXXLF mediated 
N/C interaction can be intramolecular in the cytoplasm as well as in the nucleus, whereas AR 
dimerization was predominantly found in the nucleus 
23
. Mutation of the FXXLF motif affected 
the FRET signal of the AR-YFP/AR CFP combination, but not the affinity between these two 
AR monomers, from which it was concluded that the FXXLF motif influences the dimerization, 
but it is not clear yet whether and to which extent this is contributed by intermolecular N/C 
interaction. In another study, it was investigated whether the N/C interaction occurs in the DNA 
bound AR. Wild type AR and the N/C interaction deficient mutant E897A, both double tagged 
with CFP and YFP, were used for FRET analysis in a cell line containing approximately 200 
copies of an MMTV Ras tandem array 
24
. In this system an N/C interaction was established on a 
spot in the nucleus representing the AR bound to the MMTV array. In contrast with this study, 
FRET-FRAP experiments in wild-type cells with a wild-type AR and a DNA binding deficient 
mutant, showed a clear N/C interaction in nuclei for the mutant AR, whereas that of the wild 
type AR was considerably less 
25
. This indicated that the N/C interaction does not occur when 
the AR is bound to DNA, which could imply interactions with coactivators that prevent the N/C 
interaction. This observation was substantiated by binding of an ARA54 peptide to the wild type 
AR and not to the DNA binding deficient mutant 
25
. Similarly, GST pull-down assays and ChIP 
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on a MMTV-reporter have shown that ARA54 and ARA70 are able to bind to the AR LBD and 
to an N/C interaction defective full-length AR, but not to the wild type AR 
26
. So, the AR N/C 
interaction could prevent premature/improper cofactor binding in both the cytoplasm and 
nucleus. Detection of N/C interaction on the MMTV array might be explained by a short-lived 
existence of the interaction prior to coactivator binding, that is measurable because of the 
concentration of many HREs on this array. 
  Several studies have indicated that the N/C interaction is needed for optimal functioning of the 
AR 
3, 12, 22, 27-33
. Under different experimental conditions FXXLF deletion or mutations partially 
inhibits AR activity. In mouse mammary adenocarcinoma cells the AR LBD mutant E897A has 
a clearly impaired N/C interaction and is not functional, whereas in another study with the same 
mutant tested in monkey kidney (CV1) cells, still AR activity could be measured 
24, 34
. It can be 
speculated that in a specific cellular environment the impaired activity of the E897A mutant is 
mainly due to an abolished interaction with FXXLF and LXXLL containing coactivators, which 
need the E897 residue for AR binding, rather than to a disturbed N/C interaction. Indeed, in the 
mouse mammary cells the E897A mutant was not able to recruit PolII, GRIP1 or CREB 
24
. 
GRIP-1 binds through its LXXLL motif for which E897 is essential, subsequently followed by 
CREB and PolII. The same might count for a number of AR mutants found in AIS, which show 
a disturbed N/C interaction 
12, 30, 31, 33
. Here also other mechanisms needed for AR function may 
be affected, including increased ligand dissociation.  
   The N/C interaction was also found to have variable influence on AR function on different AR 
target sites in the DNA. This was illustrated by N/C interaction defective AR mutants, which 
had, compared to the wild-type AR, a decreased activity on a transient transfected reporter 
driven by a promoter with non-specific AREs, but not with androgen-specific AREs 
27
. In 
addition to DNA sequence requirements of the N/C interaction, the interaction was also 
proposed to play a role in accessibility of the AR to chromatin embedded DNA. An AR deletion 
mutant lacking the FXXLF motif does not bind to the MMTV promoter and PSA enhancer 
when assembled in chromatin in Xenopus or mammalian kidney cells 
32
. However, on naked 
DNA the mutant was able to bind the MMTV promoter and the PSA enhancer. The role of the 
N/C interaction in chromatin access of the AR is further substantiated by the finding that the 
FXXLF deleted AR mutant is also diminished in its binding to the ATPase subunit of SWI/SNF, 
Brg1 
32
.  
  The AR FXXLF motif is highly conserved, which indicates that it is an important domain. 
Although deletion or mutation of this motif only partially inhibits AR activity in functional 
assays, in vivo it might have a more pronounced long term effect on AR function. So far, 
however, no mutations in the FXXLF motif were found in prostate cancer or other AR related 
diseases (mcgill.ca/androgendb/). 
  Inhibition of AR function by androgen depletion and administration of antiandrogens is the 
standard treatment of metastatic prostate cancer. Another method of blocking AR function could 
be inhibition of coactivator action. Therefore structural knowledge on interactions between the 
AR and its coactivators is essential. One target of inhibition could be the coactivator groove by 
blocking it with AR specific peptides, e.g. a peptide containing the AR FXXLF motif. However, 
this would not only prevent binding of AR coactivators, but it would also interupt the N/C 
interaction. Hereby the FXXLF motif in the AR NTD becomes available for interaction with 
other proteins, like MAGE-11, which can specifically bind to the FXXLF motif , stabilizes the 
AR in the absence of ligand, and in the presence of an agonist, augments exposure of AF-2 to 
the recruitment and activation by the SRC/p160 coactivators. 
20, 35
. This way, a net inhibition of 
the AR might not be achieved. For the ER antagonistic peptides were developed that can 
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succesfully block the LBD coactivator groove 
36, 37
. However, in the ER, AF-2 substantially 
contributes to the receptor transcriptional activity, whereas in the AR, AF-1 is much more 
important for transactivation than the LBD 
11, 38-41
. Therefore it could be an option to combine a 
peptide antagonist that binds to the AR LBD coactivator groove with an additional AF-1-
blocking approach. This way p160 coactivators, other AR NTD interacting coactivators, and 
FXXLF motif containing coactivators could be inhibited in an AR specific manner. 
  Taken together, the AR N/C interaction may play a fine-tuning role in stabilizing ligand bound 
AR, effective traveling of the ligand bound AR from the cytoplasm to the nucleus, access of the 
AR to chromatin embedded DNA, proper deposition of the AR on its target ARE's, and 
inhibition of premature cofactor binding. Determination of the physiological role of the AR N/C 
interaction awaits a mouse model in which the FXXLF motif is deleted. Such a model  could 
also be used for microarray analysis to determine which androgen target genes need the N/C 
interaction for their optimal regulation and under which cellular conditions. Furthermore, ChIP 
experiments with an FXXLF deletion mutant could establish the requirement of the FXXLF 
motif in protein complexes involved in regulation of expression of particular androgen 
responsive genes. 
5.2.2 AR specific target genes 
  All steroid receptors (except ER) can bind to the same high affinity consensus GRE (5’-
AGAACAnnnTGTTCT-3’). Steroid specific gene regulation is conferred by several mechanisms 
including receptor expression levels, selective interactions of receptors with specific and general 
transcription factors and coregulators, relative coregulator levels, ligand availability, and local 
chromatin structure at regulatory sites of target genes. However, although many GREs are 
recognized by AR, as well as by GR and PR, also AR specific AREs have been identified. These 
AREs are present in androgen-specifically regulated genes like SC, Slp, probasin, PEM, and 
SARG 
42-47
. 
  The SARG gene was identified in the AR
+
/GR
+
 LNCaP subline 1F5, using differential display. 
The function of the SARG protein is not known yet. It does not have any known domains that 
could predict its function. Recently, differential display data were confirmed and extended by 
micro-array analysis of 1F5 cells. This revealed several genes of which the expression is highly 
induced by androgens (van der Korput, unpublished results). Among these was SARG, which 
indicates an important role for this gene in androgen regulation of prostate cells. Together with 
the observation that 1F5 cells depend on androgens for their growth, SARG is a candidate to 
play a role in prostatic (cancer) cell growth. Elucidation of the SARG function awaits RNAi 
experiments and a mouse knock-out model. 
  Initially, models of AR DBD bound to AR specific AREs suggested that the direct repeat-like 
character of the AR specific AREs, like that of SARG, determines the mode of AR binding. This 
interaction was proposed to involve head-to-tail dimerization, similar to the orientation of NR 
heterodimers that bind to direct-repeat HREs like VDR/RXR. However, it now has been proven 
by crystallographic analysis that an AR dimer has a head-to-head conformation on both AR 
specific and non-specific AREs 
48
. The mechanism underlying AR specificity of AREs involves 
strong homo-dimerization between AR DBDs. This interaction is less strong between other 
steroid receptors. Three extra hydrogen bondings between two AR DBDs, if compared to the 
GR DBD, confer this stronger binding. In fact, one AR binds to a high-affinity left half-site of 
the AR specific ARE and the second monomer can bind to the second half-site, which might 
deviate considerably from the high affinity consensus site sequence and has a low affinity for 
the AR. Apparently, the dimerization interaction is strong enough to keep the AR dimer intact. 
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This might also explain why the AR was able to bind to the Pem1 ARE with a 5 bp spacing, 
while the GR cannot 
42
. Although the mechanism of the PemI ARE could be complex, one 
aspect might be that the strong AR dimerization overcomes the extra spacing and concomittant 
phase change of the major groove to which the AR binds if compared to a normal 3 bp spacing, 
by resisting the tension put on it by bending of the spacer in order to accomodate the AR dimer. 
  The physiological roles of androgen-specific regulated genes are not known, but knowledge on 
these genes might be important for development of specific AR targeting prostate cancer 
therapies. Mutations have been found in AIS patients at the positions of the three amino acids 
involved in the extra hydrogen bondings between AR DBDs. In PAIS patients A596T, S597G, 
S597T, S597R, and T602P substitutions were identified 
49-56
. Some of these were shown to 
impair AR function 
50, 51, 56
. It would be informative to test whether these AR mutants are active 
on non-specific AR target genes and less active on AR-specific genes. Indeed, one of the 
mutants, A596T, was tested and showed reduced activity on AR specific AREs, but not on non-
specific AREs 
57
. 
  Recently, a transgenic mouse model, SPARKI (SPecificity-affecting AR KnockIN), was 
generated in which the second zinc cluster of the AR was swapped with the second zinc cluster 
of the GR 
58
. This AR mutant showed a significant loss of function on androgen specific AREs, 
but not on non-specific AREs. SPARKI males have an apparently normal phenotype. However, 
they are subfertile. The reproductive organs are decreased in weight and spermatogenesis is 
disturbed. This model can help reveal which pathways are involved in androgen specific gene 
regulation.  
  Micro-arrays are very important tools for the identification of androgen-specific regulated 
genes. To find AREs in those genes a very useful approach can be a bioinformatics based search 
for AREs. However, to identify a real AR specific ARE, functional studies always will be 
needed. For example, by using bioinformatics at 7.5 kb upstream of the SARG transcription 
start site, a candidate ARE was found, which is identical to an artificial AR specific ARE 
previously tested as an oligonucleotide 
59
. In contrast to the artificial ARE, the -7.5 kb candidate 
ARE appeared to be non-functional and even no AR binding was found 
45
. This clearly 
illustrates that half-site sequences alone are not sufficient, but need flanking and/or more distant 
sequences to determine the androgen response of a candidate ARE. The concomitant local 
chromatin structure in which the ARE is embedded, and binding of other transcription factors to 
the flanking sequences, might also determine whether a candidate ARE is functional or not.  
  Another difficulty in finding androgen regulated genes by using bioinformatics, is that many 
known functional AREs differ considerably from the consensus sequence. So, genome wide 
screening for ARE sequences would involve a huge variety of sequences to be used as search 
string. This would result in a too high number of candidate AREs to be suitable for further 
analysis. Searching exclusively for AR specific AREs would even be more problematic. For 
this, one half site must be a high affinity, mostly near consensus sequence, and one half site 
should considerably deviate from the consensus sequence. However, this would imply screening 
with one half-site sequence, which means using a search string with only 6 bases. This would 
reveal far too many candidate AREs to handle. As the second half-site can be extremely 
variable, it would be very complicated and may be impossible to define a consensus sequence 
for AR specific AREs.  
  An approach to solve the problem of too many candidate AREs in screening of genomic 
sequences is the ChIP-on-chip technique 
60
. This technique combines protein-DNA binding with 
microarray analysis. A genome wide screening has been done to identify ER binding sequences, 
which is one step forward in limiting the number of candidate HREs 
61
. Recently, ChIP-on-chip 
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for the AR was performed on a so-called ENCODE chip, which represents approximately 1% of 
the whole genome 
62
. Several novel androgen response genes have been identified. Most AREs 
appeared to be located in regions other than proximal promoter regions. The intronic androgen 
specific ARE in the SARG gene is an example of this (Chapter 3) 
45
. ChIP-on-chip analysis of 
the complete chromosomes 21 and 22 has revealed 90 AR binding sites, among which one 
upstream of the TMPRSS2 gene 
63
. In a ChIP-on-chip approach with more than 24,000 gene 
promoter regions, 92 genes were identified as strong candidate AR regulated genes, and this 
corresponded with expression data sets of those genes 
64
. In another study, a few hundred 
androgen-regulated genes were identified with expression profiling and subsequent ChIP-on-
chip analysis of the promoter regions of those genes. This revealed more than 500 AR binding 
regions of which 22 were tested in a reporter gene assay, and 20 of these were androgen 
inducible 
65
. Most of these AR binding regions contained two or more AREs. Clustering of 
candidate AREs may indicate an androgen regulated region, but a single ARE may have no 
measurable activity in transfection experiments and therefore can be difficult to identify 
66
. 
Using ChIP-on-chip analysis may also help overcome this problem. Identification of all 
androgen regulated genes and all existing AREs, both androgen specific and non-specific, 
awaits a ChIP-on-chip analysis of the complete genome.  
5.2.3 AR LBD mutations 
  AR mutations have been found in pathological conditions as Kennedy's disease and AIS, and 
in a subset (up to 10%) of endocrine therapy resistant prostate cancers. In prostate cancer most 
mutations are found in the LBD, which could imply changes in ligand and cofactor binding. 
Well characterized mutations are T877A, L701H, H874Y, and W741C/L, which cause a 
broadened ligand specificity of the AR. These mutations render the AR, in addition to T and 
DHT, also responsive to non-cognate ligands like progesterone, estradiol, adrenal androgens, 
glucocorticoids, and even anti-androgens 
45, 67-77
. For some of these mutants the mechanism of 
broadened ligand specificity has been elucidated. Crystallographic analysis has shown that the 
T877A mutant has a modified ligand binding pocket size that can explain accomodation of 
ligands larger than T and DHT 
78
. However, also mutations of residues that do not line the 
ligand binding pocket, e.g. in AR H874Y, can confer broadened ligand specificity, most likely 
by structural changes that indirectly influence ligand binding. Crystallographic analyses of the 
different mutants bound to different non-cognate ligands explain and confirm the mechanisms 
underlying the broadened ligand specificity, such as the recently elucidated crystal structure of 
the T877A AR LBD complexed to CPA 
79
. In this mutant residue L701 in the LBD is displaced 
resulting in expansion of the ligand binding pocket. This enables CPA, which is a partial agonist 
for the wild-type AR and is bulkier than AR steroidal agonists like DHT, T, or R1881, to fit the 
pocket properly so that it can act as a full agonist for the T877A AR mutant. Similarly, an 
L701A mutant can also be activated by CPA at the same nanomolar concentrations as the 
T877A mutant 
79
. These kind of structural studies provide insight in ligand-induced 
conformational changes and could be helpful in structure-based drug design.   
  Agonistic action of antagonists on the AR mutants could be determined by proper coactivator 
interactions as a result of the changed ligand accomodation. For example, in the presence of 
ligands such as estradiol, progesterone, spironolactone, and OH-Fl, the T877A mutant showed 
an increased ligand potency in recruitment of LXXLL and FXXLF peptides 
80
. Likewise, it 
might be expected that the AR FXXLF motif interacts differently with the mutant LBD as with 
the wild-type LBD in the presence of an antagonist. So, crystallographic data of wild-type and 
mutant AR LBDs complexed with peptides in the presence of different ligands could give more 
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insight in the mechanism of AR function. This could be useful for the design of new approaches 
to specifically block AR LBD-coactivator interactions in both wild-type and mutant ARs. 
  Androgen ablation by LHRH agonists used for treatment of metastatic prostate cancer does not 
reduce serum T levels such that DHT levels in the prostate will become low enough to 
completely inhibit the AR 
81-84
. Therefore, also anti-androgens are used to counteract DHT 
action. It is believed that use of antiandrogens in prostate cancer treatment can induce androgen-
independent tumor growth in a subset of patients. Strong indications for this are provided by 
experiments in a yeast system and in prostate cancer cell lines, in which AR mutants could be 
selected for their response to non-cognate ligands, among which anti-androgens 
45, 69, 85
. The AR 
mutations found in these experiments are the same as found in antiandrogen treated patients. 
Although it is possible that those AR mutants are already present in non-treated tumors, these 
must be rare as they have not been found in primary tumors. This implies that those mutants 
could not have growth advantage in the untreated stage when DHT is at physiological levels. 
This is in accordance with the responses of wild-type and AR mutants to DHT, which are 
comparable as measured in transfection.  
  The W741C mutant can be activated by bicalutamide, but not by nilutamide and OH-Fl, 
whereas the T877A mutant does not respond to bicalutamide, but can be activated by OH-Fl and 
nilutamide 
86
. Structural modeling has revealed the possible underlying mechanisms of these 
mutants with the respective ligands 
79, 86-88
. This has led to the hypothesis that switching of anti-
androgens during prostate cancer treatment could abolish the effects of appearing AR mutations. 
This would also be in line with the phenomenon 'anti-androgen withdrawal syndrome' in which 
prostate tumors decrease in size when anti-androgen administration is temporarily stopped 
89
. 
However, only a small proportion of the cases of antiandrogen withdrawal syndrome carry AR 
mutations, which means that also growth pathways other than those regulated by AR mutants 
must be involved in tumor progression. Nevertheless, it has been argued that a therapy in which 
use of different anti-androgens and withdrawal of these compounds is alternated, could inhibit 
progression of at least a subset of prostate cancers 
86, 90
. 
  Prostate cancer related AR mutations are not only found in the LBD, but, albeit much less 
frequent, also in the NTD and DBD. In the transgenic adenocarcinoma of mouse prostate 
(TRAMP) model, AR LBD mutations were found in the tumors of non-treated mice, whereas in 
castrated TRAMP mice AR NTD mutations were found 
91
. Apparently, the androgen-depleted 
hormone status leads to mutations in the androgen-independent NTD. However, androgen 
depletion, mostly by using LHRH agonists, is often combined with antiandrogens. This 
substantiates why most AR mutations in anti-androgen treated prostate cancers are found in the 
ligand-dependent LBD as these mutations may appear under selection pressure by the anti-
androgens that can activate them. As AR mutations in the TRAMP model developed under 
physiologically normal hormone conditions, it also raised the question whether AR mutations 
could induce oncogenesis. Indeed, in all transgenic mice harboring the AR NTD mutant E231G, 
oncogenic transformation of the prostate was found 
92
. So far, the E231G mutation has not been 
found in human prostate cancer (mcgill.ca/androgendb/). The underlying mechanism could be 
an increased AR activity caused by a disturbed interaction with the negative AR regulator CHIP. 
Recently, an AR DBD mutation, K580R, which was found in a lymph node metastasis, was 
found to be oncogenic in transfection. Activation of the Akt signalling pathway might be 
involved, because this mutant increases p-Akt and p-p70 S6K levels 
93, 94
. These findings 
indicate that it is important to investigate mutations in all three AR domains, which will lead to 
a better understanding of the role of the AR in prostate cancer.  
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5.3 AR in further research and future perspectives 
  Although there is already an extensive knowledge on the molecular mechanisms of AR 
functions, many aspects remain to be elucidated, of which a few important ones are discussed 
below.  
  One feature of the AR that still is to be established is the structural conformation of the NTD. 
So far, only an α-helical structure for the 
23
FXXLF
27
 motif was found  
4, 9
. It is thought that the 
NTD, if not bound to other proteins, is very flexible and that it adopts different induced fit 
conformations depending on the proteins that bind to this AR domain. So, structural analysis of 
AR NTD might only be succesful in the context of its interacting proteins like CHIP, MAGE, 
SHP, SMRT, CBP, and p160 coactivators (see section 1.2.2). 
  Although AR mutations are found in only a subset of prostate cancer patients, further 
unraveling the functional consequences of these mutations will highly contribute to general 
understanding of AR function, which could be useful for development of new or better 
therapies.  
  RNAi could be an effective therapy for prostate cancer treatment. As the AR plays a key role 
in prostate cancer, androgen responsive genes might be selected as targets of RNAi in addition 
to RNAi of the AR itself. For this it will be important to develop a therapy that can balance 
expression of androgen up- and down-regulated genes so precisely that cell proliferation is 
completely shut down in a prostate specific manner. To develop such an approach, more 
detailed knowledge is needed on (specifically) androgen regulated genes, which has been 
achieved by using micro- array technology and now also with the recently developed ChIP-on-
chip technique 
60-62
. A good candidate for RNAi might be the recently identified 
TMPRSS2:ERG fusion gene. It is highly expressed in a substantial proportion of prostate 
cancers, androgen responsive, and correlates with recurrence and aggressiveness of the disease 
95-99
. This gene is suggested to play a role in the androgen-dependent stage of prostate cancer 
96
.  
  The AR can also have a function in mechanisms other than regulation of gene transcription. 
Recently, the AR was found to be a licensing factor for DNA replication in androgen-dependent 
prostate cancer cells, but not in normal prostate cells 
100, 101
. In the prostate cancer cells, the AR 
has to be degraded before AR signalling can promote a next round of DNA replication. So, 
paradoxically, AR stabilizing approaches would inhibit DNA replication and therefore disturb 
the cell cycle. A new approach for prostate cancer treatment could be intermittent androgen 
blockade (IMAB). This would anticipate on the effect of selection of AR mutants responding to 
antiandrogens and inhibit cell proliferation on a more general level by diminishing DNA 
replication. 
  In summary, knowledge on the molecular mechanisms of AR functions is important to 
understand AR function in order to be able to improve existing therapies and to develop new 
treatments for AR-related diseases like prostate cancer. Our current knowledge still needs 
further extension to find targets for improvement of current prostate cancer treatment or develop 
new therapies. 
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Summary 
 
  The androgens testosterone (T) and dihydrotestosterone (DHT) are steroid hormones, which 
are necessary for development and maintenance of the functions of the male sex organs, 
including the prostate. Androgens also play an important role in benign abnormalities of the 
prostate and in the growth of prostate cancer. Prostate tumors, which are not yet metastatic, are 
treated with radiotherapy or by surgical removal of the complete prostate. Therapy of 
metastasized prostate cancer aims on inhibition of androgen action, by inhibtion of the 
production of T in the testis (chemical castration) and by administration of anti-androgens. T 
and DHT exert their function by specific binding as a ligand to the androgen receptor (AR). The 
AR is a member of the family of nuclear receptors. It is expressed in androgen target cells, and 
functions as a ligand induced transcription factor. In this thesis described research project 
focusses on several molecular mechanisms of AR functions.  
  Chapter 1 gives an overview of the current knowledge on nuclear receptors in general and 
different aspects of AR functions in particular. Among the latter are: receptor structure, 
interaction with other proteins involved in transcription, the ligand-dependent interaction 
between the N-terminal domain (NTD) and the ligand binding C-terminal domain (LBD) of the 
AR (N/C interaction), expression of androgen-specific regulated genes, and the role of AR 
mutations in prostate cancer. 
 In Chapter 2 a motif in the AR NTD, 
23
FXXLF
27
, that is essential for the N/C interaction is 
described. Mutation of the phenylalanine residues or leucine in this motif completely disturbs 
the interaction. Flanking residues have a modulating role in the N/C interaction. The FXXLF 
motif can adopt an α-helix conformation and binds to the LBD surface at the same postition as 
some coactivators. Coactivators can contain one or more LXXLL or FXXLF motifs. 
Coactivators with an FXXLF motif are specific for the AR. The function of the AR N/C 
interaction is not clear as yet. The interaction can play a role in the stability of ligand binding. 
There are also indications that the N/C interaction is important for expression of endogenic 
genes, but less important in model systems that transiently express a reporter gene.  
  In Chapter 3 the characterization of the specifically androgen-regulated gene SARG is 
described. This gene was identified in the LNCaP-1F5 sub cell line, which in addition to the AR 
also stably expresses the glucocorticoid receptor (GR). In this way it is possible to distinguish 
between genes that can be activated by more than one steroid receptor and genes that are 
regulated by one specific receptor. SARG transcription in 1F5 cells can be regulated by 
androgens, but not by glucocorticoids. The SARG gene contains 4 exons and alternative splicing 
results in transcripts missing exon 2 and with an exon 1 that varies in length. Variable 
polyadenylation  leads also to transcripts of different lengths. The SARG protein consists of 601 
amino acids and is localized in the cytoplasm. However, its function has not been established 
yet. A bioinformatics-based screening of the SARG gene, including up- and down-stream 
sequences, revealed a number of candidate AR binding sites (androgen response elements or 
AREs) on the DNA, of which one that is localized in intron 1, is AR specific. EMSA and ChIP 
experiments have shown that the GR cannot bind to this ARE, and an enhancer containing this 
ARE cannot be activated by GR. It is now known that AR specific AREs have one half-site with 
a high affinity for the AR, and one low affinity half-site. Hydrogen bonds between the DBDs in 
an AR dimer are responsible for a strong AR-AR interaction, so that a relatively weak binding 
to one of the half-sites is permitted. These hydrogen bonds are not present in the GR dimer, 
which can explain why the GR dimer does not bind to an AR-specific ARE.  
 164
  Prostate tumors initially are dependent on androgens for their growth. In a late stage of tumor 
growth this is much less the case. Then the tumors are called endocrine therapy resistant. In part 
of these resistant tumors, amino acid substitutions have been found in the AR through which it 
cannot only be activated by T or DHT, but also by other steroids and even by anti-androgens. In 
Chapter 4 research is decribed in which the prostate cancer mutation hot spots H874 and T877 
are randomly mutated and mutants are selected for their activation by progesterone. This screen 
identified the same mutations as found in prostate cancer: H874Y, T877A, and T877S. These 
mutants are subsequently tested with a variety of hormones and, next to the expected activation 
by progesterone, estradiol, and hydroxyflutamide, these mutants also appeared to be sensitive to 
physiological concentrations of cortisol. This could mean that prostate tumors have obtained 
these mutant ARs by selective pressure by anti-androgens, after which these could also be 
maintained by cortisol. The broadened ligand-specificity of the mutant ARs caused by a 
substitution on position 877 can be explained by the substitution of threonine by a smaller 
amino acid residue, like alanine or serine. The amino acid at position 877 is within the ligand 
binding pocket and binds to the 17β-hydroxyl-group of androgens, whereby a smaller amino 
acid residue means that there is more space in this pocket, so that ligands larger than T or DHT, 
e.g. progesterone, also can bind, which is not possible in the wild-type receptor. Apparently, the 
interactions left are sufficient for stable binding of the ligand and/or new interactions might be 
formed. H874 is not located in the ligand binding pocket, but it is presumed that the H874Y 
substitution changes the conformation of the AR LBD, in such a way that the ligand binding 
pocket becomes available for non-androgenic hormones.  
  In Chapter 5 the research which is described in the previous chapters is placed in the broader 
context of recent literature on molecular mechanisms of AR functions. In this chapter also a 
perspective for further research on these mechanisms is given. 
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Samenvatting 
 
  De androgenen testosteron (T) en dihydrotestosteron (DHT) zijn steroïdhormonen, die 
noodzakelijk zijn voor de ontwikkeling en het instandhouden van de functies van de mannelijke 
geslachtsorganen, waaronder de prostaat. Daarnaast spelen androgenen een belangrijke rol in 
benigne afwijkingen van de prostaat en bij de groei van prostaatkanker. Prostaattumoren, die 
nog niet zijn uitgezaaid, worden behandeld door middel van radiotherapie of door chirurgische 
verwijdering van de gehele prostaat. De therapie van gemetastaseerd prostaatkanker is erop 
gericht om de werking van androgenen tegen te gaan, door de productie van T in de testis te 
remmen (chemische castratie) en door het toedienen van anti-androgenen. T en DHT oefenen 
hun werking uit door specifiek te binden als ligand aan de androgeenreceptor (AR). De AR 
behoort tot de familie van kernreceptoren. De AR komt tot expressie in doelwitcellen van 
androgenen en functioneert als een ligand-geïnduceerde transcriptiefactor. Het in dit proefschrift 
beschreven onderzoek richt zich op een aantal moleculaire mechanismen van AR functies.  
Hoofdstuk 1 geeft een overzicht van de huidige kennis van kernreceptoren in het algemeen en 
verschillende aspecten van de AR functies in het bijzonder. Onder deze laatste zijn: structuur 
van de receptor, de interactie met andere eiwitten betrokken bij de regulering van transcriptie, de 
ligand-afhankelijke interactie tussen het N-terminale domein (NTD) en het ligand-bindende of 
C-terminale domein (LBD) van de AR (N/C interactie), de expressie van androgeen-specifiek 
gereguleerde genen, en de rol van AR mutaties in prostaat kanker. 
  In Hoofdstuk 2 is een motief in de AR NTD, 
23
FXXLF
27
, beschreven dat essentieel is voor de 
N/C interactie. Mutatie van de fenylalanine residuen of van leucine in dit motief verstoort de 
interactie compleet. Omliggende aminozuur residuen hebben een modulerende rol in de N/C 
interactie. Het FXXLF motief kan een α-helix conformatie aannemen en bindt aan het LBD 
oppervlak op dezelfde plaats als sommige coactivatoren. Coactivatoren kunnen één of meerdere 
LXXLL of FXXLF motieven bevatten. Coactivatoren met een FXXLF motief zijn specifiek 
voor de AR. De functie van de AR N/C interactie is nog niet geheel duidelijk. De interactie kan 
een rol spelen bij stabiliteit van de binding van een ligand. Ook zijn er aanwijzingen dat de N/C 
interactie belangrijk is voor de expressie van endogene genen, maar van minder belang in model 
systemen, waarbij een reportergen transient tot expressie wordt gebracht.  
  In Hoofdstuk 3 wordt de karakterisering van het specifiek androgeen-gereguleerde gen SARG 
beschreven. Dit gen werd geïdentificeerd in de LNCaP-1F5 subcellijn die naast de AR ook 
stabiel de glucocorticoidreceptor (GR) tot expressie brengt. Hierdoor is het mogelijk om 
onderscheid te maken tussen genen die door meerdere steroidreceptoren geactiveerd kunnen 
worden en genen die door één specifieke receptor gereguleerd worden. SARG transcriptie kan in 
1F5 cellen wel door androgenen gestimuleerd worden maar niet door glucocorticosteroïden. Het 
SARG gen bevat 4 exonen en alternatieve splicing resulteert in transcripten die exon 2 missen en 
een exon 1 hebben dat varieert in lengte. Variabele polyadenylering leidt ook tot transcripten 
van verschillende lengtes. Het SARG eiwit bestaat uit 601 aminozuren en is gelokaliseerd in het 
cytoplasma. De functie ervan is echter nog niet vastgesteld. Een op bioinformatica gebaseerde 
screening van het SARG gen, inclusief sequenties voor en achter het gen, leverde op het DNA 
een aantal kandidaat bindingsplaatsen voor de AR (androgeen respons elementen of AREs) op, 
waarvan er één, die zich in intron 1 bevindt, AR-specifiek is. EMSA, ChIP experimenten 
hebben laten zien dat deze ARE niet in staat is de GR te binden en ook dat de enhancer die deze 
ARE bevat niet geactiveerd kan worden door de GR, maar wel door de AR. Van de AR-
specifieke AREs is nu bekend dat ze één half-site met hoge affiniteit voor de AR hebben en één 
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half-site met een veel lagere affiniteit. Waterstofbruggen tussen de twee DBDs in een AR 
dimeer zorgen voor een sterke AR-AR interactie, waardoor een zwakkere binding aan één van 
de ARE half-sites gepermitteerd lijkt. Deze waterstofbruggen komen niet voor in een GR 
dimeer, wat kan verklaren waarom de GR niet goed bindt aan een AR specifieke ARE.  
  Prostaattumoren zijn in het begin van hun groei afhankelijk van androgenen. Dit is in een laat 
stadium van tumorgroei veel minder het geval. Deze laatste tumoren zijn dus resistent geworden 
tegen de endocriene therapie. In een deel van deze resistente tumoren zijn aminozuursubstituties 
in de AR gevonden waardoor deze niet alleen geactiveerd kan worden door T of DHT, maar ook 
door andere steroïden en zelfs door anti-androgenen. In Hoofdstuk 4 is een onderzoek 
beschreven waarin de in prostaatkanker gevonden mutatie hot spots H874 en T877 random 
gemuteerd zijn en mutanten geselecteerd zijn voor hun activering door progesteron. Hierbij 
werden dezelfde mutanten gevonden als ook in prostaatkanker voorkomen:  H874Y, T877A en 
T877S. Deze mutanten zijn in vervolgexperimenten getest met een heel scala aan hormonen en 
naast de verwachte activering door progesteron, estradiol en hydroxyflutamide bleken deze 
mutanten ook gevoelig voor fysiologische concentraties cortisol. Dit zou kunnen betekenen dat 
prostaattumoren deze mutante ARs door selectiedruk van anti-androgeen hebben verkregen, 
waarna deze bovendien in stand gehouden zouden kunnen worden door cortisol. De bredere 
ligand-specificiteit van de mutante ARs veroorzaakt door een substitutie op positie 877 kan 
worden verklaard door de substitutie van threonine door een kleiner aminozuur residu, zoals 
alanine of serine. Positie 877 is onderdeel van de ligand-bindende pocket en bindt de 17β-
hydroxyl-groep van androgenen, waarbij een kleiner aminozuur betekent dat er meer ruimte is in 
deze pocket, zodat liganden groter dan T of DHT, bv. progesteron, ook kunnen binden, wat ze 
niet kunnen met de wild-type receptor. Blijkbaar zijn overgebleven interacties voldoende voor 
stabiele binding van het ligand en/of worden nieuwe interacties gevormd. H874 ligt niet in de 
ligand-bindende pocket, maar verondersteld wordt dat de H874Y substitutie een verandering in 
de conformatie van het AR LBD teweegbrengt, die de ligand-bindende pocket ook geschikt 
maakt voor niet-androgene hormonen. 
  In Hoofdstuk 5 zijn de onderzoeken die beschreven zijn in voorgaande hoofdstukken in de 
bredere context van recente literatuur over de moleculaire mechanismen van AR functies 
geplaatst. Ook is in dit hoofdstuk een perspectief aangegeven voor verder onderzoek naar deze 
mechanismen.  
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allermoeilijkste momenten. Het was een bizarre tijd, waarin we elkaar soms uit het oog verloren 
en daarna weer vonden. Onze gesprekken aan de rode keukentafel (vaak met 300 wpm) zal ik 
nooit vergeten. De laatste jaren als ik 's avonds in Rotterdam was bleef er meestal geen tijd over 
om bij je langs te gaan. Vanaf nu dus wel. Dankjewel dat je m'n paranimf wilt zijn. 
  Dan nummer 32: Lieve Ellen en Marc, jullie waren af en toe letterlijk een toevluchtsoord waar 
altijd wat te doen was. Bij jullie kon ik weer een beetje bijtrekken als dat nodig was. De door 
jullie altijd met veel belangstelling gestelde vraag: 'Hoe is het met je proefschrift?' is nu 
voorgoed verleden tijd. Ellen, dankjewel dat je m'n paranimf wilt zijn. 
  Lieve Werner en Vincent, mijn oogappeltjes. Jullie komst op de wereld was een feest. De zon 
ging echt een beetje feller schijnen in toen toch wat donkere dagen. Nu ik niet meer over het 
werk op het laboratorium in Rotterdam hoef te schrijven, zal ik voortaan veel meer tijd hebben 
om op jullie te komen passen en leuke dingen te gaan doen. Ik hoop nog heel vaak 
pannenkoeken voor jullie te bakken. 
  Lieve mama, ook jouw nooit aflatende belangstelling voor m'n promotieonderzoek is voor mij 
heel belangrijk geweest. Op mijn verhalen en gemopper reageerde je met 'volhouden!' of 'het is 
ook niet gauw goed zeg'. Nu is het goed. 
  Lieve papa, postuum wil ik je bedanken voor alle kansen die mama en jij me gegeven hebben 
om te gaan doen wat ik wilde. Jouw uitspraak 'Toe maar, dat kan je best' heeft de afgelopen 
jaren heel vaak in m'n gedachten nageklonken, en op de moeilijkste momenten mij de kracht 
gegeven om door te gaan. Ik weet hoe trots je op me zou zijn geweest. 
  En dan als laatste mijn allessie. Lieve Jeroen, eindelijk is er dan licht gaan schijnen aan het 
einde van een donkere tunnel. Nu hoef je niet meer te zeggen 's avonds na het journaal 'Ik geloof 
dat ik er weer eentje naar de computer moet sturen'. Het klonk grappig, maar het was hard nodig 
als de motivatie het wat af liet weten. Heel veel dank voor alle aanmoediging en het door jou 
opgebrachte geduld. Je hoeft er voortaan niet meer alleen op uit. Ik ga weer met je mee! 
 
 
Karine 
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